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Abstract
Abstract
The protozoan parasite Trypanosoma brucei causes human sleeping sickness and 
Nagana in domestic animals and depends on the tsetse fly for dissemination. The 
complex T. brucei  life cycle requires differentiation from the dividing long slender forms 
via the cell cycle arrested short stumpy forms (both in the mammalian bloodstream) to the 
procyclic forms of the insect vector. The signaling pathways that regulate differentiation 
are unknown but there is evidence for an involvement of cAMP. In search of the putative 
cAMP receptor, three catalytic and one regulatory PKA-like subunits have been previously 
cloned from T. brucei. The catalytic subunits possess all features of a classical PKA in 
terms of inhibitor and substrate specificity. It was shown that each of the catalytic PKA-
like subunits binds to the regulatory subunit to form a dimeric PKA-like holoenzyme. 
Most surprisingly, we found that T. brucei PKA-like kinase, despite of its apparent 
similarities to a PKA, was not activated but instead inhibited by cAMP. Out of several 
other cyclic nucleotides that were tested on their effects on PKA-like kinase, only cGMP 
was able to activate the kinase, but in millimolar and thus most likely unphysiological 
concentrations. Assuming that the activation of PKA-like kinase might depend on its 
native, subcellular environment, an in vivo kinase assay was established in this work. It 
is based on the immunological detection of the phosphorylated form of the PKA reporter 
substrate VASP that was transgenically expressed in T. brucei. Interestingly, results from 
the in vivo assay did confirm the in vitro data, suggesting that T. brucei PKA-like kinase 
is in fact inhibited rather than activated by cAMP. 
Even though these findings challenge the original assumption that T. brucei PKA-like 
kinase transmits the differentation signal mimicked by cAMP antagonists, data from this 
work nevertheless provide evidence for an involvement of T. brucei PKA-like kinase in 
relaying extracellular cues. This is suggested from an increase in in vivo PKA activity in 
the presence of treatments that have either been shown to induce LS to SS differentiation 
(etazolate) or to participate in SS to PCF differentiation (cold shock, mild acid stress). In 
addition, in vivo PKA activity was stimulated with the PDE inhibitor dipyridamole and at 
hypoosmotic stress.
VI
Abstract
In the context of a putative role for T. brucei PKA-like kinase in the regulation of 
differentiation, two of the catalytic isoforms (PKAC1 and PKAC2) were of particular 
interest. We found significant life cycle stage dependent differences in protein expression 
between the two almost identical isoforms. PKAC1 was nearly exclusively present in 
bloodstream forms and PKAC2 in procyclic cells. In addition, PKAC1, but not PKAC2 
carries a phosphorylation that is restricted to the SS stage. This phosphorylation was 
mapped to the C-terminal threonine 324 by mass spectrometry. The functions of these 
life cycle stage dependent differences between PKAC1 and PKAC2 remain unknown. 
Reverse genetics did not reveal any functional differences between the isoforms, in fact, 
PKAC1 was even able to complement PKAC2 in procyclic PKAC2 knock-out cells. 
Results from several reverse genetic experiments indicate that T. brucei PKA-like kinase 
plays an important role in cell division. Depletion of either PKA-like subunit leads to a 
cytokinesis block. Depletion of the regulatory PKA-like subunit additionally results in 
altered basal body segregation. Given that 1) both cytokinesis and basal body movement 
had been previously suggested to be regulated by the trypanosomal flagellum (Kohl et 
al., 2003) and 2) the flagellum hosts T. brucei PKA-like kinase (C. Krumbholz, this lab) 
we propose that trypanosomal flagella act as signaling compartments for coordination of 
cell division.
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Introduction
1
1.  Introduction
1.1.  Trypanosoma brucei
1.1.1.  Morphology, phylogeny and pathogenicity
Trypanosoma brucei is an eucaryotic parasite that belongs to the order of kinetoplastida. 
This unicellular organism has a length of approximately 20 µm and a flagellum 
attached to its cell body. The name giving kinetoplast, containing the DNA of the single 
mitochondrion, is located near the basal body. (Fig. 1A) Subspecies of T. brucei are the 
causative agents of African trypanosomiasis or sleeping sickness, a disease of tropical 
Africa that is transmitted by the tsetse fly. Gambian or West African sleeping sickness 
is due to the infection with T. brucei gambiense and Rhodesian or East African sleeping 
sickness is due to the infection with T. brucei rhodesiense (Fig. 1B). 
T.b. gambiense
T.b. rhodesiense
No risk
At risk
Endemic
High endemic
Epidemic
Trypanosomiasis
BA
Nucleus
Mitochondrion
Kinetoplast
Flagellum
Flagellar
pocket
Basal
body
Pro-basal
body
Sub-pellicular
microtubules
4 specialised
microtubules
Fig. 1:
A) Schematic representation of a T. brucei cell on the basis of electron microscopy studies. The relative
positions of organelles such as the nucleus (dark blue), kinetoplast (light blue), mitochnodrion (green),
basal and probasal bodies (red and yellow respectively) and the flagellum are shown. (Picture taken from
Vaughan et al. (2003))
B) Geographical extension of T. b. gambiense and T. b. rhodesiense in Africa. (WHO 1999)
African sleeping sickness is a daily threat to more than 60 million people, in 36 countries 
of sub-Saharan Africa, 22 of which are among the poorest countries in the world. Only 3 
to 4 million of these people have access to medical treatment and surveillance. 45,000 
cases of sleeping sickness were reported to the WHO in 1999, but the estimated number 
of people thought to have the disease is between 300,000 and 500,000 (WHO, 2001). 
African sleeping sickness can be treated, when diagnosed at an early stage, although 
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the drugs in use are often too expensive for the African developing countries. At late 
stages, the disease can only be cured with Melarsopol that is very toxic but so far the only 
available drug that can pass the blood brain barrier. 
Other T. brucei subspecies, among them T. brucei brucei, cause the related cattle 
disease Nagana and are a major economical problem in tropical Africa, but do not affect 
humans. 
1.1.2. Life cycle
Trypanosomes undergo major morphological and metabolic changes during their complex 
life cycle (Fig. 2). These changes are further characterized by the alternate occurrence 
of proliferating and cell cycle arrested forms. It is of vital importance for trypanosomes to 
adapt quickly to new environments as different as the mammal blood and the tsetse fly 
midgut. 
Metacyclic, non-proliferating trypanosomes are transferred via insect bite to the 
dermal tissue of the mammal where they transform into proliferating long slender (LS) 
trypanosomes and cause a local inflammation (shanker). Later they invade blood and 
lymph, which is accompanied by irregular fever and headaches of the affected host. In 
the second phase of the infection trypanosomes cross the blood brain barrier and reside 
in the cerebrospinal fluid. At this stage the host is suffering from chronic sleep disorders, 
apathy, tremor and paralysis.
LS trypanosomes are mainly present at the early stages of the infection. They exclusively 
metabolize the abundant glucose present in the blood of the mammalian host. Their 
mitochondrion is not actively engaged in energy production and most respiratory chain 
enzymes are missing. LS trypanosomes therefore depend entirely on glycolysis which 
takes place in special organelles, the glycosomes. When cells reach a threshold density, 
they differentiate into cell cycle arrested short stumpy forms (SS). SS forms differ 
morphologically from LS cells by their more compact shape and shorter flagellum. They 
are metabolically preadapted to their life in the tsetse midgut with proline as main energy 
source. Their mitochondrion is enlarged (Priest and Hajduk, 1994) and mitochondrial 
enzymes, such as pyruvate dehydrogenase, proline oxidase and α ketoglutarate 
dehydrogenase are expressed (Flynn and Bowmann, 1973). When SS forms are not 
taken up by a tsetse fly they die within three to four days. The occurrence of the cell cycle 
arrested SS forms is thought to be important to control the parasitaemia and prevent an 
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early death of the host. Since only a fraction of the LS cells differentiates into SS cells, the 
blood stream form population (BSF) is a mixture of LS and SS cells. This heterogeneous 
population is termed pleomorphic. The surface of BSF trypanosomes is completely 
covered with the variant surface glycoprotein (VSG). By antigenic variation (described 
below) this specific VSG can be exchanged. This process allows clonal variants in the 
switching population to persist the host immune system. During the bloodmeal of the 
tsetse fly on an infected mammalian host, SS cells are transmitted back to the tsetse 
vector into its midgut. There they differentiate into proliferating procyclic cell forms (PCF). 
This process takes 48 to 72 hours and is called transformation. 
Proliferating
Cell cycle arrested
Procyclin surface coat
Variant surface glycoprotein (VSG)
surface coat
Procyclic
Epimastigote
Short stumpy
Tsetse midgut
Tsetse salivary
glands
Mammalian
bloodstream
Metacyclic Long
slender
Fig. 2:
Schematic view of the T. brucei life cycle. Profound changes in morphology, surface coat, metabolism and
cell cycle phase are indicated. (Picture modified from McKean 2003)
The cell surface of PCFs is now covered by procyclin (Roditi et al., 1989). Procyclic cells 
are longer than BSF cells, they have a very large mitochondrion, which is metabolically 
active and has a complete respiratory chain (Priest and Hajduk, 1994; Van Weelden 
et al., 2003; Rivière et al., 2004; Hannaert et al., 2003). After ten days, procyclic cells 
differentiate into cell cycle arrested proventricular mesocyclic forms (not shown in figure 
2) that migrate into the salivary glands. Here they transform into proliferating epimastigote 
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forms that attach their flagella to the microvilli of the epithelial cells. Epimastigote forms 
differentiate into metacyclic forms that are cell cycle arrested and express VSG. They are 
transferred to the mammalian host during the tsetse blood meal and the life cycle starts 
again. 
1.1.3. Cell cycle
Trypanosoma brucei possess an unusually large number of single copy organelles/
compartments such as the kinetoplast, the flagellum, the mitochondrion, the lysosom 
and the Golgi apparatus. During cell division, these components must replicate and 
segregate correctly to ensure the survival of the daughter cells. The order and timing 
of the T. brucei cell cycle events have been subjects of extensive studies (reviewed in 
McKean 2003) and novel cell cycle control mechanisms have been found (Hammarton et 
al., 2003b; Ploubidou et al., 1999, compare also 1.2.). The cell cycle is initiated with the 
elongation and maturation of the pro-basal body and the nucleation of a new flagellum. 
Subsequently, the DNA of the kinetoplast and the nucleus is replicated, whereby 
kinetoplast S phase initiates before the onset of nuclear S phase and is considerably 
shorter. Early in G2 phase of the nuclear cycle, basal bodies separate in a microtubule-
mediated process also resulting in the separation of the kinetoplasts (Robinson et al., 
1991) that are coupled to the basal bodies via the tripartite attachment complex (TAC) 
(Ogbadoyi et al., 2003). Mitosis occurs with an intranuclear spindle without the disruption 
of the nuclear envelope. The actual mechanism of chromosome segregation remains 
unknown, since the number of chromosomes outnumbers the number of kinetochores 
(Ogbadoyi et al., 2000; Gull et al., 1998). The cell cycle is completed by cytokinesis with 
the formation of the cleavage furrow along the entire longitudinal axis of the dividing 
trypanosome. 
The T. brucei cell cycle can be easily studied when the nuclei and kinetoplasts are stained 
with the DNA dye DAPI. Thereby the kinetoplast provides a usefull additional marker for 
the classification of each individual cell to a certain cell cycle phases. Cells are classified 
as either 1K1N, 2K1N or 2K2N cells, according to the number of their nuclei (N) and 
kinetoplasts (K). 1K2N cells do not exist since the kinetoplasts always segregate before 
the nucleus divides. Disruptions of the cell cycle may led to the occurrence of abnormal 
K/N configurations such as 0K1N, 1K0N (zoid), 1K2N or 4K4N. 
Introduction
5
1.1.4.  Unusual biological features
Kinetoplastida diverged early on during evolution from the eukaryotic main branch. 
Thus, they possess several unique and unusual biological features that make them very 
interesting research subjects, not only for parasitologists.
T. brucei first became famous for a process called antigenic variation, a mechanism that 
the parasite has established to escape the host immune system by frequently changing 
the cell surface coat (reviewed in Borst 2002; Pays et al., 2001; Cross et al., 1998 and 
others). Each T. brucei cell is completely covered with VSG protein that is transcribed 
from a telomeric expression site. About 20 of such expression sites exist in each cell, 
but only one is active at any given time, transcribing only one specific VSG. With a 
certain frequency, one out of around 1000 different VSG genes that are present in the 
T. brucei genome can replace the VSG gene in the active expression site by reciprocal 
recombination or gene conversion. The rate of VSG switching is between 10-3 to 10-2 per 
division for trypanosomes that have recently passed trough the tsetse fly (Turner and 
Barry, 1989) and 10-6 to 10-7 for culture adapted trypanosome strains. While most of the 
trypanosome population express the same VSG molecule at their cell surface and will be 
finally killed, a small subpopulation is always able to express a different VSG gene and 
escape the attacks of the immune system.
Another quite unusual feature of this eukaryotic parasite is its mechanism of mRNA 
processing and gene regulation that involves polycistronic transcription and trans 
splicing. The protein-coding genes of T. brucei are devoid of class II introns and are 
packed in dense clusters containing both tandem repeats of the same or very similar 
ORF and completely unrelated ORFs. The intergenic regions are very short. The 
gene arrays are transcribed in long polycistronic units. Individual mature mRNAs are 
processed from primary transcripts by the addition of a cap at the 5ʼ end through trans 
splicing and a poly (A) tail at the 3ʼ end (reviewed in Tschudi et al., 2002). The cap donor 
is a spliced leader, termed miniexon, arising from the processing of a miniexon donor 
RNA (141 nucleotides). It is transcribed on arrays of repeated genes. Most interestingly, 
genes of the same primary transcription unit can show remarkably different expression 
patterns even though the transcription is regulated from the same promoter (reviewed in 
Vanhamme and Pays, 1995). This led to the major conclusion that trypanosomes control 
their gene expression primarily on the posttranscriptional level.
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1.1.5.  T. brucei strains in the laboratory
In vitro culture systems are available for bloodstream and procyclic stage Trypanosoma 
brucei (Brun and Schonenberger, 1979; Hirumi and Hirumi, 1989; Vassella et al., 1996); 
other developmental stages can only be analyzed in the tsetse host. To avoid the 
problem that all pleomorphic trypanosomes differentiate into non-proliferating SS forms, 
most research is done with the so-called monomorphic strains. These cells were adapted 
to laboratory growth by serial syringe passages between rodents (Ashcroft, 1960). They 
can be kept at relatively high cell densities and have lost their ability to differentiate into 
SS forms. However, when monomorphic cells grow to high cell densities, they acquire 
some functional and metabolic features of short stumpy cells (Breidbach et al., 2002). 
In vitro cultured monomorphic and pleomorphic BSF trypanosomes can be induced to 
transform into procyclic cells by the addition of citrate or cis-aconitate and by a decrease 
in cultivation temperature (Brun and Schonenberger, 1981; Simpson et al., 1985; Engstler 
and Boshart, 2004; reviewed in Matthews and Gull, 1994).
1.1.6.  Methods of genetic manipulation
The haploid genome of T. brucei is about 35 Mb and varies in size between the different 
trypanosoma strains in as much as 25%. It contains around 10,000 genes or predicted 
genes. The DNA of the diploid organism is organized in three size classes of chromosomes: 
the megabase chromosomes of which there are at least 11 pairs ranging from 1 to 6 Mb 
in size (numbered I-XI from smallest to largest), several intermediate chromosomes of 
uncertain ploidy ranging from 200 to 900 kb and about 100 linear minichromosomes of 
50 to 150 kb. Around 50% of the DNA sequence is coding. (Reviewed in El Sayed et al., 
2000) The 11 megabase chromosomes of the T. brucei strain TREU927/4 GUTat10.1 
were completely sequenced by the Institute for Genomic Research (TIGR) and the 
Welcome Trust Sanger Institute.  
The availibility of the T. brucei genome sequence greatly facilitates the application of 
reverse genetic methods for the analyses of protein functions. Both monomorphic and 
pleomorphic BSF and procyclic trypanosomes can be genetically manipulated by DNA 
transformation (reviewd in McCulloch et al., 2004). Stable transformants are generally 
obtained by homologous recombination of the DNA of interest together with a dominant 
selection marker gene into the target locus. In this way genes can be altered or deleted, 
expression levels changed, transgenes can be introduced and even gene-knock-downs 
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by inducible expression of double strand RNA (RNA interference) are possible. Two 
types of targeting vectors that differ in their integration mechanisms are used in T. brucei. 
The ends-in-recombination type (reviewed in Paques et al., 1999 and Symington et al., 
2002) is shown in figure 3a. A double strand break is introduced into the cloned targeting 
sequence usually by a restriction digest. After transforming T. brucei with the linear 
plasmid, the DNA is integrated into the homologous chromosomal sequence by a gene 
conversion mechanism subsequently followed by a crossing over event. This type of 
targeting vector results in the duplication of the targeting sequence and is generally used 
for the insertion of parasite-derived or foreign DNA into novel locations. The second type 
of targeting vector relies on gene replacement for transformation of the organism (ends-
out recombination (Fig. 3b)). 
linear ends-in plasmid
linear ends-out plasmid
chromosomal target
Fig. 3:
Mechanism of ends-in recombination (A) and ends-out recombination (B) to integrate a transformed
plasmid into a homologous locus in the T. brucei genome. (modified from Mc Culloch et al., 2004)
A B
chromosomal target
1.1.6.1.  Gene mutation and deletion 
For gene mutations and deletions parasites are transformed with DNA that contains both 
the mutated gene and a selection marker. Both ends of the linear DNA integrate into the 
genome by homologous recombination and result in the replacement of the WT gene by 
the mutated gene. For gene mutations, the selection marker is placed in front or behind 
the gene, whereas for gene deletions, the selection marker is placed in the open reading 
frame and substitutes part of the gene. Since T. brucei is a diploid organism, two rounds 
of transfections with two different selection markers are necessary to obtain knock-out 
cells. No promoter is required for the expression of the selection marker, which has the 
advantage that no downstream genes are affected. 
1.1.6.2.  Expression of transgenes
The expression of transgenes is achieved in two ways: For constitutive expression, the 
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gene of interest together with a selection marker is targeted to intergenic regions of T. 
brucei multigenic arrays such as the RNA polymerase I large subunit locus. Alternatively, 
gene and selection marker are targeted in reverse orientation to chromosomal 
transcription or to untranscribed regions in the T. brucei genome, such as the ribosomal 
DNA spacer or the silent VSG gene arrays. The promoter must then be included in the 
expression vector and can be inducible.
The first generation of inducible expression systems for T. brucei was developed in 1995 
(Wirtz et al., 1995). Two tetracycline repressor binding sites were added to the T. brucei 
derived PARP (procyclin acidic repetitive protein) promoter in an expression vector and 
the construct was transfected in a cell line that constitutively expressed the prokaryotic 
tetracycline repressor. From here on both the expression vectors and the expressing 
cell lines were improved to decrease leakiness and to enable the inducible expression 
of toxic gene products (Biebinger et al., 1997; Wirtz et al., 1999; Clayton laboratory, 
unpublished). The cell lines 13-90 (Wirtz et al., 1999), as well as the 1313-514 BSF 
and PCF cell lines (Clayton laboratory, 2003), constitutively express prokaryotic T7 
polymerase and tetracycline repressor and are used for the expression of T7 promoter 
driven genes or selection markers, examples being pLEW82 and pLEW100 (Wirtz et al., 
1999). pLEW82 has a tetracycline inducible T7 promoter that drives both the expression of 
the target gene and of the selection marker. Since the cell line must be established in the 
presence of tetracycline, it is only suitable for the expression of non-toxic gene products. 
By the addition of a second promoter, this problem has been overcome (pLEW100). 
The selection marker is driven by a constitutively active T7 promoter, while the gene of 
interest is driven by a tetracycline inducible PARP promoter. To avoid any read-through, 
this promoter has been placed in the opposite direction to the T7 promoter. 
1.1.6.3.  RNA interference
RNA interference was first discovered in C. elegans (Fire et al., 1998) and shortly thereafter 
proved to be a very useful tool for inducible gene knockdown in many organisms, among 
them T. brucei. In pinciple, dsRNA is processed by a ribonuclease III enzyme (DICER) into 
small interfering RNAs (siRNAs). These siRNAs direct the cleavage of the homologous 
mRNA via an RNA-induced silencing complex (RISC) (reviewed in Hannon, 2002; Ullu et 
al., 2004; Tschudi et al., 2003).
Different methods were successfully used for the introduction of dsRNA into 
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trypanosomes: dsRNA was simply transfected (Ngo et al., 1998) or it was transcribed 
as inverted repeats from a transfected vector (Shi et al., 2000; Bastin et al., 2000). The 
easiest way is to transcribe dsRNA from a single vector that has two promoters. These 
promoters are arranged as inverted repeats and transcribe the target DNA sequence in 
both directions, generating sense and anti-sense RNA very closely together. An example 
is the p2T7 vector (used in this work) that has two T7 promoters and is used for inducible 
RNA interference upon transfection in the 13-90 cell line (LaCount et al., 2000). 
1.2.  Signal transduction in Trypanosomatidae
The ability to sense environmental signals is of vital importance for all organisms, 
including trypanosomatidae. In fact, the parasitic flagellates even have some special 
requirements to signaling pathway since they must frequently respond to extracellular 
signals as they adapt to new environments within their different hosts. 
The following chapter gives an overview on what is currently known about signal 
transduction mechanisms in Trypanosomatidae. Thereby the focus lies on the control of 
life cycle and cell cycle, thus the main processes that characterize the life of the single 
cell organisms.
Cell cycle regulation has been studied in T. brucei, T. cruzi, L. major and L. mexicana 
and orthologues of many key molecules that are involved in cell cycle regulation of 
higher eukaryotes have been identified. These include cyclins and cyclin dependent 
protein kinases as well as kinases of the MAP/MOK pathway (reviewed in Hammarton 
et al., 2003b). Furthermore, the number of cyclins appears to be unusually high in 
trypanosomatidae. This could be an adaptation to the complexity of the parasitic life 
cycles with their alternating cell cycle arrested and proliferating stages that might require 
additional regulations not needed in other eukaryotes. Some of these cyclins and cyclin 
dependent protein kinases have been characterized. Thereby it was found that T. brucei 
lacks some of the classical cell cycle checkpoints and, interestingly, that cell cycle 
regulation differs between the life cycle stages of the parasite (Ploubidou et al., 1999; 
Hammarton et al., 2003a; Li et al., 2003). Thus, the mitotic exit checkpoint is absent 
in procyclic cells but present in blood stream forms. Cells from both life cycle stages 
obviously lack the G1 checkpoint, since neither S-phase nor organelle segregation is 
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prevented in the absence of cytokinesis. Another surprising result was that the nearly 
synchronous cell cycles of nucleus and kinetoplast are independently regulated (Das et 
al., 1994; Hammarton et al., 2003a).
Life cycle regulation of kinetoplastida is still poorly understood. There is some evidence 
that both calcium and cyclic AMP are involved in life cycle regulation of various 
Trypanosomatidae (Lammel et al., 1996; Stojdl et al., 1996; Sarkar et al., 1995; Strickler 
et al., 1975; Rangel-Aldao et al., 1987; Gonzales-Perdomo et al., 1988; Vassella et al., 
1997; Rolin et al., 1993; Walter et al., 1978). In addition, free fatty acids have been shown 
to induce differentiation from metacyclic to epimastigote forms in T. cruzi (Wainszelbaum 
et al., 2003). Inositolphosphoceramide is thought to be involved in the differentiation from 
metacyclic into amastigote T. cruzi forms (Salto et al., 2003). Some kinases or kinase 
activities of T. brucei have been suggested to participate in differentiation, including 
a MAP kinase and a zinc finger kinase (Aboagye-Kwarteng et al., 1991; Parsons et 
al., 1991; Parsons et al., 1993; Müller et al., 2002; Vassella et al., 2001). However, no 
connection was yet established between the different factors that are thought to influence 
differentiation and none of the underlying signaling pathways is known. 
In T. brucei, the studying of life cycle regulation became feasible with the establishment of 
an in vitro culture system for bloodstream form trypanosomes in our laboratory (Vassella 
et al., 1996). Thereby it was found that LS to SS differentiation was dependent on a 
cell density sensing mechanism (Reuner et al., 1997) that is mediated by the so called 
stumpy induction factor (SIF) (Vassella et al., 1997). SIF is a small molecule (<500 Da) 
of unknown nature that is released by the parasites themselves, accumulates at high cell 
densities and mediates differentiation into SS cells via an unknown signaling pathway. 
There is strong evidence for an involvement of cAMP in this pathway, since firstly, SIF 
enriched medium induces an 2 to 3 fold increase in intracellular cAMP and secondly, 
membrane permeable cAMP derivatives and phosphodiesterase inhibitors exactly mimic 
SIF activity.
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1.3.  cAMP signaling
Cyclic AMP is the first second messenger that was discovered more than 40 years ago 
(Rall et al., 1956). Since then it has been detected in most organisms. The components 
of the cAMP signaling pathway are well described and some are already used as drug 
targets for various clinical applications.
In higher eukaryotes, the cAMP signaling pathway is initiated by receptor mediated 
activation of heterotrimeric G-proteins that then either activate or inhibit adenylyl cyclases 
(ACs). Active ACs synthesize cyclic AMP from ATP. In eukaryotic cells the current view 
is that the majority of the cAMP signals are mediated via the activation of protein kinase 
A (PKA) and subsequent phosphorylation of various downstream factors, such as 
transcription factors, cytoskeletal proteins or metabolic enzymes. Degradation of cAMP 
to AMP is catalyzed by phosphodiesterases (PDEs).
Dictyostelium is the best examined example for cAMP dependent signaling pathways 
in lower eukaryotes. In the slime mold, cAMP functions both as first messenger outside 
the cell and as second messenger inside. It acts on chemotaxis and gene regulation, as 
well as on differentiation and development (reviewed in Saran et al., 2002). In most of 
the lower eukaryotes examined to date cAMP regulates differentiation processes and its 
effects are directly mediated by the activation of a PKA. 
The earliest publications on cyclic AMP signaling in Trypanosomatidae range back as 
far as 1974, when both an AC and a PDE activity was found in Trypanosoma gambiense 
(Walter 1974; Walter et al., 1974). Since then cyclic AMP has been suggested to 
participate in the regulation of vitally important processes in many kinetoplastida, 
including life cycle  (compare 1.2.) and host-parasite interactions (Dey et al., 1995; Von 
Kreuter et al., 1995).
There is evidence, that the cAMP signaling pathway of kinetoplastida differs from that of 
other eukaryotes. In fact, trimeric G-proteins appear to be absent in trypanosomatidae 
and it is assumed that the extracellular signal is directly sensed by adenylate cyclases 
instead. These consist of only one single transmembrane helix with a large extracellular 
domain  (Sanchez et al., 1995; Alexandre et al., 1990; Bieger et al., 2001) and thus have 
more similarities to mammalian guanylyl cyclases than to mammalian ACs that consist 
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of two bundles of six transmembrane helices each. Interestingly, T. brucei possess more 
than 100 different genes for adenylate cyclases which is around ten times more than 
have organisms with much higher complexity (Seebeck, 2001). This strongly implicates 
that cAMP signaling is a very important signaling pathway in kinetoplastida that might in 
future even surprise with an unusually high complexity. 
Phosphodiesterases have been described in various kinetoplastida (Goncalves et al., 
1980; Téllez-Inón et al., 1985; DʼAngelo et al., 2004; Zoraghi et al., 2001; Zoraghi et 
al., 2002; Gong et al., 2001; Kunz et al., 2004; Rascón et al., 2002; Walter et al., 1974; 
Rascón et al., 2000) and appear to be similar to mammalian PDEs. The best examined 
examples are the six PDEs from T. brucei out of which four have been extensively studied 
(reviewed in Seebeck, 2001). They all belong to the class I (or mammalian) PDE family 
and are highly specific for cAMP.  
1.4. cAMP dependent protein kinases
The classical cAMP receptor of higher eukaryotes, protein kinase A (PKA), exists in most 
organisms as a heterotetrameric holoenzyme consisting of two catalytic (C) and two 
regulatory (R) subunits. Catalytic PKA subunits nearly exclusively consist of a kinase 
domain and their function is restricted to their kinase activity. Regulatory PKA subunits 
regulate PKA activity by binding and inhibiting the catalytic subunits in the absence 
of cAMP. This binding is mainly mediated by a conserved sequence stretch in the R 
subunit (R R X [A/T/S] Ψ; Ψ=hydrophobic amino acid) that also exists in PKA substrates 
(substrate or pseudosubstrate sequence). In addition, regulatory subunits also mediate 
the formation of the tetrameric PKA holoenzyme by their N-terminal dimerization/docking 
domain that enables the dimerization of two regulatory PKA subunits. This dimerization/
docking domain also binds to A kinase anchoring proteins (AKAPs) that target PKA to 
specific subcellular locations. 
PKA activation is achieved by the release of the catalytic subunits from the holoenzyme 
complex caused by cAMP induced conformational changes in the regulatory subunits 
(Fig. 4). PKA substrates include transcription factors, signal transduction components 
and metabolic enzymes (reviewed in Shabb 2001).  
Diversity and presumably specificity of the cAMP signal is achieved by the existence of 
several different PKAC and PKAR isoforms and AKAPs that are distinctly expressed in 
Introduction
13
different cells and tissues (reviewed in Skalhegg and Tasken, 2000).
The best examined non-mammalian PKA is that of the slime mold Dictyostelium: In 
contrast to PKAs from higher eukaryotes, it has a dimeric structure out of only one 
regulatory and one catalytic subunit (Mutzel et al., 1987). PKA activity is regulated by 
cAMP and also, at the onset of starvation, by transcriptional control (Souza et al., 1999).
active catalytic
subunits
complex of cAMP
and regulatory
subunits
cAMP
inactive catalytic
subunit
regulatory
subunit
inactive
PKA
Fig. 4: Activation of protein kinase A
Conformational change of the R subunit is achieved upon binding of two molecules of cAMP. The catalytic 
subunits are set free and become active. (Picture taken from molecular biology of the cell 3rd edition)
In kinetoplastida, the existence of a cAMP dependent protein kinase still remains unclear, 
even though several orthologous proteins for catalytic or regulatory PKA subunits have 
been meanwhile cloned (Siman-Tov et al., 1996; Siman-Tov et al., 2002; Huang et al., 
2002; Shalaby et al., 2001). The so far only report about a cAMP dependent kinase 
activity in kinetoplastida comes from Trypanosoma cruzi (Ulloa et al., 1988) but has so far 
not been reproduced.
1.5. The T. brucei PKA-like kinase and aims of this Ph.D. project
Interest in our laboratory on cAMP dependent protein kinases origins from earlier studies 
on the differentiation of LS to SS trypanosomes, a process that appears to involve 
cAMP (Vassella et al., 1997; compare 1.2.). In search of the T. brucei cAMP receptor, 
three ortholgous proteins for catalytic PKA subunits (PKAC1, PKAC2, PKAC3) and 
one ortholgous protein for a regulatory PKA subunit (PKAR) have been cloned from (T. 
Klöckner, Ph.D. thesis 1996; C. Schulte zu Sodingen, 2000). 
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The catalytic PKA-like subunits exhibit all features that characterize a classical cAMP 
dependent protein kinase. They phosphorylate the PKA specific substrate kemptide 
and are inhibitable by the PKA specific inhibitor PKI. Recombinant PKAC3 even forms 
a heterologous holoenzyme complex with mammalian PKA subunits that dissociates 
in the presence of cAMP (N. Wild, unpublished). Given that T. brucei PKA-like kinase 
is considered as a potential regulator of differentiation, two of the catalytic PKA-like 
subunits (PKAC1 and PKAC2) are of particular interest: PKAC1 and PKAC2 expression 
was found to be developmentally regulated (E. Vassella, unpublished). Additionaly, life 
cycle stage dependent posttranslational modifications were detected in these isoforms 
(S. Schimpf, Diploma thesis 2000, T. Klöckner, Ph.D. thesis 1996). 
First aim of this Ph.D. project was therefore to characterize both PKAC1 and PKAC2 
biochemically and functionally in vivo.
The regulatory PKA-like subunit of T. brucei has an unusually long N-terminus that 
is devoid of a dimerization domain. Apart from that, TbPKAR possess all features of 
a typical PKAR subunit, such as two predicted cNMP binding sites in tandem and a 
classical inhibitor sequence that mediates the binding to the catalytic subunit. In fact, 
coimmunoprecipitation studies revealed that T. brucei PKAR is able to bind each of the 
catalytic T. brucei PKA-like subunits, which was the first proof for the existence of a 
PKA-like holoenzyme in T. brucei (C. Schulte zu Sodingen, Ph.D. thesis 2000). Given 
that the T. brucei PKA-like kinase appears to possess all characteristics of a classical 
cAMP dependent protein kinase, it came as a surprise that the kinase was not activable 
with cyclic AMP. This was not only true for immunopurified PKA-like kinase but also for 
(PKI-inhibitable) kinase activity in crude cell extracts, thus in the absence of most in vitro 
artefacts. 
Second major aim of this Ph.D. project was therefore to discover the mechanism of 
activation for T. brucei PKA-like kinase. This was approached in two different ways: First 
it was planed to test further cyclic nucleotides on their abilities to activate T. brucei PKA-
like kinase. The second approach was to establish an in vivo assay for PKA activity in T. 
brucei. This way kinase activity can be studied in its native subcellular environment that 
might be required for kinase activation.
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What is the function of this PKA-like kinase that appears to be insensitive towards cyclic 
AMP? Even though it might possibly not act as the receptor of the cAMP signal that is 
thought to regulate differentiation, the kinase nevertheless appears to have an important, 
probably essential function. This is suggested from the failure to genetically knock-out 
any PKA-like subunit in BSF trypanosomes. 
Further major aim of this Ph.D. project was therefore to investigate the function of this 
interesting, T. brucei PKA-like kinase with its yet undefined mechanism of activation. For 
this, it was aimed to take advantage of the whole spectrum of reverse genetic tools that is 
currently available for T. brucei. Especially the method of inducible gene knock-down by 
RNA interference that has been recently established in T. brucei (compare 1.1.6.3.) was 
most promising since it allows to functionally analyze even essential genes. 
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2. Materials and Methods
2.1. Material
2.1.1. Trypanosoma strains
2.1.1.1. Wild type strains
MITat1.2 (NY subclone) monomorphic PCF and BSF    Cross and Manning, 1973; Cross, 1975
Note that the Bern subclone of MITat1.2 (I. Roditi) has an additional PKAC allele that has the 5ʼpart of  PKAC2 and the 3ʼ part of PKAC1
(Data not shown in this work). 
MITat1.4 G. Cross, New York
AnTat1.1 (Antwerp Trypanozoon antigen type 1.1)
P. Overath, Tübingen
Geigy et al., 1975; Delauw et al., 1985
2.1.1.2. Transgenic strains
Transgenic cell lines have been named according to the T. brucei community nomenclature 
rules of Clayton et al. (1998). However, in most cases alternative names will be used in 
this thesis to facilitate reading. In the tables below, these names are indicated in bold 
letters (headline). In some cases, more than one name exists for the same cell line, which 
is then shown as “alternative name”. All transgenic cell lines that have been generated 
in this Ph.D. project are listed. In addition, two cell lines are listed, that have been used 
but were already available. An overview about all transgenic cell lines used in this work 
is given in attachment 5.
MITat1.4 Ty1-PKAC1 1
Made by: Paul Hassan
Name according to nomenclature: MITat1.4 ∆pkac1::BSD / PKAC1::ty1-pkac1 BLE
Alternative name: (Pauls MITats)
Clone or pool number(s): clone 1
Date of construction: 2000
Contains the Constructs: pTy1-PKAC1 
p∆PKAC1BSD
Selection markers: blasticidin [2 µg/ml]; phleomycin [2 µg/ml]
Note:
The cell line was later shown not to be derived from MITat1.4, 
it is probably MITat1.2 Bern subclone. It was only used for the 
purification of Ty1-PKAC1 for mass spectrometry.
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Ty1-T324 2
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone ∆pkac1::BSD / PKAC1::ty1-pkac1 BLE
Alternative name: PKAC1 k.o / Ty1-T324
Clone or pool number(s): clone K6
Date of construction: 7 / 2002
Contains the Construct(s): p∆PKAC1BSD
pTy1-PKAC1 
Selection markers: blasticidin [2 µg/ml]; phleomycin [2 µg/ml]
Note: -
Ty1-E324 3
Made by: S. Kramer
Name according to nomenclature:
MITat1.2 NY subclone ∆pkac1::BSD / PKAC1::ty1-pkac1(T324E) 
BLE
Alternative name: -
Clone or pool number(s): clone G2
Date of construction: 7 / 2002
Contains the Construct(s): p∆PKAC1BSD
pTy1-PKAC1-E324 
Selection markers: blasticidin [2 µg/ml]; phleomycin [2 µg/ml]
Note: -
Ty1-A324 4
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone ∆pkac1::BSD / PKAC1::ty1-pkac1(T324A) 
BLE
Alternative name: -
Clone or pool number(s): clone A1; clone A11, clone A12
Date of construction: 7 / 2002
Contains the Construct(s): p∆PKAC1BSD
pTy1-PKAC1-A324
Selection markers: blasticidin [2 µg/ml]; phleomycin [2 µg/ml]
Note: -
T324 5
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone ∆pkac1::BSD / PKAC1::PKAC1 BLE
Alternative name: -
Clone or pool number(s): clone K2
Date of construction: 11 / 2002
Contains the Construct(s): p∆PKAC1BSD
pPKAC1-T324
Selection markers: blasticidin [2 µg/ml]; phleomycin [2 µg/ml]
Note: -
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A324 6
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone ∆pkac1::BSD / PKAC1::pkac1(T324A) BLE
Alternative name: -
Clone or pool number(s): clone A3
Date of construction: 11 / 2002
Contains the Construct(s): p∆PKAC1BSD
pPKAC1-A324
Selection markers: blasticidin [2 µg/ml]; phleomycin [2 µg/ml]
Note: -
E324 7
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone ∆pkac1::BSD / PKAC1::pkac1(T324E) BLE
Alternative name: -
Clone or pool number(s): clone G2-2
Date of construction: 2 / 2003
Contains the Construct(s): p∆PKAC1BSD
pPKAC1-E324
Selection markers: blasticidin [2 µg/ml]; phleomycin [2 µg/ml]
Note: -
HA-PKAC2 8
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone PKAC2::ha-pkac2 NEO
Alternative name: -
Clone or pool number(s): HA-S2; HA-S4
Date of construction: 2 / 2002
Contains the Construct(s): pHA-PKAC2NEO 
Selection markers: neomycin [2 µg/ml]
Note: -
Ty1-PKAC1 9
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone PKAC1::ty1-pkac1 BLE
Alternative name: -
Clone or pool number(s): clone 1; clone 2
Date of construction: 1 / 2004
Contains the Construct(s): pTy1-PKAC1
Selection markers: pheomycin [2 µg/ml]
Note: -
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Ty1-PKAC3 10
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone RRNA::ty1-pkac3 HYG
Alternative name: -
Clone or pool number(s): Pool
Date of construction: 2 / 2004
Contains the Construct(s): pTSAribTy1-PKAC3
Selection markers: hygromycin [4 µg/ml]
Note: -
Ty1-PKAR 11
Made by: C. Schulte zu Sodingen
Name according to nomenclature: MITat1.2 “single marker” T7POL TETR NEO RDNA::ty1-PKAR BLE
Alternative name: pLew82PKARwttag
Clone or pool number(s): C2
Date of construction: See C. Schulte zu Sodingen
Contains the Construct(s): pLew82Ty1-PKAR
Selection markers: phleomycin [4 µg/ml], select in the presence of tetracycline
Note: -
Ty1-PKAC1 dead 12
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone PKAC1::ty1-pkac1(N165A) BLE
Alternative name: -
Clone or pool number(s): clone 11, clone 12, clone 14
Date of construction: 1 / 2004
Contains the Construct(s): pTy1-PKAC1dead
Selection markers: phleomycin [2 µg/ml]
Note:
The mutation is frequently repaired by gene conversion using the 
WT PKAC1 allele as template.
PKAC2 knock-out 13
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone ∆pkac2::NEO / ∆pkac2::HYG
Alternative name: PKAC2 null mutant
Clone or pool number(s): clone 2-1
Date of construction: 6 / 2002
Contains the Construct(s): p∆PKAC2HYG
p∆PKAC2NEO
Selection markers: hygromycin [1 µg/ml]; neomycin [1 µg/ml]
Note:
This is the only existing clone. Cells were first transfected with 
p∆PKAC2HYG and subsequently with p∆PKAC2NEO.
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PKAC2 hemizygous knock-out 14
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone ∆pkac2::HYG
Alternative name: PKAC2 WT/k.o.
Clone or pool number(s): clone 2
Date of construction: 5 / 2002
Contains the Construct(s): p∆PKAC2HYG
Selection markers: hygromycin [1 µg/ml]
Note: -
PKAC1 hemizygous knock-out 15
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone ∆pkac1::BSD
Alternative name: PKAC1 WT/k.o.
Clone or pool number(s): clone 5
Date of construction: 6 / 2002
Contains the Construct(s): p∆PKAC1BSD 
Selection markers: blasticidin [1 µg/ml]
Note: -
13-90 p2T7 PKAR 16
Made by: S. Kramer
Name according to nomenclature: MITat1.2 13-90 T7POL TETR NEO HYG RDNA::T7POL PKAR BLE
Alternative name: -
Clone or pool number(s): clone 1, clone 4, clone 6, clone 8
Date of construction: 12 / 2000
Contains the Construct(s): p2T7 PKAR
Selection markers: hygromycin [5 µg/ml]; neomycin [2.5µg/ml]; phleomycin [2.5 µg/ml]
Note: -
1313-514 p2T7TAblue PKAC3 17
Made by: S. Kramer
Name according to nomenclature:
MITat 1.2. 1313-514 T7POL TETR NEO BLE RDNA::T7POL 
PKAC3 HYG
Alternative name: -
Clone or pool number(s): clone 1, clone 4, clone 8
Date of construction: 4 / 2004
Contains the Construct(s): p2T7TAblue PKAC3
Selection markers: hygromycin [2 µg/ml]; neomycin [2µg/ml]; phleomycin [0.2 µg/ml]
Note:
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VASP 18
Made by: S. Kramer
Name according to nomenclature: MITat1.2 NY subclone RRNA::VASP HYG
Alternative name: -
Clone or pool number(s): clone 1 (only one clone available)
Date of construction: 9 / 2003
Contains the Construct(s): pTSAribVASP
Selection markers: hygromycin [4µg/ml];
Note:
1313-514 p2T7TAblue PKAC1/2 19
Made by: S. Kramer
Name according to nomenclature:
MITat 1.2 1313-514 T7POL TETR NEO BLE RDNA::T7PRO 
PKAC1 HYG
Alternative name: -
Clone or pool number(s): clone 2, clone 3
Date of construction: 4 / 2004
Contains the Construct(s): p2T7TAblue PKAC1/2
Selection markers: hygromycin [2 µg/ml]; neomycin [2µg/ml]; phleomycin [0.2 µg/ml]
Note:
2.1.2. Bacteria Strains
E. coli DH5 α F
- endA1 hsdR17 (rk
- mk
+) supE44 thi-1 recA1 gyrA (Nalr) relA1 
∆(lacZYA-argF)U169 (f80lacZ∆M15)
M15 Nals Strs rifs lac- ara- gal- mtl- F- recA+ uvr+ 
2.1.3. Antibodies
2.1.3.1. Primary antibodies
name organism origin western IF
anti-PKAC1/2 rabbit T. Klöckner (Ph.D. thesis, 1996) 1:500
anti-PKAR rabbit C. Schulte zu Sodungen (Ph.D. thesis, 
1996)
1:500
anti-HA
Hybridoma (clone 12CA5)
concentrated hybridoma 
supernatant
mouse M. van den Boogard undiluted
anti-Ty1 IgG1-Hybridoma (BB2) mouse K. Gull lab (Manchester) 1:50
anti-Ty1 Ascites mouse M. van den Boogard 1:300
anti-VASP AB19728 rabbit
kind gift from Thomas Renné and Ulrich 
Walter (Medizinische Universitätsklinik 
Würzburg) Halbrügge et al., 1990
1:5000
anti-VASP M4 rabbit immunoGlobe Antikörpertechnik GmbH 1:5000
anti-PFR (L13D6) mouse K. Gull lab (Manchester) 1:2000 1:10
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anti-NUP mouse K. Ersfeld and K. Gull undi-luted
Anti-Digoxigenin-AF Fab 
fragments sheep Roche 1:5000
2.1.3.2 Secondary antibodies
Anti-rabbit-IgG-alcaline phosphatase Böhringer Mannheim
Anti-mouse-IgG-alcaline phosphatase Böhringer Mannheim
Odyssey Infrared Imaging Goat-Anti-Mouse IRDye800 LI-COR
Odyssey Infrared Imaging Goat-Anti-Mouse Alexa680 LI-COR
Odyssey Infrared Imaging Goat-Anti-Rabbit IRDye800 LI-COR
Odyssey Infrared Imaging Goat-Anti-Rabbit Alexa680 LI-COR
Alexa 488 goat Anti-Mouse Molecular Probes
2.1.4. Oligos
Name Sequence Gene Origin
C3-ATG cgggatccATGACGACAACTCCCAC PKAC1 T. Klöckner
C3-Stop ggggtaccgtcgaCTAAAAACCACGGAATG PKAC1 T. Klöckner
PKA-N153>A.u.Eco31I 
ACT GAG GTC TCG GCT CTG CTA CTT GAT 
GGG AAG PKAC1 S. Kramer
PKAC1seq.l.19/7/01 GCA GTG AAA ACC AAG AAA GGG PKAC1 S. Kramer
PKA-N153->A.l.Eco31I
ACT GAG GTC TCT GAG CCT CAG GTT TCA 
AGT CAC G PKAC1 S. Kramer
PKAC1.II.L.11/7/01 GCG CAC GCC CAT ACG TCA TTA TTC AGC PKAC1 S. Kramer
3.7.01 5ʼlower Ala GGC ACG GTC TCG GGG CTA GTG GAG GAG PKAC1 S. Kramer
4.7.01 5ʼupper TAA TGG AGT TGT CAC ACC S. Kramer
PKAC1.II.(T>A).Eco31I
.U.11/7/01 
GTG TCG GTC TCA GCC CCT TCG CAA CAG 
GTT GCA TTC PKAC1 S. Kramer
PKAC1.II.L.11/7/01 GCG CAC GCC CAT ACG TCA TTA TTC AGC PKAC1 S. Kramer
3.7.01 5ʼlower Glu GGC ACG GTC TCG GTT CTA GTG GAG GAG PKAC1 S. Kramer
PKAC1.II.(T>E).Eco31I
.U.11/7/01
GTG TCG GTC TCA GAA CCT TCG CAA CAG 
GTT GCA TTC PKAC1 S. Kramer
19.11.01 ty1/upper CGGTGAGGTCCATACTAAC PKAC1 S.Kramer
HA-SalI-TbPKAC2 upp
AGT TCG AGT CGA CGT ACC CAT ACG ACG 
TCC CAG ACT ACG CTG AAC CGC AAA CGT 
ATG TG
PKAC2 S. Kramer
TbPKAC2-Cterm.lower CTT TAC GAG ATC CCG AGC PKAC2 S. Kramer
34-ATG CGG GAT CCA TGC TGT TGG TGT TAC TT PKAC2 T. Klöckner
34-STOP GGG GTAC CTA AAA CCC ACG GAA CT PKAC2 T. Klöckner
PKAC3HindTy1ATG.u.
CTG GAA GCT TAT GAC CGG TGA GGT CCA 
TAC TAA CCA GGA CCC ACT TGA CAA GTC 
GGA TGG GTG CTT G   
PKAC3 S. Kramer
PKAC3-BamHI CTG GGG ATC CTC AGA TCC TCG TGT ATTC PKAC3 S. Kramer
VASP-HindIII.u ACG TAA GCT TAT GAG CGA GAC GGT CAT C VASP S. Kramer
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VASP-BamHI-l
ACG TGG ATC CTC AGG GAG AAC CCC GCT 
T VASP S. Kramer
2.1.5. Probes
Length [bp] binds to construction
PKAC1/2 1005 full length PKAC1
PCR product from pC3-1 with the oligos C3-
ATG and C3-Stop 
PRP8 1139 3ʼ part of PRP8 XhoI/BglII fragment from pC3-1
MCP 1029 3ʼ part and 3ʼUTR of MCP XhoI/SalI fragment from pC34-1
2.1.6. Constructs
For increased clarity all constructs that have been made or used in this work are 
described together in this chapter rather than in the result section. Complete sequences 
of all constructs are available on the attached CD as GCK files.
Overview about the plasmids that were made or used in this Ph.D. project
1 pTy1-PKAC1 15 pLew82 Ty1-PKAR
2 pTy1-PKAC1-dead 16 p2T7 PKAR
3 pTy1-PKAC1-A324 17 pSL301/PKA-R-YFP_3ʼ_tr1a
4 pTy1-PKAC1-E324 18 p2T7_tiA_GFP
5 pPKAC1-T324 19 pTSArib-Ty1-PKAC3
6 pPKAC1-A324 20 pTSAribVASP
7 pPKAC1-E324 21 Ph.D615neo gamma
8 p∆PKAC1BSD 22 pBlueScript_VASP
9 p∆PKAC2NEO 23 p2T7 PKAC3
10 p∆PKAC2HYG 24 p2T7TA blue
11 pC34-1 25 p2T7TA blue PKAC3
12 pPKAC2NEO 26 p2T7TA blue PKAC1/2
13 pHA-PKAC2NEO 27 p2T7 PKAC1/2
14 pC3-1
pTy1-PKAC1 1
Construction: See N. Wild (pTbPKA alpha N-Ty1 Phleo orgin.)
Date of construction: unknown
Made by: N. Wild
Short description: Upon transfection, one WT PKAC1 allele is replaced by Ty1 epitope 
tagged PKAC1. 
Digest for transfection: HindIII / SdaI
Selection marker: phleomycin [2 µg/ml]
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pTy1-PKAC1-dead 2
Construction:
N153 of PKAC1 was mutated to alanine with the type II restriction 
enzyme Eco31I. Two PCR reactions with the template pTy1-PKAC1 were 
performed using the oligos PKA-N153->A.u.Eco31I and PKAC1seq.l.19/7/
01 (A) and PKA-N153->A.l.Eco31I and PKAC1seq.u.19/7/01 (B). The PCR 
products were digested with Eco31I / BamHI (A) and Eco31I / XbaI (B) and 
both ligated into the XbaI / BamHI digested backbone of pTy1-PKAC1. The 
success of the mutagenesis was confirmed by sequencing (18.6.03).
Date of construction: 6 / 2003
Made by: S. Kramer
Short description: For expression of catalytically inactive Ty1-PKAC1 (dead mutant). 
Digest for transfection: HindIII / SdaI
Selection marker: phleomycin [2 µg/ml]
pTy1-PKAC1-A324 3
Made by: S. Kramer
Construction:
Thr324 of Ty1-PKAC1 was mutated to alanine with the type II restriction 
enzyme Eco31I. Therefore two PCR reactions with the template pTy1-
PKAC1 were performed using the oligos 5ʼlower Ala and 4.7.5ʼupper (A) 
and PKAC1.II.(T>A).Eco31I.U.11/7/01 and PKAC1.II.L.11/7/01 (B). The 
PCR products were digested with Eco31I / XbaI (A) and Eco31I / BamHI 
(B) and both ligated into the XbaI / BamHI prepared backbone of the vector 
pTy1-PKAC1. The success of the site directed mutagenesis was controlled 
by sequencing.
Date of construction: 7/ 2001
Short description:
Threonine 324 of Ty1-PKAC1 was mutated to alanine for functional 
analysis of the stumpy specific phosphorylation. 
Digest for transfection: HindIII / SdaI
Selection marker: phleomycin [1 µg/ml]
pTy1-PKAC1-E324 4
Made by: S. Kramer
Construction:
Thr324 of Ty1-PKAC1 was mutated to alanine with the type II restriction 
enzyme Eco31I. Therefore two PCR reactions with the template pTy1-
PKAC1 were performed using the oligos 5ʼlower Glu and 4.7.5ʼupper (A) 
and PKAC1.II.(T>E).Eco31I.U.11/7/01 and PKAC1.II.L.11/7/01 (B). The 
PCR products were digested with Eco31I / XbaI (A) and Eco31I / BamHI 
(B) and both ligated into the XbaI / BamHI prepared backbone of the vector 
pTy1-PKAC1. The success of the site directed mutagenesis was controlled 
by sequencing.
Date of construction: 7/ 2001
Short description:
Threonine 324 of Ty1-PKAC1 was mutated to glutamate for functional 
analyses of the stumpy specific phosphorylation. 
Digest for transfection: HindIII / SdaI
Selection marker: phleomycin [1 µg/ml]
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pPKAC1-T324 5
Made by: S. Kramer
Construction: The Ty1 epitope tag of pTy1-PKAC1 was removed by digestion with AgeI 
and subsequent religation. 
Date of construction: 9 / 2002
Short description: Targeting construct for PKAC1 without Ty1 epitope tag. Used as control 
for the functional analysis of the stumpy specific phosphorylation. 
Digest for transfection: Hind III / SdaI
Selection marker: phleomycin [1 µg/ml]
pPKAC1-A324 6
Made by: S. Kramer
Construction: The Ty1 epitope tag of pTy1-PKAC1A324 was removed by digestion with 
AgeI and subsequent religation. 
Date of construction: 9 / 2002
Short description: Targeting construct for PKAC1 (T324->A) without Ty1 epitope tag. Used 
for the functional analysis of the stumpy specific phosphorylation. 
Digest for transfection: Hind III / SdaI
Selection marker: phleomycin [1 µg/ml]
pPKAC1-E324 7
Made by: S. Kramer
Construction:
The Ty1 epitope tag of pTy1-PKAC1E324 was removed by digestion 
with AgeI and subsequent religation. The construct was controlled by 
restriction analyses.
Date of construction: 9 / 2002
Short description: Targeting construct for PKAC1 (T324->E) without Ty1 epitope tag. Used 
for the functional analysis of the stumpy specific phosphorylation. 
Digest for transfection: Hind III / SdaI
Selection marker: phleomycin [1 µg/ml]
p∆PKAC1BSD 8
Made by: Paul Hassan (pA5A3BSDnew)
Construction: See P. Hassan
Date of construction: See P. Hassan
Short description: For deletion of one PKAC1 allele. 
Digest for transfection: EcoRI / BglII
Selection marker: blasticidin [1-2 µg/ml]
p∆PKAC2NEO 9
Made by: Paul Hassan (pB5B3NEO)
Construction: See P. Hassan
Date of construction: See P. Hassan
Short description: Deletion of one PKAC2 allele.
Digest for transfection: EcoRI / XmnI
Selection marker: neomycin [1-2 µg/ml]
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p∆PKAC2HYG 10
Made by: Paul Hassan (pB5B3HYGnew)
Construction: See P. Hassan
Date of construction: See P. Hassan
Short description: Deletion of one PKAC2 allele.
Digest for transfection: XcmI / XmnI
Selection marker: hygromycin [1-2 µg/ml]
pC34-1 11
Made by: T. Klöckner
Construction: See T. Klöckner
Date of construction: See T. Klöckner
Short description: Bacterial cloning vector, contains PKAC2 with 3ʼ and 5ʼ UTR and MCP.
Digest for transfection: -
Selection marker: -
pPKAC2NEO 12
Made by: S. Kramer
Construction:
The neomycin phosphotransferase gene of p∆PKAC2Neo was isolated as 
BglII / XbaI fragment, treated with Klenow polymerase and cloned into the 
BsaBI site of pC34-1. 
Date of construction: 12 /2001
Short description: targeting construct for PKAC2, intermediate construct for the construction 
of pHA-PKAC2NEO
Digest for transfection: was never transfected
Selection marker: neomycin [1-2 µg/ml]
                                                                 pHA-PKAC2NEO 13
Made by: S. Kramer
Construction:
The HA epitope tag was introduced at the SalI site of PKAC2 by pcr 
amplification with the primers HA-SalI-TbPKAC2 and TbPKAC2-Cterm.l. 
The PCR product was digested with Sall and EcoRI and exchanged 
against the SalI/EcoRI fragment of pPKAC2NEO.
Date of construction: 1/2001 – 2 /2001
Short description:
Targeting construct for epitope labeling of PKAC2 with the HA tag. Upon 
transfection into trypanosomes one PKAC2 allele is replaced by the N-
terminal HA-epitope tagged PKAC2. The construct was partly sequenced. 
Digest for transfection: ClaI / BstZ17I
Selection marker: neomycin [1-2 µg/ml]
pC3-1 14
Made by: T. Klöckner
Construction: See T. Klöckner
Date of construction: See T. Klöckner
Short description: Bacterial cloning vector that contains the PRP8 sequence; used in this 
work as template for amplification of the PRP8 probe.
Digest for transfection: -
Selection marker: -
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pLEW82 Ty1-PKAR 15
Made by: C. Schulte zu Sodingen (TbRIwttag)
Construction: See C. Schulte zu Sodingen
Date of construction: See C. Schulte zu Sodingen
Short description: expression of Ty1-PKAR in the presence of tetracycline
Digest for transfection: NotI
Selection marker: phleomycin [1-5 µg/ml] only in presence of tetracycline!
p2T7 PKAR 16
Made by: S. Kramer
Construction:
The N-terminal PKAR fragment (501 bp) was mobilized from pSL301/
PKA-R-YFP_3ʼ_tr1a (C. Krumbholz) with EagI and HindIII, the EagI site 
was filled with Klenow polymerase. The RNAi vector p2T7_tiA_GFP was 
equally prepared with BamHI (filled with Klenow polymerase) and HindIII 
and both vector and insert were ligated. 
Date of construction: 11 / 2000
Short description: Construct for inducible RNAi targeted against TbPKAR
Digest for transfection: NotI
Selection marker: phleomycin [3 µg/ml]
pSL301/PKA-R-YFP_3ʼ_tr1a 17
Made by: C. Krumbholz
Construction: See C. Krumbholz
Date of construction: See C. Krumbholz
Short description: Contains PKAR N-terminus; was used for the construction of p2T7-PKAR 
Digest for transfection: -
Selection marker: -
p2T7_tiA_GFP 18
Made by: LaCount et al. (2000)
Construction:
Date of construction:
Short description: Original RNAi vector, contains GFP
Digest for transfection: NotI
Selection marker: phleomycin [3 µg/ml]
pTSArib-Ty1-PKAC3 19
Made by: S. Kramer
Construction:
The Ty1 epitope tag was introduced with PCR. PKAC3 was amplified from 
Ph.D615neo gamma with the primers PKAC3HindTy1ATG.u. and PKAC3-
BamHI and cloned HindIII / BamHI in the equally prepared pTSArib. 
Date of construction: 12 / 2003
Short description: Overexpression of Ty1 epitope tagged PKAC3.
Digest for transfection: SphI
Selection marker: hygromycin [4 µg/ml]
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pTSAribVASP 20
Made by: S. Kramer
Construction:
VASP was amplified from pBlueScript_VASP with the oligos VASP-HindIII.u 
and VASP-BamHI-l. The VASP fragment was cloned BamHI/HindIII in the 
equally prepared pTSArib.
Date of construction: 7 / 2003
Short description: Expression of transgenic VASP in T. brucei as in vivo PKA substrate.
Digest for transfection: SphI
Selection marker: hygromycin [4 µg/ml]
Ph.D615neo gamma 21
Made by: C. Schulte zu Sodingen
Construction: See C. Schulte zu Sodingen
Date of construction: See C. Schulte zu Sodingen
Short description: Used as template for Ty1 epitope tagging of PKAC3.
Digest for transfection: not transfected in this work
Selection marker: neomycin
pBlueScript_VASP 22
Made by: Haffner et al. ,1995
Construction: Cloned via SmaI / PstI
Date of construction:
Short description: Clone p14/1 in pBlueScript 1 SK(-), Acc. No. Z46389
Digest for transfection:
Selection marker:
p2T7 PKAC3 23
Made by: T. Riek
Construction: see T. Riek
Date of construction: see T. Riek
Short description: The PKAC3 fragment of this plasmid was recloned into p2T7TA blue.
Digest for transfection: NotI
Selection marker: phleomycin [2.5 µg/ml]
 
p2T7TA blue 24
Made by: C. Clayton (unpublished)
Construction:
Date of construction:
Short description: original construct from the Clayton laboratory
Digest for transfection: NotI
Selection marker: hygromycin [2 µg/ml]
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p2T7TA blue PKAC3 25
Made by: S. Kramer
Construction: The N-terminal fragment of PKAC3 was transferred from p2T7 PKAC3 (T. 
Riek) into p2T7TA blue using the XhoI and BamHI site.
Date of construction: 3 / 2004
Short description:
Digest for transfection: NotI
Selection marker: hygromycin [2 µg/ml]
p2T7TA blue PKAC1/2 26
Made by: S. Kramer
Construction:
The N-terminal fragment of PKAC1 (corresponding to amino acids 10 to 
216) was recloned from p2T7 PKAC1/2 (P. Hassan) into p2T7TA blue 
using the XhoI and BamHI sites.
Date of construction: 3 / 2004
Short description:
Digest for transfection: NotI
Selection marker: hygromycin [2 µg/ml]
p2T7 PKAC1/2 27
Made by: Paul Hassan
Construction: see Paul Hassan
Date of construction:
Short description: used to reclone PKAC1 into p2T7TAblue
Digest for transfection: NotI, not transfected in this work
Selection marker: phleomycin [3 µg/ml]
2.1.7. Enzymes
Restriction endonucleases NEB, Frankfurt; MBI Fermentas, St. Leon-Rot
T4 DNA Ligase NEB, Frankfurt
Alkaline phosphatase, Calf Intestinal (CIP) NEB, Frankfurt
Klenow Fragment of DNA Polymerase I NEB, Frankfurt
Pfu DNA Polymerase MBI Fermentas, St. Leon-Rot
Expand High Fidelity PCR System Roche, Basel
Expand long Template PCR System Roche, Basel
Pwo DNA Polymerase Roche, Basel
Taq DNA Polymerase Roche, Basel
2.1.8. Chemicals
Standard chemicals Merck, Darmstadt; Roth, Karlsruhe
Radiochemicals Amersham Bioscience, Freiburg
Medium additives Difco, Detroit, USA; Gibco BRL, Eggenstein
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Fine chemicals 
Roche, Basel; Cayla, Toulouse; Fluka, Neu Ulm; 
Merck, Darmstadt; Pharmacia, Freiburg; Serva, 
Heidelberg; Sigma, Deisenhofen
Cyclic nucleotides Biolog, Bremen
2.1.9. Frequently used media and buffers
All media were prepared with double distilled water and subsequently sterilized by 
filtration. FCS was incubated for 1 hours at 56 °C before use. 
HMI9 medium:
(Hirumi and Hirumi, 1989; modified by Vassella and Boshart (1996)
Iscoves modified medium for 1 l; 3.024 g NaHCO3; 136 mg hypoxanthine; 82.2 mg 
bathocuproine sulfonate; 0.2 mM 2-mercaptoethanol; 39 mg thymidine; 100,000 u 
penicillin; 100 mg streptomycin; 182 mg cysteine; 10% FCS 
SDM79 medium:
SDM79 basic medium was prepared as described by Brun and Schonenberger 
(1979) with the following modifications: Instead of folic acid we used 9.1 g p-
aminobenzoic acid folic and 1.82 g biotin as well as vitamin-mix. The medium was 
supplemented with 7.5 mg hemin, 100,000 u penicillin, 100 mg streptomycin, 0.1 
mM glycerine and 10% FCS. Quantiites refer to 1 l of medium. 
Conditioned 
SDM79:
PCF cells were harvested at a cell density between 1 x 107 and 2 x 107 cells/ml. The 
supernatant (conditioned SDM79) was sterilized by filtration.
DTM:
DTM basic medium (Overath et al., 1986) was supplemented as described in 
Ziegelbauer et al. (1990) with the following modification: 10 mM glycerine was used 
instead of glycine. 28.2 mg bathocuproin sulphonate, 182 mg cysteine and 7.5 mg 
hemin were added. Quantities refer to 1 l of medium. 
Cytomix:
10 mM K2HPO4/KH2PO4 pH 7.6; 2 mM EGTA; 120 mM KCl; 150 µM CaCl2; 25 mM 
HEPES; 5 mM MgCl2; 0.5% glucose; 1 mM hypoxanthine; 100 µg/ml BSA
DNA loading dye 
(10 x):
0.1 M EDTA pH 8; 0.5% Bromophenol blue; 0.5% Xylencyanol blue; 40% 
saccharose
Laemmli buffer 
(2 x):
125 mM Tris-HCl pH 6.8; 0.1% SDS; 10% v/v glycerol; 0.004% Bromophenol blue; 
0.2% 2-Mercaptoethanol
Laemmli buffer 
(6 x):
350 mM Tris-HCl pH 6.8; 0.28% SDS; 30% v/v glycerol; 0.6 M DTT; 0.012% 
Bromophenol blue; 0.6% 2-Mercaptoethanol
EB buffer: 10 mM Tris-HCl pH 8; 10 mM NaCl; 10 mM EDTA; 0.5% SDS
LB medium and 
agar plates:
10 g /l tryptone; 5 g/l yeast extract; 10 g/l NaCl; pH 7
For agar plates 16 g agar was added to 1 l LB medium.
MOPS buffer: 200 mM MOPS and 80 mM NaOAc (pH 7.0); 1 mM EDTA
SDS electro- 
phoresis buffer: 
25 mM Tris-Base; 200 mM glycine; 3.46 mM SDS
SSC (1x): 15 mM sodium citrate pH 7; 150 mM NaCl
SOB-medium: 
20 g/l tryptone; 5 g/l yeast extract; 10 mM NaCl; 2.5 mM KCl; 10 mM MgCl2; 10 mM 
MgSO4; pH 7
PBS: 10 mM Na2HPO4 and 1.8 mM KH2PO4 (pH 7.4); 140 mM NaCl; 2.7 mM KCl
TAE: 40 mM Tris-HCl and 40 mM NaOAc (pH 8.0); 1 mM EDTA
TBS/TBST: 20 mM Tris-HCl pH 7.6; 137 mM NaCl; ad 0.05% Tween for TBST
TDB
20 mM Na2HPO4; 2 mM NaH2PO4  pH 7.7; 20 mM glucose; 5 mM KCl; 80 mM NaCl; 
1 mM MgSO4; 
TE: 10 mM Tris-HCl pH 7.6; 1 mM EDTA
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 2.1.10. Equipment
Stratagene Stratacooler Stratagene, Heidelberg
Odyssey IR-Scanner Licor, Lincoln (Nebraska, USA)
Casy® I Cell analyzer (Modell TTC) Schärfe System, Reutlingen
Electro Cell Manipulator 630 BTX San Diego, California
Gene Amp PCR System 2400 Perkin Elmer, Weiterstadt
Spectrophotometer DU 640 Beckman Instruments, München
ABI PRISM 3100 Genetic Analyzer Applied Biosystems, Norwalk (USA)
Geldoc 2000 Bio-Rad, München
StratalinkerTM Stratagene, Heidelberg
Hybridization Oven Mini-oven MKII MWG Biotech, Ebersberg
Microscopes Axioskop Zeiss, Jena
Axiovert Zeiss, Jena
Diavert Leitz, Wetzlar
Invert-Microscope IM35 Zeiss, Jena
Gene Pulser Bio-Rad, München
Liquid Scintillation Counter Beckman Instruments, München 
Sonifier 250 (Branson) Heinemann, Schwäbisch Gmünd
Vacuum Concentrator Bachofer, Reutlingen
Centrifuge Sorvall RC5C DuPont-Sorvall, Bad Homburg
Centrifuge 2K15 (with cooling device) Sigma, Deisenhofen
Table centrifuge Biofuge B Heraeus Christ, Hanau
2.1.11. Kits
peq Gold RNA pure Kit peqLab, Erlangen
Qiagen Plasmid Purification Kit Qiagen, Hilden
Quiax II Gel extraction Kit Qiagen, Hilden
PCR purification Kit Qiagen, Hilden
Prime-It® RmT Random Primer Labeling Kit Stratagene, Heidelberg
DIG DNA Labeling and Detection Kit Roche, Basel
ECL Chemiluminiscence Detection Kit Amersham, Freiburg
2.1.12. Software
Gene Construction Kit 2    Textco, New Hampshire (USA)
IP-lab 3.9.1     Scanalytics, Fairfax (USA)
Oligo 4.0     National Biosciences, Plymouth (USA)
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2.2. Methods and Protocols
2.2.1. T. brucei
2.2.1.1. Culture of monomorphic BSF
Monomorphic Trypanosoma strains were cultured in HMI9 medium at 37 °C, 5% CO2 in 
a humidified incubator. Logarithmically growing cells were generally kept at cell densities 
below 7 x 105 cells/ml. Cell densities were counted regularly with the Neubauer cell 
chamber. 
2.2.1.2. Culture of PCF
Procyclic trypanosoma strains were cultured in SDM79 at 27°C. The cell density was 
kept between 2 x 106 and 2 x 107 cells/ml. Cells may be diluted to lower cell densities, 
when they are already culture adapted or when the medium is supplemented with 20-
50% conditioned SDM79. Cell densities were measured with the CASY cell counter. 
2.2.1.3. Differentiation of monomorphic LS cells into SP cells
The laboratory adapted monomorphic trypanosoma strains are not able to differentiate 
into SS cells. However, when grown to high cell densities, monomorphic strains have 
some properties of SS cells (Breidbach et al., 2002), among them they exhibit the life cycle 
stage specific PKA phosphorylation that was examined in this work. These monomorphic 
cells at high cell densities will be further referred to as SP cells, for stationary phase. To 
get SP trypanosomes, logarithmically growing monomorphic BSF cells were grown from 
<104 cells/ml to cell densities of about 5 x 106 cells/ml without dilution.
2.2.1.4. Differentiation of monomorphic BSF into procyclic cells
Logarithmically growing monomorphic BSF cells were transformed into SP cells, 
harvested and resuspended in SDM79 at a cell density of 2 x 106 cells/ml. The 
transformation was induced by addition of 6 mM cis-aconitate and cultivation at 27 °C. 
Monomorphic MITat1.2 cells do transform into PCF but usually die around 10 days after 
the induction of the transformation. In contrast, pleomorphic strains like AnTat1.1 proceed 
in the life cycle.
 
2.2.1.5. Stable transfection of monomorphic BSF cells
Monomorphic BSF cells at cell densities between 5 and 8 x 105 were harvested, washed 
once in cytomix (37 °C) and resuspended in cytomix (37 °C) at a cell density of 1 x 107 
/ 400 µl. For each transfection, 400 µl of cell suspension was transferred into a sterile 
cuvette together with 10 µg linearized plasmid DNA [1 µg/µl]. The electroporation was 
performed with the electro cell manipulator 630 (BTX, San Diego, California) at 1.5 kV, 
175 Ω and 25 µF. After electroporation, cells were transferred immediately into 50 ml HMI9 
(37 °C). 18 hours after the transfection the selection marker was added in the appropriate 
concentration. Transfectants were usually visible 4-6 days later. If clonal transfections 
were needed, cells were serially diluted on 24 well tissue culture plates immediately after 
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the transfection. Each construct was transfected between 5 to 10 times in parallel.
2.2.1.6. Stable transfection of PCF cells
Logarithmically growing PCF cells at cell densities between 5 x 106 and 1 x 107 were 
harvested, washed once in cytomix (4° C) and resuspended in cytomix (4 °C) at a 
cell density of 1 x 107 / 400 µl. For each transfection, 400 µl of cell suspension was 
transferred into a sterile cuvette together with 10 µg linearized plasmid DNA [1 µg/µl]. 
The electroporation was done with the electro cell manipulator 630 (BTX, San Diego, 
California) at 1.5 kV, 175 Ω and 25 µF. After electroporation, cells were transferred 
immediately into 10 ml 30% conditioned SDM79 (pre warmed to 27 °C) and cultivated. 
The selection marker was added 18 hours later. Transfectants were visible after 12 to 14 
days. If clonal transfectants were needed, 5 ml of a 1:1, 1:10 and 1:100 dilution of the 
transfected cells were plated on 96 well tissue culture plates (50 µl per well) as soon as 
the selection marker was added. Each construct was transfected only once or twice.
2.2.1.7. Freezing and thawing of T. brucei cells
For freezing 5 x 106 BSF or 5 x 107 PCF cells were harvested and resuspended in cold 
culture medium with 10% glycerol v/v (0 °C) in cryotubes. Cells were slowly cooled down 
to –80 °C with the Strata Cooler and transferred to liquid nitrogen for long term storage. 
Cells were thawed quickly in a 37° C water bath, washed once in 10 ml culture medium 
and transferred to warm culture medium. If necessary, selection markers were added 
earliest one hour after the thawing. In some cases PCF cells require conditioned medium 
after thawing. 
2.2.1.8. Harvest of T. brucei cells
Cells were generally harvested by centrifugation at 4 °C and 1400 g (BSF) or 900 g 
(PCF) for 10 minutes. For transfection, BSF cells were harvested at 37 °C. According to 
requirements, cells may be washed once or twice in an appropriate buffer (TDB, PBS) at 
the respective temperature. 
2.2.1.9. Methanol fixation and Dapi staining of T. brucei cells
Approximately 5 x 105 cells were resuspended in 50 µl of medium, spread on a glass 
microscope slide, air-dried, and fixed overnight in methanol at –20 °C. Slides were 
removed, the methanol was allowed to evaporate, and 40 µl of 0.1 µg / ml DAPI (4,6-
Diamidino-2-phenylindole) in Vectashield Mounting Medium (Vector Laboratories, 
Burlingame) was added to the slide and spread by the addition of the coverslip. Slides 
were examined under UV light (350 nm excitation). 
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2.2.1.10. Paraformaldehyde fixation of T. brucei cells
0.4% Paraformaledehyde: 4 g paraformaldehyde were resuspended in sterile PBS, pH 7.0. 1 ml 1M NaOH  
   was added and the solution was heated at 80°C until the paraformaldehyde was  
   completely solved. 1 ml aliquots were stored at -20°C. 
1-5 x 106 cells were harvested, resuspended in 0.2 ml DTM w/o FCS and carefully mixed 
with 0.3 ml 4% paraformaldehyde.The fixation was carried out at 4 °C over night.
2.2.1.11. Immunofluorescence
Paraformaldehyde fixed cells were washed once in PBS and incubated in 0.5 ml 0.1 M 
Na2HPO4 / NaH2PO4  pH 7.2 / 0.1 M glycine for 15 minutes. For permeabilization, 0.5 
ml 0.2% triton v/v was added for exactly 5 minutes. Cells were washed once in 0.5 ml 
PBS / 1% BSA w/v and incubated with the primary antibody in PBS / 1% w/v BSA for one 
hour at 4 °C. After two washing steps in PBS / 1% w/v BSA cells were incubated with the 
secondary antibody in PBS / 1% w/v BSA for one hour at 4 °C in the dark. Cells were 
washed twice in PBS / 1% w/v BSA and once in PBS. All centrifugations were carried out 
for 10 minutes at 600 g and 4 °C.
2.2.2. Nucleic acids
2.2.2.1. T. brucei
2.2.2.1.1. Isolation of genomic DNA from T. brucei
2.5x107 to 1x 108 cells were harvested, washed in PBS and lysed in 500 µl EB-buffer / 100 
µg Proteinase K at 37 °C for at least two hours without resuspending the cell pellet. The 
DNA was purified by phenol extraction: 1 ml phenol (pH 8) was added to the lysed cells. 
After mixing (10 minutes on overhead shaker), the aqueous layer was separated from 
the organic layer by centrifugation (5 min, 20000 g) and removed into a fresh tube. The 
procedure was repeated with 1 ml phenol / chloroform (pH 8) and finally with chloroform 
to remove traces of phenol. The DNA was precipitated with 1 volume isopropanol and 
1/25 volume 5 M NaCl and washed with 70% ethanol.
  
2.2.2.2. E. coli
2.2.2.2.1. Preparation of electrocompetent E. coli cells
5 ml of an E. coli overnight culture was transferred to 500 ml LB medium and grown to 
an optical density (OD600) between 0.6 and 0.8. The bacteria were cooled down on ice for 
20 minutes and harvested by centrifugation (4000 g, 15 min, 4 °C). The cell pellet was 
resuspended in 500 ml sterile ddH2O (4 °C) and incubated on ice for 30 minutes. Cells 
were washed once in 250 ml ddH2O (4 °C) (4000 g, 15 min, 4 °C) and once in 25 ml 10% 
glycerine (4 °C). The bacteria pellet was resuspended in 3 ml 10% glycerine, aliquoted in 
Eppendorf reaction tubes, frozen in liquid nitrogen and finally stored at –80 °C for up to 
12 months. All resuspension steps were carried out very carefully.
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2.2.2.2.2. Transfection of E. coli with plasmid DNA
The electroporation of E. coli cells was carried out according to the method of Dower et 
al. (1988). 40 µl competent cells were thawed on ice, mixed with 1-3 µl of DNA, incubated 
on ice for one minute and placed into a cuvette (4 °C). The electroporation was done 
with the GenePulser (Bio-Rad) at 25 µF, 2.5 kV and 200 Ω. Cells were transferred into 
1 ml SOB-medium (37 °C) immediately after the transfection and incubated  for 45 min 
at 37 °C on a shaker. Cells were plated to LB agar plates with the appropriate antibiotics 
(usually ampicillin) and incubated overnight at 37 °C.
2.2.2.2.3. Isolation of plasmid DNA from E. coli
Small amounts of plasmid DNA was isolated from E. coli using a standard alkaline lysis 
protocol (Sambrook et al., 1989). Higher quantities of plasmid DNA (100-500 µg) were 
isolated with the Qiagen plasmid purification kit as described by the manufacturers.
2.2.2.2.4. Long time storage of E. coli cells
1 ml of E. coli overnight culture was added to 1 ml of glycerine buffer (25 mM Tris-HCl pH 
8.0; 65% glycerine; 0.1 M MgSO4,) in cryotubes and stored at –80 °C.
2.2.2.3. Standard cloning protocols 
2.2.2.3.1. Agarose gel electrophoresis
DNA fragments were separated on agarose gels (1% agarose, 1µg/ml ethidiumbromid) in 
TAE buffer with 10 V/cm. Samples were mixed with 0.1 volume 10 x DNA loading buffer. 
Sizes of DNA fragments were determined by comparison with DNA ladders (GeneRuler 
1 kb ladder (MBI) and others). DNA was visualized with the Geldoc 2000 or on a UV 
illumunator.
2.2.2.3.2. DNA isolation from agarose gels
DNA was extracted from agarose gels with the Qiaex II Gel Extraction Kit (Qiagen) 
according to the instructions of the manufacturer.
2.2.2.3.3. Modification of DNA
The following methods were performed as described at Sambrook et al. (1989) or as 
described by the manufacturers of the used enzymes: DNA cleavage with restriction 
endonucleases, Ligation of DNA fragments, dephosphorylation of DNA with alkaline 
phosphatase and Klenow enzyme reaction. 
2.2.2.3.4. DNA amplification (PCR)
DNA was amplified by polymerase chain reaction with either Pfu DNA Polymerase, Expand 
High Fidelity PCR System, Expand long Template PCR System, Pwo DNA Polymerase 
or Taq DNA Polymerase as described by the manufacturers of the enzymes / kits. The 
choice of polymerase was dependent on the application (lenght of PCR product, required 
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accuracy etc.). The Gene Amp PCR System 2400 (Perkin Elmer) was used for cycling. 
Primer were designed with the Oligo 4.0 Software (National Biosciences, Plymouth) that 
also calculates the ideal annealing temperatures. PCR products were purified with the 
PCR Purification Kit (Qiagen). 
2.2.2.3.5. Precipitation of DNA
DNA was precipitated by addition of 1 volume isopropanol and 0.1 volume 3 M sodium 
acetate (pH 7.0) and subsequent centrifugation at 20,000 g for 20 minutes at 4 °C. The 
DNA pellet was washed once with 70% ethanol, allowed to dry and resuspended in either 
ddH2O or TE buffer. Precipitation of genomic DNA was done with 0.08 volume 5 M NaCl 
instead of sodium acetate.
2.2.2.3.6. Quantification of DNA
Purity and quantity of nucleic acids were determined by measuring the absorption at 260 
and 280 nm. An OD260 of 1 is equivalent to 50 µg/ml dsDNA. The ratio of OD260/OD280 
indicates the purity of the preparation and is ideally 1.8. The measurements were done 
with the spectrophotometer DU 640.
2.2.2.3.7. Sequencing of DNA
DNA was sequenced either at the Seqlab Sequence Laboratories (Göttingen) (hot shot 
sequencing) or on the Abi PRISM 3100 Genetic Analyzer (Applied Biosystems, Norwalk 
(USA)). Samples were prepared as required by Seqlab or as described by Applied 
Biosystems. 
2.2.2.4. Southern blot analyses
Restriction enzyme digests of genomic DNA were separated on a 0.8% agarose gel 
together with a DNA size marker. After documentation (Geldoc 2000), the gel was soaked 
in 0.25 N HCl for 15 minutes (depurination), in 0.5 M NaOH/ 1.5 M NaCl for 30 minutes 
(DNA denaturation) and in 1 M Tris-HCl pH 7.4/1.5 M NaCl for 30 minutes (neutralization). 
The DNA was transferred to a nylon membrane over night in 20 x SSC by capillary forces 
as described by Sambrook et al. (1989). The DNA was covalently bound to the damp 
membrane by UV crosslinking (Stratalinker, autocrosslink function). The detection was 
done either with radioactive or digoxigenine labeled probes:
Radioactive detection:
The radioactive labeling of the probe was carried out with the Prime-It RmT Random Primer Labeling Kit 
according to the instructions of the manual. The prehybridization of the membrane was done in QuickHyb 
(Stratagene) for one hour at 65°, followed by the hybridization for another hour. The membrane was rinsed 
three times with 2 x SSC/ 0.1% SDS and washed three times in 0.1 x SSC/ 0.1% SDS (65 °C) for 30 
minutes each. The detection was done either by autoradiography or with the phosphorimager.
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Digoxigenine labeling:
Probes were labeled with Digoxigenine with the aid of the DIG DNA Labeling and Detection Kit as described 
by the manufacturer. Membranes were prehybridized with DIG Easy Hyb solution for at least one hour. 
Hybridization with the DIG labeled probe was carried out overnight in fresh DIG Easy Hyb solution. The 
membrane was rinsed three times with 2 x SSC/ 0.1% SDS and washed three times in 0.1 x SSC/ 0.1% 
SDS (65 °C) for 30 minutes each. The membrane was incubated 1 min in buffer 1 (Tris-HCl 100 mM pH 
7.5 / 150 mM NaCl), 30 min in buffer 1 / 0.5% blocking reagent, 1 min in buffer 1, 30 min with anti-DIG-AP 
in buffer 1, 3 x 10 min in buffer 1 and 2 min in buffer 3 (Tris-HCl 100 mM pH 9.5 / NaCl 100 mM / MgCl2 
50 mM). For detection the membrane was overlaid with 4 mM NBT / 4 mM BCIP in buffer 3 and incubated 
without light for 1 to 12 hours, until bands were visible. The reaction was stopped with Tris-HCl pH 8.0 / 
EDTA 1 mM. 
2.2.3. Proteins
2.2.3.1. Preparation of protein lysates from T. brucei
BSF or PCF cells were harvested by centrifugation (10 min, 1400 g, 4 °C), resuspended 
in ice cold PBS and transferred to an 1.5 ml Eppendorf tube. Cells were centrifuged (30 
ʻʼ, 10000 g, 4 °C) and the cell pellet was resuspended in an appropriate volume of PBS. 
An equal volume 2 x Laemmli buffer was added, the lysate was incubated at 100 °C for 
3 to 5 minutes and finally ultrasonificated for 20ʼʼ (Branson Sonifier 250, output control 
7). Usually 1 x 106 cells to 5 x 106 cells were used for 10 µl of final cell lysate (one lane 
on SDS PAGE), depending on the abundance of the protein and the antibody used for 
detection. Cell lysates were stored at –20 °C and were stable for about 12 months. 
2.2.3.2. Discontinuous SDS polyacrylamide gel electrophoresis (SDS PAGE)
separation gel (10%):  acrylamide/ bisacrylamide 37.5:1
(rotiphorese Gel 30) 
20 ml
1.5 M Tris-HCl pH 8.8; 0.4% SDS 15 ml
H2O bidest 25 ml
10% w/v APS 0.2 ml
TEMED 0.04 ml
stacking gel acrylamide/ bisacrylamide 37.5:1
(rotiphorese Gel 30)
1.95 ml
0.5 M Tris-HCl pH 6.8; 0,4% SDS 3.75 ml
H2O bidest 9.15 ml
10% w/v APS 75 µl
TEMED 15 µl
The separation of proteins by their differences in molecular weight was done in the one 
dimensional discontinuous gel electrophoresis (Laemmli, 1970). 10% acrylamide gels 
out of separation gel and stacking gel were poured according to the instructions above. 
The gel electrophoresis was carried out in SDS electrophoresis buffer at 130 Volt. For 
size markers, See BlueTM Pre-Stained Standard (Invitrogen) (250, 98, 64, 50, 36, 30, 16, 
6, 4 kDa) or SeeBlue® Plus2 Pre-Stained Protein Standard (Invitrogen) (250, 148, 98, 64, 
50, 36, 22, 16, 6, 4 kDa) were used.
Material and Methods
38
2.2.3.3. Staining of proteins in polyacrylamide gels with Coomassie Blue
SDS gels were stained in Coomassie solution (0.1% Coomassie Brilliant Blue R250; 
10% acetic acid; 50% methanol) for 10 minutes to 12 hours and destained in 10% v/v 
HCl (3 times 10 minutes) on a shaker. Gels were packed in cellophane paper avoiding air 
bubbles, wetted with 10% glycerol and dried over night.
2.2.3.4. Western blot analyses
The electrophoretic transfer of proteins from SDS gels to PVDF membranes was 
done with the semi dry technique according to Kyhse-Andersen (1984). The blot was 
assembled from the cathode to the anode as follow: 6 Whatman papers wetted in anode 
buffer I (300 mM Tris pH 10.4; 20% methanol), 3 Whatman papers wetted in anode buffer 
II (30 mM Tris pH 10.4; 20% methanol), PVDF membrane (preequilibrated in methanol), 
gel, 6 Whatman papers wetted in cathode buffer (25 mM Tris pH 9.4; 20% methanol; 40 
mM 6-aminohexanoic acid). The blotting was done with a current density of 0.8 mA/cm2 
for one hour. The immunological detection of the proteins was either done with enhanced 
chemiluminescence (ECL) or with the Licor Western blot detector according to the 
following protocols:
    ECL: 
• Incubate membrane with TBST/ 5% skim milk powder for 1 hour at RT 
• Incubate membrane in TBST/ 1% skim milk powder/ primary antibody for 1 hour at RT 
• Wash membrane two times short and 3 times 10 minutes in TBST
• Incubate membrane in TBST/ 1% skim milk powder / secondary antibody (peroxidase coupled)
• Wash membrane two times short and 3 times 10 minutes in TBST
• Treat membrane according to the instructions of the ECL Chemiluminiscence Detection Kit 
(Amersham) and detect bands with autoradiography.
    LiCor Western blot detector:
• Incubate membrane with PBS/ 5% skim milk powder for 1 hour at RT 
• Incubate membrane in PBS 0.1% Tween/ 1% skim milk powder / primary antibody for 1 hour at 
RT.
• Wash membrane two times short and 3 times 10 minutes in PBS 0.2% Tween.
• Incubate membrane in PBS 0.1% Tween / 1% skim milk powder / secondary antibody (IRDye800 
or Alexa 680) in the dark.
• Wash membrane two times short and 3 times 10 minutes in PBS 0.2% Tween in the dark.
• Dry membrane between two Whatman papers
• Scan membrane with the Odyssey IR Scanner according to the instructions of the manufacturer. 
If necessary, bands can be quantified with the Odyssey Software.
Dried membranes were stored in the dark and can be rescanned for about 12 months.
Antibodies were removed from the membrane by incubation in stripping buffer (100 mM 
2-mercaptoethanol; 62.5 mM Tris-HCl; 2% v/v SDS; pH 6.7) at 50 °C for 30 min and 
subsequently washed 2 x 10 minutes in either TBST or PBS. 
2.2.3.5. Affinity purification of antibodies
Antiserum was affinity purified according to the method of Olmsted (1981). 250 µg 
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recombinant protein were transferred to a 9 cm wide well of an SDS gel, separated and 
transferred to a PVDF membrane. The membrane was stained with Ponceau solution 
(0.1% PonceauS in 1% acetic acid) and the protein band was cut out. The membrane 
strip was incubated in 5% skim milk powder/ PBS for 1 hour, washed 3 times short 
and 3 times 10 minutes in PBS and incubated for 3-4 hours with 1 ml antiserum at RT. 
Subsequently the stripe was washed 3 times short and 3 times 10 minutes in PBS and 
the antibody was eluted by addition of 1 ml 0.2 M glycine/ 1 mM EGTA pH 2.2 for exactly 
10 minutes. The eluate was transferred to an Eppendorf tube that contained 200 µl 1 M 
Tris-HCl pH 8.0 for neutralization. For stabilization, 200 µg / ml BSA was added and the 
eluate was dialyzed for 12-24 hours against PBS, changing the PBS three times. The 
antibody was stored at 0 °C in the presence of 0.02% NaN3. 
2.2.3.6 Covalent coupling of anti-Ty1 to protein G sepharose
For immunoprecipitations, anti-Ty1 was covalently coupled to protein G sepharose beads 
(Amersham Pharmacia, Uppsala (Sweden); 50% slurry). 1 ml protein G-sepharose 
beads were preequilibrated in “borate buffer low” (50 mM boric acid; 3 M NaCl, pH 9.0) 
and mixed with 500 µl anti-Ty1 hybridoma supernatant for 3 hours at RT. Subsequently, 
the supernatant was removed by centrifugation (1400 g, 3 min) and the antibody 
containing protein G-sepharose beads were washed twice in 10 ml “borate buffer” low 
and resuspended in 10 ml “borate buffer high” (200 mM boric acid; 3 M NaCl, pH 9.0). 
After addition of dimethylpimelimidate (cross-linker) at 20 mM the beads were incubated 
for 30 min at RT on a shaker, washed once in 10 ml 0.2 M ethanolamine and incubated 
for 2 hours in 10 ml 0.2 M ethanolamine at RT. The beads were washed twice with 10 
ml PBS/ 0.02% NaN3, resuspended in 400 µl PBS/ 0.02% NaN3 and stored at 4 °C. The 
antibody containing sepharose beads can be used for immunoprecipitations for at least 
2 years.
2.2.3.7. Immunoprecipitation
IP stock buffer 50 mM Tris-HCl pH 7.5; 2 mM EGTA; 150 mM NaCl
IP buffer IP stock buffer complemented with 1 mM NaVO4; 0.5% aprotinin;
2 µg/ml leupetin and 1 mM PMSF (prepare freshly)
IP* buffer IP + 0.2% Nonidet P40
IP2* buffer IP + 0.4% Nonidet P40
Washing buffer 10 mM Tris-HCl pH 7.0; 5 mM Mg-acetate; 150 mM NaCl
Washing buffer * 10 mM Tris-HCl pH 7.4; 5 mM Mg-acetate, 2.5 mM NaF
The immunoprecipitation procedure was carried out either on ice or at 4 °C using ice 
cold buffers only. Solutions that contained protein G/A sepharose beads were generally 
pipetted with a cut pipette tip, to avoid shearing of the beads.
Cell pellets of 5 x 107 cells were thawn on ice, resuspended in 100 µl IP buffer and mixed 
with 100 µl IP2* buffer for cell lysis. Lysates were incubated on ice for 10 minutes and the 
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non-soluble cell components were pelleted by centrifugation (20,000 g , 20 min, 4 °C). 
The supernatant extract was transferred to a fresh tube. 
If the required antibody is already coupled to protein G sepharose beads, 20 µl of these 
beads were mixed with the supernatant for 1 hour to overnight on an over head mixer. 
Ty1-PKAR was precipitated quantitatively only with an overnight incubation while for most 
proteins one hour of immunoprecipitation was sufficient. If the required antibody is not 
coupled to protein G sepharose beads, the supernatant is mixed with the antibody (e.g. 
200 µl HA hybridoma supernatant) for 1 hour and then with 20 µl protein G sepharose 
beads (equilibrated in IP* buffer) for an additional hour or overnight. In the case of the HA 
antibody, the high antibody volume results in lower NP40 concentrations (0.1%) in the 
final precipitation reaction that were not corrected.
After short centrifugation (30ʼʼ microfuge) the supernatant was removed and if necessary 
concentrated with Microcon 30 tubes (Amicon) to control for the completeness of the 
precipitation by Western blot analysis. For kinase assays, the protein loaded beads were 
washed twice in IP* buffer, twice in washing buffer and once in washing buffer* and 
finally resuspended in the appropriate volume washing buffer*. For other experiments 
(e.g. coimmunoprecipitation) the beads were washed three times in IP* buffer and twice 
in IP buffer. Generally it was not necessary to eluate the protein from the beads for the 
applications used in this work. Samples for Western blots were prepared by heating an 
aliquot of the immunoprecipitate (IP) or the supernatant (SN) in an equal volume of 2 x 
Laemmli buffer at 95°C for 5 min. 
2.2.3.8. Purification of Ty1-PKAC1 for mass spectrometry
For mass spectrometry, Ty1-PKAC1 was purified by immunoprecipitation from the cell 
line MITat1.4 Ty1-PKAC1 (P. Hassan) essentially as described above, with the following 
modifications:
60 to 240  tubes with 2*108 cells each were resuspended in 200 µl IP buffer, lysed with 
200 µl IP* buffer, incubated for 10 minutes on ice and centrifuged (20000 g, 20 min, 4 
°C). The supernatants of 60 tubes were pooled in a 50 ml falcon tube and incubated with 
500 µl Ty1-Protein G-sepharose beads overnight. The beads were washed once in 50 
ml IP* buffer, twice in 50 ml IP* buffer without protease and phosphatase inhibitors and 
twice in 50 ml PBS. The beads were cooked in an equal volume of 2 x Laemmli buffer 
and transferred to an SDS gel (large size) using 2-8 lanes depending on the amount of 
cells. The gel was stained in Coomassie solution (0.1% Coomassie Brilliant Blue R250; 
10% acetic acid; 50% methanol) for one hour to overnight and destained in 10% v/v 
acetic acid until bands were visible. A typical Coomassie stained gel is shown in figure 5. 
The phosphorylated and unphosphorylated PKAC1 bands were cut with a sterile scalpel 
and transferred to a fresh tube. A small part of the gel band was reheated at 100°C in 
an approximately equal volume of 2 x Laemmli buffer and analyzed on a Western blot to 
ensure that the correct bands were cut. The PKAC1 containing gel slices were then sent 
to E. Krause (MDC, Berlin Buch) for mass spectrometry.
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Ty1PKAC1
PKAR
36 kDa
50 kDa
64 kDa
Fig. 5: Purification of immunoprecipitated Ty1-PKAC1 on SDS gel for mass spectrometry:
Ty1-PKAC1 was immunoprecipitated from 4.8 x 1010 cells and applied to SDS PAGE (8 lanes). The gel was 
stained with Coomassie. The Ty1-PKAC1 double bands (phosphorylated and unphosphorylated) and the 
PKAR bands are marked with arrows. 
2.2.3.9. In vitro Kinase assays
PKA kinase assay using a peptide as substrate:
5 x MES buffer: 250 mM MES pH 6.9; 2 mM EGTA; 5 mM Mg-
acetate; 50 mM NaCl
reaction mix:
500  µl 5 x MES buffer; 250 µl DTT [100 mM]; 125 
µl BSA [10 mg/ml]; 25 µl peptide substrate [5 mM]; 
241.6 µl ATP [1 mM]; γ-32P-ATP [5 µl = 50 µCi]; 
ad 1.5 ml
Either kemptide (LRRASLG; Kemp et al., 1976; Kemp et al., 1977) or an optimized PKA substrate 
(RRRRSIIFI, Songyang et al., 1994) were used as peptide substrates. Both are equally well substrates for 
T. brucei PKA-like kinase (data not shown). Each assay was usually done in triplicates and at least once in 
the presence of 5 µM PKI 5-24 to control for  the specificity of the reaction. 30 µl reaction mix were added 
to each tube that already contained 10 µl of H2O or additives such as PKI or cNMPs. The assay was 
started with the addition of 10 µl immunoprecipitated kinase, which equals protein from 1 x 106 to 2 x 106 
cells. Samples were shaken slightly at 30°C for 15 min. Afterwards, 30 µl of each sample was transferred 
to phosphocellulose (P81 Whatman) filter (2 x 2 cm). The filters were washed four times 10 min in 75 mM 
phosphoric acid and once in acetone. The radioactivity of the bound peptide substrate was measured in a 
liquid scintillation counter.
2.2.3.10. In vivo Kinase assays with the PKA reporter substrate VASP
Transgenically expressed human VASP has been used as a reporter substrate to 
measure T. brucei PKA activity in vivo. Since the assay has been established in this work 
its exact performance varies between the different experiments and the exact conditions 
are shown in the legend of each figure. 
The protocol described below has been found most suitable and already considers some 
results from this work for example the activation of PKA-like kinase by a decrease in 
temperature.
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• Culture VASP expressing trypanosomes to a cell density between 5*105 and 7*105 cells/ml. (Note: 
lower cell densities might results in problems of VASP detection on the Western blot) 
• Fill Eppendorf tubes with 1 ml of VASP cells, incubate at 37°C while slightly shaking. No more than 10 
samples should be handled in one assay.
• Perform the experiment. If possible, the duration of an experiments should not exceed 10 minutes. All 
cells should remain at the 37°C shaker for the same time, this means that during kinetic experiments 
the substance of interest is added at different time points. Note that a control must always be 
performed in parallel for each assay. It is not sufficient to consider the null value as a control. 
• Harvesting: Centrifuge samples (10,000 g, 30”, 37°C) and remove the supernatant by suction (fast!). 
Ad 4 µl 6x Laemmli buffer to the cells and incubate at 95°C for 5 minutes.
• Analyze the extent of VASP phosphorylation from a quantitative Western blot.
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3. Results
3.1. PKAC1 and PKAC2 differ in their life cycle stage dependent 
posttranslational modifications and expression
Three related protein kinase A homologues to catalytic subunits of PKAs from other 
organisms have been cloned from the genome of the T. brucei strain AnTat in this laboratory 
(T. Klöckner, Ph.D. thesis 1996). From these, PKAC1 and PKAC2 are remarkably similar. 
Their amino acid sequences are 98% identical and the only differences lie at their N- and 
C-termini. The genes for PKAC1 and PKAC2, located at adjacent gene loci, most likely 
arose from a single precursor gene during an evolutionary recent gene duplication event. 
Antibodies raised against small peptides of the distinct N-termini of PKAC1 and PKAC2 
were not able to discriminate between the isoforms (T. Klöckner, Ph.D. thesis 1996). The 
available antibody (anti-PKAC1/2) recognizes both, PKAC1 and PKAC2 (T. Klöckner, 
Ph.D. thesis 1996). For this reason, PKAC1 and PKAC2 together will subsequently be 
referred to as PKAC1/2 whenever a differentiation by other means is impossible. 
Given this high degree of homology between the two isoforms it came as a surprise 
that different mRNA levels are expressed in the different T. brucei life cycle stages. 
PKAC1 mRNA is predominantly expressed in blood stream forms and PKAC2 mRNA 
in procyclic cells (E. Vassella, unpublished). Furthermore, multiple bands on Western 
blot indicated possible protein modifications (T. Klöckner, Ph.D. thesis 1996). Life cycle 
stage dependent differences in expression and structure of PKAC1 and PKAC2 were of 
interest, since these kinases were candidates to be involved in signaling events triggering 
differentiation (Vassella et al., 1997). 
3.1.1. TbPKAC1/2 is posttranslationally modified in SS and PCF cells
Three PKAC1/2 forms have been distinguished by their different apparent molecular 
weights on Western blot: one fast running form predominantly present in LS cells, one 
slow running form mainly found in SS cells and one form that runs only slightly slower 
than PKAC1/2 from LS cells and is exclusively present in procyclic cells (T. Klöckner, 
Ph.D. thesis 1996). We conclude from this that PKAC1/2 of SS cells and of PCF cells 
carries posttranslational modifications that are absent from LS cells. These modifications 
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will be further referred to as “stumpy specific” or “PCF specfic”. 
All subsequent biochemical analyses of the PKAC1/2 modifications will be done 
exclusively with monomorphic trypanosomes, since they are easier to handle and to 
manipulate than pleomorphic cells. Although these laboratory adapted strains are unable 
to differentiate into short stumpy cells, they aquire some features of this life cycle stage 
when grown to high cell densities (Breidbach et al., 2002). Among these is the stumpy 
specific modification. Monomorphic trypanosomes grown to high cell densities will further 
be called SP cells, for stationary phase. 
A Western blot with PKAC1/2 from the different life cycle stages is shown in figure 6.
LS SP PCF
Fig. 6: Life cycle stage dependent changes in TbPKAC1/2 gel
mobility:
Western blot with protein lysates from different life cycle stages
(LS, SP, PCF) probed with anti-PKAC1/2. Three different PKAC1/2
forms are clearly distinguishable by their different gel mobility. Note
that LS cells do always contain a certain percentage of SP-
PKAC1/2 and vice versa, since it is difficult to obtain pure cultures
of LS or SP cells.
3.1.1.1. The stumpy specific modification
At first, our interest focussed on the biochemical characterization of the stumpy specific 
modification. It was shown previously with phosphatase treatments that the stumpy 
specific modification is a Ser/Thr phosphorylation that is probably localized at the protein 
surface, since it is accessible to phosphatases (S. Schimpf, Diploma thesis 2000). It 
was further shown with phospho specific antibodies that this phosphorylation is not 
located at threonine 179 in the kinase activation loop. The activation loop threonine is 
highly conserved in all PKAs and its constitutive phosphorylation is essential for kinase 
activity (Shoji et al., 1979; Steinberg et al., 1993; Adams et al., 1995). Likewise to the 
activation loop threonine in mammalian PKAs, Thr179 of T. brucei PKAC1 was found to 
be constitutively phosphorylated in all analysed life cycle stages (S. Schimpf, Diploma 
thesis 2000). 
3.1.1.1.1. In silico search for potential PKAC1/2 phosphorylation sites
The first aim was to map the stumpy specific phosphorylation site. Prior to mass 
spectrometry, it was tried to predict potential phosphorylation sites of PKAC1 and PKAC2 
in silico. For this, phosphorylation probabilities of all serine and threonine residues from 
PKAC1 and PKAC2 were calculated, according to the method of Blom et al. (1999) 
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with the WEB based software Net Phos Prediction (http://www.cbs.dtu.dk/services/
NetPhos). Only 13 Ser/Thr residues of PKAC1 and 11 Ser/Thr residues of PKAC2 have a 
phosphorylation probability higher than 0.5 and are thus likely to become phosphorylated 
(Table 1).
In a second step, each of these putative phosphorylation sites was examined for its 
probability to be on the protein surface. The surface probability was calculated according 
to the method of Emini et al. (1985) and Janin et al. (1978) with the aid of the software 
Gene Inspector (Textco). Accordingly, eight of the putative PKAC1/2 phosphorylation 
sites were predicted to be on the protein surface with a surface probability higher than 
1 1), and could therefore possibly be the stumpy specific phosphorylation site. They are 
shadowed in table 1. 
Table 1: In silico search for phosphorylation
sites on the surface of PKAC1 and PKAC2
Potential serine/ threonine phosphorylation sites
of TbPKAC1 and TbPKAC2 were predicted
according to the method of Blom et al. (1999)
using the web based software NetPhos
(http://www.cbs.dtu.dk/ services/NetPhos/).
Phosphorlyation sites having a phosphorylation
probability of 0.5 and higher are indicated in the
table. Homologous amino acids between PKAC1
and PKAC2 are shown in the same line. The
probabilty to be on the protein surface was
calculated for each of these potential
phosphorylation sites according to the method of
Emini et al. (1985), using the data of Janin et al.
(1978). Thereby a surface probability of 1 is
defined as the average surface probability of all
amino acids from a given protein.
All predicted phosphorylation sites that are likely
to be on the protein surface are shadowed.
S6 0.989 3.00
S18 0.842 S20 0.842 1.00
S46 0.987 S48 0.987 0.35
S116 0.701 S118 0.701 0.20
S302 0.998 S304 0.998 1.25
S307 0.896 S309 0.896 0.50
S311 0.938 S313 0.938 0.30
S320 0.741
T2 0.582
T4 0.956
T5 0.763 3.00
T179 0.978 T181 0.978 0.30
T224 0.750 T226 0.750 0.25
T265 0.961 T267 0.961 0.25
T324 0.660
0.25
0.25
2.25
no value
1.50
0.30
1.25
0.50
0.30
1.75
1.00
0.35
0.20
Ser/Thr
(position)
Surface
access
probability of
phosphory-
lation
probability of
phosphory-
lation
PKAC2PKAC1
Surface
access
Ser/Thr
(position)
Interestingly, only two of these sites are found in both, PKAC1 and PKAC2 (S18/20 and 
S302/304). Two putative phosphorylation sites are present in PKAC2 only (T5, S6) and 
four sites are restricted to PKAC1 (T2, T4, S320, T324). Since we knew from previous 
immunoprecipitation studies with epitope tagged PKAC1 that the stumpy specific 
phosphorylation site is definitely present in PKAC1 (Schimpf, Diploma thesis 2000), it 
is unlikely that T5 or S6 of PKAC2 are the stumpy specific phosphorylation sites. This 
leaves six putative phosphorylation sites as candidates for the stumpy specific PKAC1/2 
phosphorylation. 
The next aim was the identification of the stumpy specific phosphorylation site using 
mass spectrometry:
1) According to the used method, 1 is defined as the average surface probability of all amino acids.
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3.1.1.1.2. The stumpy specific phosphorylation was mapped to Thr324 via mass 
spectrometry.
Ty1-epitope tagged PKAC1 (Ty1-PKAC1) from SP cells (MITat1.4 Ty1-PKAC1, provided 
by P. Hassan) was purified by immunoprecipitation, separated on SDS PAGE and stained 
with Coomassie Brilliant Blue as described in method 2.2.3.8. Since only around half of 
PKAC1 is phosphorylated in SP cells, it was possible to isolate both the unphosphorylated 
(lower) and phosphorylated (upper) Ty1-PKAC1 band from the same lane of the gel. 
The phosphorylation pattern of Ty1-PKAC1 from both bands was then compared using 
mass spectrometry by Eberhard Krause (MDC, Berlin Buch). For this, the proteins were 
digested with endoproteinases and the molecular weights of the resulting peptides were 
determined. Several digests with different endoproteinases (trypsin, chymotrypsin, Lys-
C and Asp-N) were performed. Masses were determined both in the linear and in the 
reflectron mode of the mass spectrometer. While measurements in the linear mode are 
possible even with relatively low amounts of protein, measurements in the reflectron mode 
result in more accurate masses. A summary of the results from all mass spectrometry 
experiments is shown in figure 7A and B. The graphic color indicates for each experiment 
whether a peptide was found unmodified, modified, both unmodified and modified or not 
detectable. 
The peptides that contain the activation loop threonine 179 (T191 in Ty1-PKAC1) were 
found phosphorylated in both the upper and lower PKAC1 band. These data confirm 
the results from earlier experiments with phosphospecific antibodies described above 
(Schimpf, diploma thesis 2000). 
Differences in phosphorylation between the upper and lower bands were mainly detected 
in the PKAC1 C terminus. The corresponding potentially phosphorylated peptides from 
the Lys-C and Asp-N digest were then sequenced by ESI-QTOF MS (E. Krause, MDC 
Buch) in order to confirm the identity of the peptides and to determine the exact position of 
phosphorylation. A phosphorylation site at position Thr324 (which corresponds to Thr336 
in Ty1-PKAC1) was detected in the peptides from both the Lys-C and Asp-N digest. The 
other potentially phosphorylated peptides were either not found with ESI-QTOF or could 
be unequivocally assigned to non phosphorylated peptides. 
One stumpy specific PKAC1 phosphorylation site was therefore identified C-terminal at 
position Thr324, thus at one of the phosphorylation sites that had been predicted with the 
in silico  approach  described above. PKAC2 has an alanine at the homologous position 
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Fig. 7: Mapping the stumpy specific phosphorylation site of PKAC1 using mass spectrometry:
A and B) Summary of all mass spectrometry experiments
Ty1-PKAC1 from SP cells (MITat1.4 Ty1-PKAC1) was purified via immunoprecipitation and separated on
SDS PAGE as described in 2.2.3.8. . Both, the proteins of the upper (phosphorylated) (A) and lower
(unphosphorylated) (B) band were analyzed by E.Krause using mass spectrometry (MDC, Berlin Buch).
After reduction and alkylation of the cystein residues, the protein containing gel slides were in-gel digested
with different endoproteinases (Trypsin (A,B,C), Chymotrypsin (D,E), Asp-N (F,G) and Lys-C (H,I)). The
peptides were extracted and their masses were determined both in the linear (A,B,D,F,H) and reflectron
mode (C,E,G,I) of the mass spectrometer. The graphic color indicates for each experiment whether a
peptide was found unmodified (light blue), modified (red), both unmodified and modified (orange) or not
detectable (white). Note that the positions of the amino acids correlate to the Ty1-PKAC1 sequence; the
corresponding positions in WT PKAC1 are obtained by substracting 12. Both the activation loop Thr179
(Thr191 in Ty1-PKAC1) and the position of the stumpy specific phosphorylation site at Thr324 (Thr336 in
Ty1-PKAC1) are marked with an asterix.
C) The stumpy specific phosphorylation site in the PKAC1 C-terminus
The aligned C termini of PKAC1 and PKAC2 are shown. The stumpy specific phosphorylation site at
Thr324 of PKAC1 is highlighted yellow. PKAC2 has an alanine at the homologous position. Differences
between the two isoforms are shadowed (gray).
C
310 320 330
PKAC1 … S P G D T S N F E S Y P E S G D K G S P P L T P S Q Q V A F R G
PKAC2 … S P G D T S N F E S Y P E S G D K R L P P L A P S Q Q L E F R G
sequence differences between PKAC1 and PKAC2
T SS phosphorylation site of PKAC1
312 322 332
to PKAC1 Thr324. An alignment of the C-termini of PKAC1 and PKAC2, highlighting the 
PKAC1 phosphorylation site, is shown in figure 7C. 
3.1.1.1.3. The stumpy specific phosphorylation is absent from PKAC2
The mass spectrometry data above implicate that the stumpy specific phosphorylation 
is absent from PKAC2. However, although PKAC2 has no homologous serine or 
threonine to the threonine 324 of PKAC1, it could also be phosphorylated at a distinct 
site. We therefore examined PKAC2 for the presence or absence of a stumpy specific 
phosphorylation detectable as electrophoretic mobility shift. 
For this, PKAC2 was provided with an HA-epitope tag in order to enable its distinction 
from PKAC1 on a Western blot. The tag was added to the PKAC2 N-terminus rather 
than to its C-terminus since it was known from Ty1-epitope tagged PKAC1 that an N-
terminal tag does not interfere with protein expression. The HA-PKAC2 gene was then 
targeted into the PKAC2 locus, rather than expressed from an external site to maintain 
WT expression level and avoid a potentially lethal phenotype (Fig. 8). Clonal cell lines 
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that expressed HA-PKAC2 were easily obtained (clones HA-S2 and HA-S4). PKAC1 and 
PKAC2 from LS and SP cells of this cell line were detected with anti-PKAC1/2 (Fig. 9A). 
Subsequently, the antibodies were removed and HA-PKAC2 was detected with anti-HA 
(Fig. 9B).
 
BstZ171 ClaI
HA-PKAC2MCP RAB7
PKAC2MCP RAB7 genomic locus of PKAC2
pHA-PKAC2NEO
Fig. 8: Replacement of WT PKAC2 by HA-PKAC2
A neomycine resistence gene (NEO: neomycine phosphotransferase, green) together with the 5'UTR and
3'UTR of ACTIN (green, unfilled) was inserted into the 3'UTR of PKAC2. The HA-epitope tag (red) was
introduced at the N-terminus of PKAC2 (blue). The ClaI/BstZ171 digested plasmid integrates into the WT
locus of PKAC2 by homologous recombination.
NEO
As expected, PKAC2 is difficult to detect with anti-PKAC1/2 due to its equal molecular 
weight with PKAC1 and lower expression level (see chapter 3.1.2.). With anti-HA, 
however, PKAC2 is easily detectable as a single band that has equal molecular weight in 
LS and SP cells. The band is absent in cell lysates from WT cells (data not shown). There 
is no indication of a band shift and hence no evidence for stage-specific phosphorylation 
of PKAC2.
LS SP
Fig. 9: PKAC2 lacks the stumpy specific phosphorylation
PKAC2 was tagged with an N-terminal HA-epitope tag to enable its distinction from PKAC1 (cell line: HA-
PKAC2). Cell extracts of LS and SP cells of this cell line were used for Western blotting.
A) Both PKAC1 and PKAC2 were detected with anti-PKAC1/2. Note that PKAC2 constitutes only a small
fraction of PKAC1/2 in BSF cells. The PKAC2 WT band is hidden behind the abundant PKAC1 band.
PKAC2 is less abundant in LS cells than in SP cells (see chapter 3.1.2.).
B) After the removal of the antibodies HA-PKAC2 was detected with anti-HA. No differences in gel
mobilities were detectable between HA-PKAC2 from LS and SP cells.
LS SP
anti-PKAC1/2
A B
anti-HA
HA-PKAC2
PKAC2 /PKAC1-unphos.
PKAC1-phos.
3.1.1.1.4 The stumpy specific phosphorylation has no influence on kinase activity
After the stumpy specific PKAC phosphorylation was successfully mapped and found to 
be restricted to PKAC1, its functional analysis was now feasible. Before starting reverse 
genetic analyses it was at first tested whether the phosphorylation influences the activity 
of PKAC1 in vitro. 
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For this, Ty1-PKAC1 was immunoprecipitated from LS and SP cells with Ty1-protein G 
sepharose beads. Equal amounts of the immunoprecipitates were tested for their abilities 
to phosphorylate the PKA specific peptide substrate kemptide with γ32ATP. To exclude the 
presence of any non-specific, coprecipitated kinases, an immunoprecipitate from WT cells 
was used as a control. Further proof for the specificity of the detected kinase activity is 
provided by the absence of coprecipitated activity with inactive dead mutant (see chapter 
3.2.2, not done in this experiment). Each assay was also performed in the presence of 
the PKA specific inhibitor PKI 5-24 (Kemp et al., 1991). The amount of phosphorylated 
kemptide was quantified and PKI inhibitable activity directly reflects PKAC1 activity 
(Fig. 10A). The measured activities were corrected for the slightly different amounts of 
precipitated Ty1-PKAC1 protein from LS and SP cells, as calculated from a quantitative 
Western blot (Fig. 10B and C). 
Fig. 10: Comparison of PKAC1 activity in LS and SP cells:
Ty1-PKAC1 was immunoprecipitated from LS and SP cells of the cell line Ty1-PKAC1 with anti-Ty1
protain G sepharose beads, using 5*107 cells for each precipitation. To exlude the coprecipitation of an
unspecific kinase activity the immunoprecipitate from an equal amount of WT cells (MITat1.2) was used as
a control. Equal amounts of the immunoprecipitates were tested for their abilities to phosphorylate the
PKA specific peptide substrate kemptide with �32PATP in the presence and absence of 10 �M PKI. Each
assay was done in triplicates. The amount of phosphorylated kemptide was quantified using a liquid
scintilation counter and the average values of the three assays are shown together with the standard
deviations (error bars) (A). To ensure that equal amounts of LS and SP PKA were used, the amount of
PKAC1 in the immunoprecipitates from LS and SP cells was quantified. Therefore amounts of the
precipitate were applied in triplicates to a Western blot and detected with anti-PKAC1/2 (red, secondary
antibody Rabbit Alexa 680) and anti-Ty1 (green, secondary antibody Mouse IRDye800). PKAC1 was
quantified with the Odyssey Software (Licor) (B). The (relative) activity of Ty1-PKAC1 was then calculated
as the quotient from the CPM values of the kinase assay and the (relative) amount of Ty1-PKAC1 as
quantified from the Western blot (C).
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No kinase activity was detected in the immunoprecipitate from the control cells (WT 
cells) that do not contain Ty1-PKAC1. The relative kinase activities from LS and SP cells 
were 241.3±75 (LS) and 245.9±90 (SP) (CPM / [Ty1-PKAC1]). This means that stumpy 
specific phosphorylation does not affect in vitro activity of PKAC1. 
3.1.1.1.5. Site directed mutagenesis at Thr324 of PKAC1 results in the loss of the 
stumpy specific phosphorylation
In order to confirm that Thr324 was in fact the site of the stumpy specific PKAC1 
phosphorylation, mutant cell lines were made that had an alanine or glutamate instead 
of the threonine at position 324. Two transfection rounds were necessary to generate the 
mutant cell lines: The first PKAC1 allele was silenced using the construct p∆PKAC1BSD 
(provided by Paul Hassan). The second PKAC1 allele was subsequently replaced by 
either the mutant PKAC1 genes or unmutated PKAC1, the later serving as a control. 
This way three stable clonal cell lines were obtained (T, A, E). In order to enable 
immunoprecipitations, the mutant cell lines were also produced with a N-terminal Ty1-
epitope tagged PKAC1 (Ty1-T324, Ty1-A324, Ty1-E324). All cell lines are summarized 
in figure 11. 
Southern blot analyses confirmed that both targeting constructs were correctly integrated 
into the PKAC1 genomic locus. The first PKAC1 WT allele was replaced by the PKAC1 
knockout construct and the second one by the mutated Ty1-PKAC1. One of the  Southern 
blots is shown in figure 12. 
PKAC1/2 from LS and SP cells of the mutant cell lines was then detected on a Western 
blot probed with anti-PKAC1/2 (Fig. 13 and B). The Ty1-epitope tagged versions of the 
mutant PKAC1s were also detected with anti-Ty1. It can be seen that PKAC1 from LS 
and SP cells have equal molecular weights in the alanine or glutamate mutant cell lines, 
while PKAC1 of the control cell lines (T324 and Ty1-T324) still had the ability to become 
phosphorylated in SS cells. Thus, the threonine 324 phosphorylation is in fact the stumpy 
specific phosphorylation, responsible for the observed gel mobility shift. The experiment 
does also provide further proof for the absence of the stumpy specific phosphorylation in 
PKAC2. PKAC1 from the glutamate mutant cell line runs slightly higher on SDS PAGE 
than unphosphorylated WT PKAC1 which is due to its additional negative charge. 
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PRP8 ORF1BSD
PRP8 BLE Ty1 PKAC1 ORF1T
324
PRP8 ORF1BSD
PRP8 BLE PKAC1 ORF1T
324
Ty1-T324
E324
A324
T324
Ty1-E324
Ty1-A324
MITat1.2
MITat1.2
MITat1.2
MITat1.2
MITat1.2
MITat1.2
�pkac1::BSD / PKAC1::ty1-pkac1 BLE
�pkac1::BSD / PKAC1::PKAC1 BLE
PRP8 ORF1BSD
PRP8 BLE Ty1 PKAC1 ORF1A
324
PRP8 ORF1BSD
PRP8 BLE Ty1 PKAC1 ORF1E
324
PRP8 ORF1BSD
PRP8 BLE PKAC1 ORF1A
324
PRP8 ORF1BSD
PRP8 BLE PKAC1 ORF1E
324
Fig. 11: Site directed mutagenesis at the stumpy specific phosphorylation site of PKAC1
Both alleles of the PKAC1 genomic locus are shown as a not-to-scale drawing, indicating the postions of
PKAC1 (grey), the selection marker (blue), the Ty1-tag (red) and the site of the mutation (yellow circle).
The neigboring genes of PKAC1 (PRP8 and ORF1) are shown as white boxes.
The first PKAC1 allele was replaced by a blasticidin resistence gene (transfection with p�PKAC1BSD).
The second PKAC1 allele was replaced by the PKAC1 mutants with and without Ty1-epitope tag, using the
constructs pTy1-PKAC1, pTy1-PKAC1-A324, pTy1-PKAC1-E324, pPKAC1-T324, pPKAC1-A324 and
pPKAC1-E324. The cell lines will further be refered to as Ty1-T324, Ty1-A324, Ty1-E324, T324, A324 and
E324, as indicated in bold letters.
The PKAC1/2 genomic locus is described in more detail in attachment 1.
�pkac1::BSD / PKAC1::ty1-pkac1(T324A) BLE
�pkac1::BSD / PKAC1::ty1-pkac1(T324E) BLE
�pkac1::BSD / PKAC1::pkac1(T324A) BLE
�pkac1::BSD / PKAC1::pkac1(T324E) BLE
3.1.1.1.6. Phenotypic analysis of the Thr324 mutant cell lines
The PKAC1 mutant cell lines (T324->A, T324->E) were examined in more detail in order 
to detect potential phenotypes that are due to either the loss of the phosphorylation 
(T324->A) or the constitutive presence of a (phosphorylation simulating) negative charge 
(T324->E).
We did observe a slight reduction in growth with a population doubling time ranging 
from 7 to 9 hours (in comparison to 5.5-6 hours in WT cells) in all cell lines, including the 
control (Fig. 14A). In order to clarify whether this observed growth phenotype was due 
to a block in a certain cell cycle phase, both nuclei and kinetoplast were stained with the 
DNA dye DAPI. With this method three different cell cycle phases are distinguishable 
in trypanosomes: cells with one kinetoplast and one nucleus (1K1N), cells with two 
kinetoplasts and one nucleus (2K1N) and cells with two kinetoplasts and two nuclei 
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Fig. 12: All mutant cell lines have the correct genotype.
Southernblot: Genomic DNA of the mutant cell lines Ty1-T324, Ty1-A324, Ty1-E324, T324, A324 and
E324 (#K6, #A1, #G2, #K2, #A3, #G2-2 respectively) was digested with NdeI / NcoI, separated on an
agarose gel and transferred to a nylon membran. The blot was probed with a PRP8 specific probe (black
line) rather than with a PKAC1/2 probe to also enable the detection of the deleted PKAC1 allele.
Maps of the PKAC1 genomic locus with the integrated constructs are shown for each detected fragment.
The position of PKAC1 (blue), the selection markers (red) and the PKAC1 neighboring genes PRP8 and
ORF1 (unfilled) are indicated. The expected sizes of the DNA fragments are 4980 bp (WT), 2516 bp
(�PKAC1) and 1977 bp (Ty1-PKAC1, all mutants).
The genomic PKAC1/2 locus is shown in more detail in attachment 1.
PRP8 ORF1PKAC1
NdeI NdeI
ORF1PRP8 BSD
NdeI NcoI
ORF1PRP8 Ty1-PKAC1
BLE
NdeI NcoI
WT
�PKAC1::BSD
Ty1-PKAC1
LS SP LS SP LS SP
Ty1-T324 Ty1-A324 Ty1-E324 Ty1-PKAC1-phos.
PKAC2
anti-
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Fig. 13: The stumpy specific phosphorylation is absent in the PKA mutant cell lines A324 and E324
Western blots with protein extract of LS and SP cells (SP, SP1, SP2; SP2 cells were harvested at higher
cell densities than SP1) of the cell lines Ty1-T324, Ty1-A324, Ty1-E324 (A) and T324, A324, E324 (B)
were incubated with anti-PKAC1/2 and in the case of the Ty1-cell lines additionally with anti-Ty1 (after the
removal of the PKAC1/2 antibodies).
A) In the cells lines that contain Ty1 epitope tagged PKAC1, PKAC1 and PKAC2 are clearly
distinguishable with the PKAC1/2 antibody due to the increased molecular weight of Ty1-PKAC1. While
Ty1-PKAC1 from the control cell line (Ty1-T324) still has the stumpy specific phosphorylation, it is absent
from the mutant cell lines Ty1-A324 and Ty1-E324.
B) In the cell lines with untagged PKAC1, PKAC1 and PKAC2 cannot be distinguished. However, only
PKAC1/2 from the control cell line (Ty1-T324) has the stumpy phosphorylation but none of the mutant cell
lines. This experiment provides further proof for the absence of the stumpy specific phoshorylation in
PKAC2.
Ty1-PKAC1-T324->E
Ty1-PKAC1-unphos. /Ty1-PKAC1-T324->A
A
B
PKAC1-unphos. /PKAC2
PKAC1-T324->E
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(2K2N). However, in all mutant cell lines the distribution of these K/N configurations 
appeared approximately normal (Fig. 14B). The only exception was the presence of an 
unusually high percentage of cells with abnormal K/N configurations (distinct from 1K1N, 
2K1N and 2K2N) found in all cell lines, including the control cell lines. Since the deletion 
of one PKAC1 allele results in the reduction of PKAC1 protein, the observed phenotypes 
in growth probably result from gene dosage, rather than from the T324 mutations.  This 
gene dosage phenotype of PKAC1 is investigated in more detail in chapter 3.4.2.2.3. 
The next step was to look whether kinase activation was affected in the mutant cell 
lines. Although no differences in kinase activity were found between PKAC1 from LS 
and PKAC1 from SP cells (see fig. 10 in chapter 3.1.1.1.4.), we were never able to test 
whether the kinase activation mechanism was dependent on the stumpy phosphorylation, 
since PKAC1 from both LS and SP cells is always a mixture of phosphorylated and 
unphosphorylated protein. With the availability of the PKAC1 mutant cell lines this problem 
was overcome and we therefore compared the different PKAC1 mutants in respect to their 
reaction on PKA activating agents. Since activation of T. brucei PKA-like kinase was still 
unsolved, both cAMP and cGMP (Shalaby et al., 2001; compare also chapter 3.3) were 
tested for kinase activation. Kinase assays were performed with immunoprecipitated Ty1-
PKAC1 from all mutant cell lines in the presence of 0.1 mM cAMP or cGMP. The amount 
of phosphorylated PKA substrate (kemptide) was quantified (Fig. 14C). Since the assay 
was not corrected for equal amounts of protein from the different cell lines, the absolute 
values of the activities are not comparable. None of the mutant PKAs was activated by 
cyclic AMP, while PKA activities were doubled in the presence of cGMP. The significance 
of cGMP for kinase activation will be discussed later. In this context, it is only important 
to stress the absence of any differences in activation between the different mutant PKAs 
and the WT PKA-like kinase (control).
Furthermore, the stumpy specific phosphorylation was examined for any influence on 
the differentiation process into procyclic cells. Therefore, SP cells of the cell lines Ty1-
T324, Ty1-A324, Ty1-E324, T324, A324, E324 were in vitro transformed into PCFs. The 
success of the transformation was controlled morphologically and in addition, the growth 
was measured (Fig. 14D). All mutant cell lines were equally well able to transform into 
procyclic cells. 
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Fig. 14: Phenotypic characterization of the PKAC1 Thr324 mutant cell lines :
A) Growth: Cells of the cell lines Ty1-T324, Ty1-A324, Ty1-E324, T324, A324 and E324 were grown for
264 hours. Cell densities were measured regularly in a Neubauer chamber and cells were kept at cell
densities below 8 *105 cells/ml.
B) K/N configurations: 400 DAPI stained cells from three slides were analyzed for each cell line (T324,
A324, E324, Ty1-T324, Ty1-A324, Ty1-E324). The average values of the three analyses are shown and
the standard deviations are indicated as error bars.
C) PKA Activation: A kinase assay was performed with immunoprecipitated Ty1-PKAC1 of the cell lines
Ty1-T324, Ty1-A324 and Ty1-E324. For activation, 0.1 mM cAMP or cGMP was added. Each assay was
done twice (double bars). Note that the absolute activities of the different cell lines are not comparable
since the precipitated protein amounts were not corrected. Aliquots of the immunoprecipitates were
applied to a Western blot probed with anti-PKAC1/2 to control for the success of the immunoprecipitation
(bottom).
D) Transformation into PCFs: The mutant cell lines T324, A324, E324, Ty1-T324, Ty1-A324 and Ty1-
E324 were transformed into procyclic cells in vitro. The cell density was measured regularly and the cells
were kept at cell densities below 1*107 cells/ml. In addition, the success of the transformation was
controlled morphologically.
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Altogether, we were unable to detect any differences between the cell lines with WT 
PKAC1 and the PKAC1 mutant cell lines. Thus, we did not find a function for the stumpy 
specific phosphorylation using this reverse genetic approach. 
3.1.1.2. The PCF modification
The second PKAC1/2 modification that was identified with the gel mobility shift 
experiments is exclusively present in procyclic cells. The gel mobility shift is much smaller 
than the gel mobility shift of the stumpy specific phosphorylation. Previous experiments 
to determine the nature of the PCF modification failed. 
The analysis of the PCF modification in this work was restricted to two questions:
The first was to find out, whether the PCF modification was present in both PKAC1 
and PKAC2. It seems present in PKAC2, since PKAC2 is the dominant isoform in PCF 
cells with PKAC1 hardly being detected on a Western blot (compare chapter 3.1.2.). If 
the PCF modification would be absent from PKAC2, the gel retardation would not be 
detectable on a Western blot probed with anti-PKAC1/2. In order to examine whether the 
PCF modification is also present in PKAC1, we transformed PKAC2 knock-out cells (the 
cell line is described in chapter 3.4.2.2.1.) into procyclic cells. The gel mobility of PKAC1 
during that transformation was monitored by a Western blot (Fig. 15A). It can be seen that 
PKAC1 also show the gel retardation initiating a PCF specific modification.
Secondly, the time point of the PKAC1/2 modification was determined. For this, 
monomorphic WT SP cells were in vitro transformed into procyclic cells and the gel 
mobility of PKAC1/2 as well as the growth of the cells was monitored (Fig. 15B). It can 
be seen that PKA is modified between 12 and 14 hours after the initiation of an in vitro 
transformation, exactly at the time when cells restart proliferating.
No attempt was made to map the PCF-specific phosphorylation site. 
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Fig. 15: The PKAC1/2 PCF modification:
A) The PCF modification is present in PKAC1
PKAC2 knock-out cells (described in chapter
3.4.2.2.1.) were in vitro transformed into procyclic
cells. Cell samples were harvested after the times
indicated and analyzed by a Western blot probed
with anti-PKAC1/2. The PCF bandshift, in this cell
line exclusively due to a PKAC1 modification, is
marked with an arrow.
B) The PCF modification is detectable 14 hours
after the initiation of transformation
MITat1.2. BSF cells were in vitro transformed into
procyclic cells. Cells were harvested after the
times indicated and PKAC1/2 was detected via a
Western blot probed with anti-PKAC1/2. The PKA
PCF band shift is marked with an arrow.
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3.1.2. Protein expression levels of PKAC1 and PKAC2 in BSF and PCF
PKAC1 and PKAC2 differ not only in their posttranslational modification patterns but also 
in their life cycle stage dependent changes in mRNA steady state levels. With Northern 
blots it was previously shown that PKAC1 mRNA is mainly found in BSF cells, while 
PKAC2 mRNA is the abundant transcript in procyclic cells (E. Vassella, unpublished). 
Thus, it seems that the expression of PKAC1/2 is mainly regulated via mRNA stability, 
as is the case for most T. brucei genes. However, since protein expression in T. brucei 
is also frequently regulated on the translational and posttranslational level, the actual 
expression of PKAC1 and PKAC2 protein is not predictable from mRNA steady state 
levels. 
We therefore aimed to investigate the protein expression levels of PKAC1 and PKAC2 
in the different developmental stages by a Western blot. Since our antibody cannot 
distinguish between PKAC1 and PKAC2 and both isoforms have nearly identical 
molecular weights, it was necessary to artificially increase the molecular weight of one 
isoform. This was achieved by the replacement of one PKAC1 allele by the (heavier) 
Ty1-epitope tagged PKAC1. The second PKAC1 allele was silenced with the construct 
p∆PKAC1BSD (provided by P. Hassan). In this way both isoforms are easily distinguishable 
on a Western blot by their different mobilities, the slower form being Ty1-PKAC1 and the 
faster form being exclusively PKAC2. The cell line (Ty1-T324) was already available from 
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the functional analyses of the stumpy specific phosphorylation described above. For the 
analysis of the life cycle stage specific expressions, this cell line was transformed into SP 
cells and PCF cells. 
PKAC1 and PKAC2 expression of LS, SP and PCF cells was compared via Western blot 
probed with anti-PKAC1/2 and anti-Ty1. In addition, the blot was incubated with anti-PFR 
(paraflagellar rod) to control for equal loading. (Fig. 16)
It can be seen that the total amount of PKAC1/2 remains approximately constant 
throughout the life cycle stages, although the expression of each isoform changes 
significantly. Thus, PKAC1 is the dominant PKA in BSF cells and is expressed at 
approximately equal levels in both LS and SP cells but is not detectable in PCF cells. 
PKAC2 is mainly expressed in procyclic cells, but constitutes a minor proportion of the 
BSF PKAC1/2 that is slightly higher in SP cells than in LS cells. 
These life cycle stage specific differences in PKAC1 and PKAC2 expression correspond 
roughly to the results from the transcription analyses. 
LS SP PCF
Ty1-PKAC1-phos.
PKAC2
Ty1-PKAC1-phos.
PFR
anti-
PKAC1/2
anti-Ty1
anti-PFR
(loading control)
Fig. 16: Expression of PKAC1 and
PKAC2 protein in the different life cycle
stages of T. brucei.
A) Simplified genetic map of the PKAC1/2
genomic locus in the cell line Ty1-T324.
Both alleles of the PKAC1/2 locus are
shown. One PKAC1 allele was replaced by
Ty1-PKAC1, the other by a blasticidine
resistence gene using the construct
p�PKAC1BSD (P. Hassan). Both PKAC2
alleles remained unchanged. The PKAC1/2
genomic locus is shown in more detail in
attachment 1.
B) Cell extracts from LS, SP and PCF cells
of the monomorphic cell line Ty1-T324
(clone 6) were applied to a Western blot.
Both Ty1-PKAC1 (upper bands) and
PKAC2 (lower bands) were detected with
anti-PKAC1/2. Additionaly, Ty1-PKAC1 was
detected with anti-Ty1 after the PKAC1/2
antibodies had been removed. PFR was
used to control for equal loading.
A
B
PKAC1
PKAC2
PKAC2Ty1
Ty1-PKAC1-unphos.
Ty1-PKAC1-unphos.
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3.2. Composition of the T. brucei PKA-like holoenzyme
PKAs from higher eukaryotes are heterotetramers consisting of two regulatory and two 
catalytic subunits. Whether this classical subunit composition also applies to T. brucei 
PKA-like kinase still remains unknown. Although C. Schulte zu Sodingen could show 
via coimmunoprecipitation studies that PKAC1/2 and PKAC3 are able to bind to the 
regulatory subunit (Ph.D. thesis 2000), the question of holoenzyme composition could 
not be solved with this approach. 
To determine the subunit composition of T. brucei PKA-like kinase, three different 
approaches, all based on coimmunoprecipitation studies, have been used. The 
differences lie in the detection  of the coprecipitated proteins. 
3.2.1. Coimmunoprecipitation studies with subsequent immunoblotting
Firstly, immunoprecipitations of each subunit were coupled to detect the potentially 
coprecipitated subunits via a Western blot using specific antibodies. Two problems needed 
to be solved in advance: Firstly, a coprecipitation of the same subunit (homodimer) is not 
detectable with this method. Secondly, specific antibodies are only available for PKAR 
and PKAC3 since anti-PKAC1/2 cannot distinguish between PKAC1 and PKAC2. As a 
solution, each subunit of T. brucei PKA-like kinase was provided with an epitope tag. 
Epitope tagged subunits run slower on SDS gel and are easily distinguishable from WT 
subunits. Different epitope tags for PKAC1 and PKAC2 enable a distinction between the 
two. 
 
3.2.1.1. Generation of cell lines that express epitope tagged subunits
Four different stable cell lines were needed, one for the expression of each epitope 
tagged subunit of T. brucei PKA-like kinase. Therefore, Ty1 epitope tagged versions of 
PKAR, PKAC3, PKAC1 and HA epitope tagged PKAC2 were (over)expressed either from 
extragenic sites (PKAR, PKAC3) or by gene replacement of one WT allele (PKAC1 and 
PKAC2). All cell lines and constructs are summarized in table 2. Note that in each cell line 
all four WT subunits are present along with one epitope tagged subunit. 
At first, the expression of the different epitope tagged proteins was controlled. For this, 
Western blots were stained with subunit specific antibodies (red) and the epitope tag 
antibody (green) (Fig. 17A).
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subunit Name of the cell line Clone Construct Epitope tag Expression
C1 Ty1-PKAC1 #1 pTy1-PKAC1 Ty1 gene replacement
C2 HA-PKAC2 #S2 pHA-PKAC2 HA gene replacement
C3 Ty1-PKAC3 pool pTSArib Ty1-PKAC3 Ty1 overexpression (rDNA locus)
R Ty1-PKAR
(C. Schulte zu Sodingen)
#C2 pLew82 Ty1-PKAR Ty1 overexpression (rDNA locus)
Table 2: Overview about the cell lines with the epitope tagged subunits of T. brucei PKA-like kinase. 
Name and clone number is indicated for each cell line together with the name of the construct used for 
transfection. pTSArib integrates into the ribosomal promoter region (Xong et al., 1998). pLew82 integrates 
into the non transcribed ribosomal spacer region. Expression is driven by the T7 promoter. (Wirtz et al., 1999) 
The Ty1-PKAR cell line was already available (C. Schulte zu Sodingen, Ph.D. thesis 2000).
Yellow bands result from color blending and represent the epitope tagged PKA-like subunits 
(red and green). It can be seen that all epitope tagged proteins are actually expressed 
(yellow bands). As expected, in the gene replacement cell lines (Ty1-PKAC1 and HA-
PKAC2) the expression levels of the epitope tagged and WT subunits were approximately 
equal. They are easily distinguishable due to the gel mobility shift caused by the epitope 
tag. However, in the overexpression cell lines (Ty1-PKAC3 and Ty1-PKAR) the amount 
of epitope tagged subunit was higher than the amount of WT subunit. This complicated 
the detection of the corresponding WT subunit. In comparison to WT cells, PKAC3 
expression was 10 times higher in the Ty1-PKAC3 cells and upon tetracycline induction 
Ty1-PKAR expression was 2.5 times higher (Fig. 17B). However, the overexpression 
cell lines are nevertheless suitable for the subsequent coimmunoprecipation studies, 
since the interaction between two subunits is always confirmed ʻfrom both sitesʻ with 
two independent precipitations. Any influence of the unnaturally high expression levels 
of Ty1-PKAR and Ty1-PKAC3 on the result of the coimmunoprecipitation experiment will 
thus be noticed. 
3.2.1.2. Catalytic subunits are only coprecipitated with the regulatory PKA subunit 
but not with another catalytic subunit 
The different epitope tagged subunits from the cell lines described above were 
immunoprecipitated with anti-Ty1 or anti-HA protein G sepharose beads. The precipitates 
were applied to four Western blots, each containing samples of each immunoprecipitation. 
The Western blots were probed with the three different PKA antibodies (red) and 
additionally with the epitope tag antibodies (green) (Fig. 18). It can be seen that PKAR is 
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the only subunit that was coprecipitated with Ty1-PKAC1, HA-PKAC2 and Ty1-PKAC3. 
None of the catalytic subunits were found to coprecipitate with any of the other catalytic 
subunits or the same (untagged) catalytic subunit. Ty1-PKAR coprecipitates all three 
catalytic subunits as seen previously. There is no evidence that Ty1-PKAR coprecipitates 
Ty1-
PKAC1
HA-
PKAC2
Ty1-
PKAC3
anti PKAC1/2 PKAC1/2 PKAC3 PKAR
anti Ty1 HA Ty1 Ty1
cellline:
Fig. 17: Expression of the epitope tagged subunits Ty1-PKAC1, HA-PKAC2, Ty1-PKAC3 and Ty1-
PKAR.
A) Detection of the epitope tagged subunits of T. brucei PKA-like kinase on a Western blot
The expression of the epitope tagged proteins from the cell lines Ty1-PKAC1, HA-PKAC2, Ty1-PKAC3
and Ty1-PKAR was controlled on a Western blot. For this, cell extract from 5*106 cells of each cell line
was applied to SDS PAGE and the resulting Western blot was incubated with the different PKA antibodies
(anti-PKAC1/2, anti-PKAC3, anti-PKAR). In addition, each Western blot was also incubated with anti-Ty1
or anti-HA antibody, as indicated. Rabbit Alexa680 (red) was used for the detection of the PKA antibodies
while MouseIRDye800 (green) was used as secondary antibody for the detection of anti-Ty1 and anti-HA.
Proteins that are recognized by both antibodies appear yellow.
It can be seen that each epitope tagged subunit is expressed (yellow bands).
B) Expression levels of Ty1-PKAC3 and Ty1-PKAR in comparison to WT cells
Cell lysates from 5*106 cells of the Ty1-PKAC3 and Ty1-PKAR cell lines and of WT cells were applied to
SDS PAGE and the resulting Western blot was probed with anti-PKAC3 or anti-PKAR and additionally with
anti-Hsp60 that served as loading control. The PKA antibodies were detected with Rabbit Alexa680 (red).
The Hsp60 antibody was detected with MouseIRDye800 (green). The amount of PKAR and PKAC3 in the
overexpression cell lines and in WT cells was quantified using the Odyssey Software (Licor) and is shown
in the diagram below (WT=100%). The data were corrected for unequal loading using Hsp60.
Note that both PKAC3 and PKAR are always detected as double bands on Western blots. This is probably
due to posttranslational modifications that have not been examined further in this work.
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precipate:
Fig. 18: Coimmunoprecipitation studies with the different epitope tagged subunits
The interactions between the different subunits of T. brucei PKA-like kinase were examined using
coimmunoprecipitation studies. For this, Ty1-PKAC1, HA-PKAC2, Ty1-PKAC3 and Ty1-PKAR were
immunoprecipitated with the epitope tag antibodies anti-Ty1 or anti-HA (4 different precipitations). The
precipitates were run on four SDS gels, each precipitate was loaded to each gel. The gels were blotted,
and each blot was probed with a different PKA antibody together with the respective anti-tag antibody anti-
Ty1 or anti-HA, as indicated. Anti-rabbit Alexa680 (red) was used as secondary antibody for the PKA
antibodies while MouseIRDye800 (green) was used as secondary antibody for anti-Ty1 and anti-HA. Note
that the HA antibody recognizes one unspecific band at around 50 kDa (white circle). Also, anti-PKAC3
recognizes PKAC1/2 (cross reaction), although to a much lower extent than it recognizes PKAC3 (white
square).
Each Western blot is shown three times. On the left side it is shown with both secondary antibodies. PKA
that is recognized by both antibodies appears yellow. In the center the same blots are shown with the PKA
antibodies only (red) and on the right side with the epitope tag-antibodies only (green).
The first lane of each blot contains immunoprecipitate of the Ty1-PKAC1 cell line. Ty1-PKAC1 was
detected with anti-PKAC1/2 (blot 1 and 2) and anti-Ty1 (blot 1,3,4) as expected. The only coprecipitated
PKA subunit was PKAR (red band on blot 4). Coprecipitation of WT PKAC1/2 can be excluded since WT
PKAC1/2 would have been detectable as a red band in blot 1 with lower molecular weight than Ty1-
PKAC1. Furthermore, coprecipitation of PKAC3 is also excluded, since PKAC3 would have been
detectable on blot 3. The second lane of each blot contains immunoprecipitate of the HA-PKAC2 cell line.
HA-PKAC2 was detected with anti-PKAC1/2 (blot 1 and 2) and anti-HA (blot 2), as expected. Again, the
only coprecipitated PKA subunit was PKAR (blot 4). It has the same size than the (stronger) unspecific
band of the HA-antibody and is therefore best visible in the absence of that band (center row). Neither WT
PKAC1/2 nor PKAC3 were coprecipitated. The third lane of each blot contains immunoprecipitate from the
Ty1-PKAC3 cell line. As expected, Ty1-PKAC3 was detected with anti-PKAC3 (blot 3) and anti-Ty1 (blot
1,2,4). Again, only PKAR (blot 4) but none of the other PKA subunits is coprecipitated with Ty1-PKAC3.
The fourth lane contains immunoprecipitate of the Ty1-PKAR cell line. Ty1-PKAR was detected with anti-
PKAR (blot 4) and anti-Ty1 (blot 1,3,4). PKAC1/2 (blot 1,2) and PKAC3 (blot3) were coprecipitaed with
Ty1-PKAR.
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the WT regulatory subunit, although this cannot be excluded, since Ty1-PKAR is difficult 
to distinguish from untagged PKAR due to a very slight change in gel mobility.
These results implicate that the T. brucei PKA-like holoenzyme is a dimer that consists 
of one regulatory and one of three catalytic subunits (C1R1). It therefore differs from the 
classical tetrameric PKA subunit composition (C2R2).
3.2.2. No further coimmunoprecipitated PKAR subunits were detectable on a 
Coomassie stained gel
Genes for several putative cNMP binding proteins have in the meantime been found in 
the T. brucei genome database (see also chapter 3.5.1.). Some of these might potentially 
be additional interacting regulatory subunits. 
Therefore, the coimmunoprecipitation experiment was repeated with the Ty1-PKAC1 
cell line as described above with the exception that the coprecipitated proteins were 
detected with the protein dye Coomassie Blue, rather than with PKA specific antibodies. 
To enable the distinction between unspecific coprecipitated proteins and proteins that 
bind to Ty1-PKAC1, a control immunoprecipitation was performed with WT cells. 3*108 
cells were used for each immunoprecipitation. The Comassie stained gel with the 
immunoprecipitates of WT and Ty1-PKAC1 cells is shown in figure 19. As expected, both 
Ty1-PKAC1 and PKAR were precipitated from Ty1-PKAC1 cells, but not from WT cells. 
However, no additional proteins selectively coprecipitated with Ty1-PKAC1.
Fig. 19: Detection of coprecipitated proteins of Ty1-PKAC1
on a Coomassie stained gel
Ty1-PKAC1 was immunoprecipitated from 3*108 WT cells
(control) and 3*108 Ty1-PKAC1 cells with anti-Ty1-protein G
sepharose beads. The protein containing beads were heated in
Laemmli buffer and applied to SDS page. The gel was stained
with Coomassie Blue. It can be seen that Ty1-PKAC1 and
(coprecipitated) PKAR were present in the immunoprecipitate
from the Ty1-PKAC1 cell line, but absent from the
immunoprecipiate of WT cell, as expected.
In addition, two other proteins were detected in the
immunoprecipitates. However, since these proteins were present
in the immunoprecipitate of both WT cells and Ty1-PKAC1 cells,
they are either unspecifically precipitated or protein components
of the anti-Ty1-protein G sepharose. The smaller protein might be
identical to Protein G (6.5 kDa).
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Two proteins were detected in both the WT and Ty1-PKAC1 precipitate. They can 
therefore be attributed to proteins that are either unspecifically coprecipitated or to 
proteins that origin from the Ty1-protein G sepharose beads (e.g. protein G). 
Thus, no further PKAC1 binding partners were detected with that method.
3.2.3. No kinase activity was coprecipitated with an inactive PKAC1 (dead mutant)
In order to ensure that no further (yet unknown) catalytic subunits were coprecipitated, 
we made one additional experiment that was based on the detection of (potential) 
coprecipitated kinase activity, rather than on the detection of the protein itself. For this, a 
cell line was produced that had one WT PKAC1 allele replaced by a dead mutant PKAC1. 
Dead mutant PKAC1 is catalytically inactive due to an amino acid substituation (N165-
>A) in its catalytic center. The dead mutant PKAC1 was additionally provided with an 
Ty1-epitope tag to enable immunoprecipitation. If T. brucei PKA-like kinase is a dimer, as 
suggested from the experiments above, no kinase activity should be coprecipitated. 
Ty1-PKAC1-dead from three independent clones of the cell line Ty1-PKAC1-dead (#11, 
12, 14) was immunoprecipitated with anti-Ty1. As a positive control, (active) Ty1-PKAC1 
from two independent clones (#1,2) of the Ty1-PKAC1 cell line was also precipitated. 
The immunoprecipitates were assayed for their abilitiy to phosphorylate the PKA specific 
substrat kemptide, as described earlier. The amount of phosphorylated kemptide was 
quantified as a measure of kinase activity (Fig. 20). 
No activity was precipitated with any of the dead mutant PKAC1 clones, although the 
immunoprecipitation was successfull (Western blot). In contrast, the positive control, 
Ty1-PKAC1, showed significant activity that could be inhibited with the PKA specific 
inhibitor PKI. Conclusively, no additional catalytic subunit or contaminating kinase was 
coprecipitated with Ty1-PKAC1. 
Taken together, all three coimmunoprecipitation experiments revealed that T. brucei PKA-
like kinase is a dimer consisting of one regulatory subunit and one out of three catalytic 
subunit isoforms. No evidence for additional interacting proteins or kinase activities was 
obtained. 
Results
66
0
5
10
15
20
no inhibitor
PKI
control Ty1-PKAC1 Ty1-PKAC1-dead
#1 #2 #11 #12 #14
anti-PKAR
anti-PKAC1/2
anti-Ty1
anti-Ty1 and
anti-PKAC1/2
Fig. 20: No kinase activity is coprecipitated with PKAC1 dead mutants:
Ty1-PKAC1-dead from three independent clonal cell lines (#11,12,14) and Ty1-PKAC1 from two
independent clonal cell lines (#1,2; positive control) was immunoprecipitated with anti-Ty1 protein G
sepharose beads. To control for the specificity of the precipitation, an additional immunoprecipitation was
performed using WT cells (control). Equal amounts of the precipitates were assayed for kinase activity as
described in 2.2.3.9.. Each reaction was done three times and in addition once in the presence of the PKA
specific inhibitor PKI (Kemp et al., 1991). The graphic (top) shows the kinase activities (in 1000 CPM) for
each clone. Mean values of the three reactions are shown and the standard deviations are indicated by
error bars.
Parts of the immunoprecipitates were used for Western blotting (bottom) to control for the success of the
precipitation and to ensure that equal amounts of the proteins were used for the kinase assays. PKAC1
was detected with anti-PKAC1/2 and anti-Ty1. Coimmunoprecipitated PKAR was detected with anti-PKAR.
The secondary antibodies Rabbit Alexa680 (red) and MouseIRDye800 (green) were used for the detection
of anti-PKAC1 / anti-PKAR and anti-Ty1, respectively.
It can be seen that no kinase activity is coprecipitated with the dead mutant of PKAC1.
PKAR
Ty1-PKAC1-phos.
Ty1-PKAC1-unphos.
Ty1-PKAC1-phos.
Ty1-PKAC1-unphos.
Ty1-PKAC1-phos.
Ty1-PKAC1-unphos.
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3.3. Activation of T. brucei PKA-like kinase
3.3.1. cGMP, not cAMP causes in vitro dissociation of the holoenzyme
The dissociation of the holoenzmye of PKA-like kinase by cyclic nucleotides was studied 
using the following in vitro assay: The holoenzyme complex of catalytic and regulatory 
subunit was immunoprecipitated via Ty1-PKAC1 and remained coupled to the protein G 
sepharose beads. Upon addition of cAMP or cGMP, release of PKAR into the supernatant 
was monitored. All reactions were performed in the presence of PKI 5-24, a PKA specific 
peptide inhibitor that binds to the catalytic center of all characterized PKAs (Kemp et al., 
1991). This way the reassociation of the holoenzyme complex was prevented with the 
aim to drive the reaction towards holoenzyme dissociation. After 60 minutes of incubation 
at 30 °C, beads and supernatant were separated by filtration and the amount of PKAC1 
and PKAR in each fraction was analyzed by a Western blot (Fig. 21). 
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Fig. 21: The holoenzyme of PKA-like kinase partially dissociates in the presence of mM
concentrations of cGMP, but not of cAMP.
Holoenzyme of PKA-like kinase was coupled to anti-Ty1 protein G sepharose beads via the Ty1-PKAC1
subunit. The beads were incubated with cAMP [1 mM] or cGMP ([0.1 mM] and [1 mM]) in the presence of
PKI [5 �M] for 60 minutes at 30�C on a shaker. Each reaction was performed in duplicates.
In case of holoenzyme dissociation, PKAR would be released from the beads into the supernatant. The
supernatant was separated from the beads by filtration. Ty1-PKAC1 and PKAR coupled to the beads
(beads) and free PKAR released into the supernatant (SN) were detected via a Western blot probed with
anti-PKAC1/2 and anti-PKAR. It can be seen that both Ty1-PKAC1 and PKAR are always detected in the
beads fraction. A partial release of the regulatory subunit into the supernatant was only observed in the
presence of 1 mM cGMP, but not with cAMP. Note that the film was overexposured on purpuse to stress
the absence of any PKAR in the supernatant without cAMP.
Upon incubation with cAMP, both PKAC1 and PKAR were detected in the “beads fraction” 
but completely absent from the supernatant, thus, cAMP was unable to dissociate the 
PKA-like kinase holoenzyme. These results were consistent with the inability of cAMP 
to activate PKA-like kinase as observed previously (Schulte zu Sodingen, Ph.D. thesis 
2000). In contrast, incubation with >0.1 mM cGMP led to the partial release of PKAR into 
the supernatant. No holoenzmye dissociation was detected in the absence of PKI (data 
not shown).
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3.3.2. cGMP, but not cAMP can activate PKA-like kinase in vitro 
The holoenzyme dissociation experiments described above already implicate that the 
activation of T. brucei PKA-like kinase differs from the classical PKA activation mechanism 
that involves cAMP. 
Therefore, the influence of both cAMP and cGMP on the activity of PKA-like kinase was 
tested. In addition the effects of the lipophilic derivatives pCPT-cAMP and pCPT-cGMP 
on kinase activity were examined in order to enable a comparison of these in vitro data 
with subsequent in vivo experiments. The holoenzyme of PKA-like kinase was purified 
by immunoprecipitation via Ty1-PKAC1. Equal amounts of the immunoprecipitate were 
incubated with the different cyclic nucleotides at different concentrations and tested for 
their ability to phosphorylate the PKA substrate RRRRSIIFI 1) with γ32 P-ATP. As a control 
for the specificity of the measured activity we used catalytically inactive PKAC1 dead 
mutant (N165->A) (described in chapter 3.2.3.).
 
As can be seen in figure 22A, an increase in kinase activity was only detected in the 
presence of cGMP or pCPT-cGMP, but not with cAMP or its derivatives. Kinase activity 
was found to increase 5 fold in the presence of 1 mM cGMP and 1.5 fold in the presence 
of 0.1 mM cGMP. Interestingly, 10 times more pCPT-cGMP was needed to give the same 
activating effect as cGMP. 
We next examined whether there were any differences in activation between the 
holoenzymes isoforms RC1, RC2 and RC3. Therefore, kinase assays were performed 
with activity precipitated via HA-PKAC2, Ty1-PKAR or Ty1-PKAC3 (Fig. 22B-D). 
None of the holoenzyme isoforms was activated by cAMP. When the holoenzyme was 
precipitated via HA-PKAC2 or Ty1-PKAR a five fold activation was achieved with 1 mM 
cGMP and an 1.5 to 2 fold activation was observed with 0.1 mM cGMP. These results are 
consistent with the activation of the holoenzyme observed after precipitation with Ty1-
PKAC1. In contrast, Ty1-PKAC3 precipitated holoenzyme was not activated by cGMP. It 
should be noted that Ty1-PKAC3 has a ten times higher expression level than PKAC3 in 
WT cells (see Fig. 17B in chapter 3.2.1.1.). It is therefore possible that only a fraction of 
PKAC3 is bound to the regulatory subunit. Most of the enzyme might be already active 
and hence no activation results from addition of cyclic GMP.
1)  RRRRSIIFI is a small peptide that was identified as the best PKA substrate with the aid of an oriented peptide library 
(Songyang et al., 1994). For T. brucei PKA-like kinase it works equally well as the classical PKA peptide substrate kemptide 
(LRRASLG) (data not shown). 
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3.3.3. T. brucei PKA-like kinase is not activated by cXMP, cIMP, cUMP or 
cCMP
The cGMP concentration necessary for activation of the T. brucei PKA-like kinase of 1 
mM is between 1 to 3 orders of magnitudes higher than cGMP concentrations needed 
to activate cGMP dependent kinases (PKGs) in other organisms (compare table 8 in 
4.1.2.1.). Furthermore, neither guanylyl cyclases nor cGMP specific phosphodiesterases 
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Fig 22: PKA-like kinase is activated with cGMP and pCPT-cGMP, but not with cAMP
Holoenzyme of T. brucei PKA-like kinase was immunoprecipitated via Ty1-PKAC1 (A), HA-PKAC2 (B),
Ty1-PKAC3 (C) or Ty1-PKAR (D). The immunoprecipitated PKA-like kinases were tested on their abilities
to phosphorylate the PKA specific substrate RRRRSIIFI (Songyang et al., 1994) with �32P-ATP in the
absence (control) and presence of different cyclic nucleotides or cyclic nucleotide derivatives. The amount
of phosphorylated PKA substrate was quantified with a liquid scintillation counter as a measure of kinase
acitivity. Each reaction was done in triplicates. Average values are shown (white bars) and the standard
deviation is indicated by error bars. Additionally, each reaction was done once in the presence of the PKA
specific inhibitor PKI (grey bars).
For experiment A) two additional controls were performed:
First, the specificity of the measured activity was controlled using an inactive mutant kinase (Ty1-PKAC1-
dead). It can be seen that no contaminating kinase activity was coprecipitated with the dead mutant Ty1-
PKAC1. Secondly, the success of the immunoprecipitations was controlled on a Western blot with samples
of the immunoprecipitates. The Western blot was probed with anti-PKAC1/2, anti-PKAR and anti-Ty1,
using anti-rabbit Alexa680 (red) and anti-MouseIRDye800 (green) as seondary antibodies. It can be seen
that both immunoprecipitations were successfull. PKAR was coprecipitated with Ty1-PKAC1 and Ty1-
PKAC1-dead.
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have yet been described in trypanosomes and it is still unclear whether cGMP is present 
at all. Therefore, it remains doubtable whether cGMP is in fact the physiological PKA 
activator in T. brucei. Alternatively, PKA-like kinase could be activated by other cyclic 
nucleotides that are distinct from both cAMP and cGMP. One might expect the activating 
cyclic nucleotide to be structurally more similar to cGMP than to cAMP. We therefore 
tested the purine based cyclic nucleotides cyclic Xanthosine monophosphate (cXMP) 
and cyclic Inosine monophosphate (cIMP) for their abilities to activate PKA-like kinase. 
Both, cXMP and cIMP differ only at position C2 of the guanine nucleobase from cGMP. 
In addition, we tested two pyrimidine based cyclic nucleotides (cUMP and cCMP). (Fig. 
23A) The results of the kinase assay are shown in figure 23B. It can be seen that none 
of the tested cyclic nucleotides was able to activate T. brucei PKA-like kinase, although 
there was a very slight increase in kinase activity after incubation with the purine based 
cyclic nucleotides cIMP and cXMP. Thus, none of the tested cyclic nucleotides was any 
better than cGMP.
 
3.3.4. Detection of in vivo kinase activity with the PKA reporter substrate 
VASP
The unusually high cGMP concentrations needed for kinase activation could also be 
an artefact of the in vitro conditions of the kinase assay. Activation might depend on 
conditions, cofactors or on a specific intracellular localization not available in vitro. An in 
vivo approach was therefore chosen to further investigate the kinase activation. 
3.3.4.1. Transgenic expression of the PKA reporter substrate VASP in T. brucei
The mammalian vasodilator-stimulated phosphoprotein (VASP) plays an important role in 
actin filament assembly and cell motility in a variety of organisms and cell types (Krause 
et al., 2003). In addition, it is a substrate for PKA and PKG making it a useful reporter for 
cyclic nucleotide signaling (Smolenski et al., 1998; Aktas et al., 2003; Hou et al., 2003; 
Deguchi et al., 2002 and others). VASP has three phosphorylation sites that are specific 
for either PKA or PKG. In this context only the PKA specific phosphorylation site at Ser157 
is of interest. Phosphorylation at this site results in an apparent shift of molecular mass 
from 46 to 50 kDa (Smolenski et al., 1998) and can thus be detected on a Western blot. 
We aimed to use VASP as a reporter substrate to analyze in vivo PKA activity in T. 
brucei. Since trypanosomes have no genes that are homologous to VASP, it was 
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necessary to express VASP transgenically. For this, VASP cDNA from human HL-60 cells 
(Haffner et al., 1995; kindly provided by the laboratory of Ulrich Walter, Würzburg) was 
cloned into the overexpression vector pTSArib (Xong et al., 1998) and transfected into 
trypanosomes (MITat1.2). Only one hygromycin resistant clone was obtained showing 
a slight growth phenotype. Cells adapted to normal growth after one week in culture. 
The expression of VASP was controlled by a Western blot. VASP from 5*105 cells was 
easily detectable with the polyclonal antibody AB19728 (kind gift from Thomas Renné 
and Ulrich Walter, Würzburg; Halbrügge et al., 1990) (Fig. 24) and equally well with anti-
VASP M4 (Immunoglobe) (data not shown). Two VASP bands could be distinguished 
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Fig 23: PKA-like kinase is not activated with
cXMP, cIMP, cCMP or cUMP.
A) Structures of the different cyclic
nucleotides that were tested on their ability to
activate T. brucei PKA-like kinase (pictures
taken from www.biolog.de).
B) Kinase assay: The holoenzyme of PKA-like
kinase was immunopurified via Ty1-PKAC1.
Equal amounts of the immunoprecipitate were
tested on their ability to phosphorylate the PKA
specific substrate RRRRSIIFI (Songyang et al.,
1994) with �32P-ATP in the absence (control)
and presence of different cyclic nucleotides (1
mM), as indicated. The amount of
phosphorylated PKA substrate was quantified
with a liquid scintillation counter and directly
reflects kinase acitivity. Each reaction was
done in triplicate. Mean values are shown
(white bars) and the standard deviation is
indicated by error bars. Additionally each
reaction was done once in the presence of the
PKA specific inhibitor PKI (grey bars).
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by their different apparent molecular weight representing phosphorylated (50 kDa) and 
unphosphorylated VASP (46 kDa). Thus, VASP is in fact phosphorylated by a T. brucei 
kinase with a PKA-like substrate specificity. 
36
50
64
98
[kDa] VASP
Fig. 24: Western blot: Detection of the transgenically
expressed PKA reporter substrate VASP in T. brucei
VASP cDNA from human HL60-cells (Haffner et al., 1995)
was cloned into the overexpression vector pTSArib (Xong et
al., 1998) and the resulting plasmid (pTSAribVASP) was
transfected into MITat1.2 cells. One hygromycine resistant
clone was obtained that was controlled for VASP expression
on a Western blot with the polyclonal antibody AB197228
(kind gift from Ulrich Walter, Würzburg), using cell extract of
5*105 cells. The antibody recognized two bands of
approximately 46 and 50 kDa. These bands represent the
phosphorylated and unphosphorylated VASP form (at
Ser157). No further proteins were detected with the VASP
antibody.
We did, however, observe differences in the extent of basal VASP phosphorylation 
between different experiments. The reason remained unclear until it became apparent 
that temperature influences VASP phosphorylation (compare chapter 3.4.1.2.). The 
variations in basal VASP phosphorylation between the different experiments described 
in this chapter can thus be attributed to slightly different cell harvesting procedures. 
However, the samples of one assay were always treated equally and conclusions were 
only drawn from comparisons among different samples of the same assay. 
3.3.4.2. VASP phosphorylation increases in the presence of the PDE inhibitors 
dipyridamole and etazolate
At first it was tested whether changes in VASP phosphorylation were detectable with 
the new reporter cell line. To test for activation by cyclic nucleotides of the VASP 
phosphorylating kinase, we used the PDE inhibitors dipyridamole and etazolate. Both 
are inhibitors of all known T. brucei PDEs (Rascón et al., 2002; Zoraghi et al., 2001; Kunz 
et al., 2004; Zoraghi et al., 2002) that were shown to increase intracellular cAMP and 
possibly cGMP. 
Cells of the VASP expressing cell line were incubated in the presence of 100 µM 
dipyridamole (dissolved in DMSO at 200 mM) or etazolate (dissolved in PBS at 5 mM) 
and as a control with equal concentrations of the respective solvents. Samples of the 
cells were harvested after 0, 1, 2, 5 and 10 minutes and  applied to a Western blot, 
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subsequently probed with anti-VASP M4 (Fig. 25A). VASP phosphorylation at Ser157 was 
monitored via the gel retardation of the phosphorylated VASP form (band shift), using the 
Odyssey Software (Licor) for the quantification of the protein bands (Fig. 25B). 
time [min]: 0 1 2 5 10 0 1 2 5 10
Fig. 25: VASP phosphorylation increases in the presence of the PDE inhibitors dipyridamole
and etazolate
5*105 cells from the VASP reporter cell line were incubated in the presence of 100 �M dipyridamole
(desolved in DMSO at 200 mM) or 100 �M etazolate (desolved in PBS at 5 mM) at 37�C on a shaker
for the times indicated. Control cells were incubated with an equal volume of either DMSO or PBS.
Cells were harvested (30", 10000g, 37�C) and heated with 6 x Laemmli buffer for 5 minutes at 99�C.
VASP was detected on a Western blot incubated with anti-VASP M4 (compare also method 2.2.3.10.).
A) Western Blots of three independent experiments (I,II,III) for dipyridamole (top) and etazolate
(bottom).
B) VASP phosphorylation (VASP-phos. / (VASP-phos + VASP-unphos.)) was quantified using the
Odyssey Software (Licor). Mean values of the three experiments (I-III) are shown for dipyridamole (top)
and etazolate (bottom). The standard deviations are indicated by error bars.
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A significant increase of VASP phosphorylation was detected after only one minute 
incubation with either dipyridamole or etazolate. When incubated with dipyridamole, 
VASP phosphorylation was increased from 40% to 70% and did not decrease during 
the time of observation (10 minutes). Etazolate induced a lower increase of VASP 
phosphorylation from 40% to only around 50%. Furthermore, etazolate induced VASP 
phosphorylation slightly decreased after 10 minutes. The observed differences in the 
induction of VASP phosphorylation between dipyridamole and etazolate might be due 
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to the different affinities of the inhibitors towards T. brucei PDEs (compare table 10 in 
4.3.1.1.).  
The obtained data clearly show that the VASP based in vivo kinase assay works in T. 
brucei and is suitable for the detection of fast changes in the activity of a T. brucei kinase. 
This kinase is probably a PKA orthologous protein, since on the one hand VASP Ser157 
is a PKA specific phosphorylation site and, on the other hand, PDE inhibitors are bound 
to increase cNMP levels.
 
3.3.4.3. VASP phosphorylation decreases in the presence of the PKA specific 
inhibitor KT5720
Whether VASP phosphorylation really reflects PKA activity and not the activity of some 
other kinase was further examined with the aid of the cell permeable PKA specific 
inhibitor KT5720. KT5720 belongs to the group of isoquinolinesulfonamide (K252 group) 
that were identified as highly potent inhibitors of cNMP dependent kinases and PKC 
(Hidaka et al., 1984). Although structurally unrelated to ATP, the inhibitors compete with 
ATP for the ATP binding sites of these kinases. KT5720 was found to be highly specific 
for PKA with an IC50 value of 0.056 µM for mammalian PKAs (Kase et al., 1987). 
 If VASP is a PKA substrate, it should become dephosphorylated in the presence of the 
PKA inhibitor and remain so even when dipyridamole is added. 
VASP expressing cells were incubated in the presence of KT5720 for 12 minutes and 
protein samples were taken every two minutes. During the last two minutes dipyridamole 
was added. VASP phosphorylation was monitored via a Western blot. As can be seen in 
figure 26A, VASP phosphorylation decreased in the presence of the PKA inhibitor. It is 
thus very likely that VASP is in fact phosphorylated by a PKA activity. 
However, most surprisingly, dipyridamole was still able to initiate VASP phosphorylation 
even in the presence of KT5720. This can only be explained by the presence of a 
cNMP dependent kinase that is not affected by KT5720. We therefore examined the 
inhibitory effect of KT5720 on T. brucei PKAC1, PKAC2 and PKAC3 with an in vitro 
kinase assay (Fig. 26C). Ty1-PKAC1, HA-PKAC2 and Ty1-PKAC3 were purified by 
immunoprecipitation and tested for their abilities to phosphorylate the PKA peptide 
substrate RRRRSIIFI with γ32P-ATP as described above (chapter 3.3.2.). KT5720 was 
added in different concentrations. The activity of both PKAC1 and PKAC2 was decreased 
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with 10 µM KT5720 to 15-17%. Higher concentrations of KT5720 did not cause a further 
decrease. In contrast, the activity of PKAC3 was not affected even at 100 µM KT5720. 
Thus, it seems that PKAC3 is not inhibited by KT5720. The remaining dipyridamole 
stimulated activity in the presence of KT5720 can therefore be attributed to PKAC3. 
These experiments do not prove that PKAC1/2/3 are the cNMP regulated kinase(s) 
detected in the VASP phosphorylation assay, but the results are still compatible with that 
interpretation. 
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Fig. 26: KT5720 inhibits VASP phosphorylation
A) 5*105 cells of the VASP reporter cell line were incubated with 10 �M of the PKA specific inhibitor
KT5720 (desolved in DMSO at 2 mM) for 12 minutes. Control cells were incubated with an equal volume
of DMSO. After 10 minutes, 100 �M dipyridamole (desolved in DMSO at 200 mM) was added. Cells were
harvested (1', 10,000 g, 4�C) and VASP was detected on a Western blot probed with anti-VASP. The
experiment was repeated three times (I, II, III).
B) VASP phosphorylation (VASP-phos. / (VASP-phos. + VASP-unphos.)) was quantified using the
Odyssey Software (Licor). Mean values from the three experiments (A I,II,III) are shown and the standard
deviations are indicated by error bars.
C) KT5720 selectively inhibits PKAC1 and PKAC2, but not PKAC3
The effects of KT5720 on the activities of the different catalytic subunits of T.brucei PKA-like kinase were
assayed in vitro. For this, immunoprecipitated Ty1-PKAC1, Ty1-PKAC2 and Ty1-PKAC3 were tested on
their abilities to phosphorylate the PKA specific substrate RRRRSIIFI (Songyang et al., 1994) with �32P-
ATP in the presence of different concentrations of KT5720 (1-100 �M). PKI (5 �M), that had been shown
previsiously to inhibit all three T.brucei PKAs, was used as a positive control. Each assay was repeated
three times. Average values are shown and the standard deviations are indicated by error bars. It can be
seen that PKAC1 and PKAC2 are inhibited by 10 �M KT5720, while PKAC3 is still active in the presence
of even 100 �M KT5720.
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3.3.4.4. VASP phosphorylation increases with pCPT-cGMP and decreases with 
pCPT-cAMP
The in vivo kinase assay was therefore used to address the question of which 
cyclic nucleotide was responsible for PKA activation. However, no changes in VASP 
phosphorylation were detected with 250 µM of the membrane permeable cNMP 
derivatives pCPT-cAMP or pCPT-cGMP (data not shown), although these concentrations 
of pCPT-cAMP were sufficient to induce LS to SS differentiation in pleomorphic 
trypanosomes (Vassella et al., 1997) or to arrest growth in monomorphic cells (Reuner, 
Ph.D. thesis 1997; Schimpf, Diploma thesis 2000). 
Given the limited cell permeability, VASP expressing cells were incubated with higher 
concentrations of these cNMP derivatives. Incubation of VASP expressing cells with 5 
mM pCPT-cGMP increased VASP phosphorylation (Fig. 27A/B, left), compatible with 
the in vitro data. The unusually high concentration of pCPT-cGMP needed to increase 
VASP phosphorylation in vivo corresponded to the results from the in vitro kinase assays 
(compare Fig. 22A in chapter 3.3.2.) that clearly showed that pCPT-cGMP is less suitable 
for activation of PKAC1 than cGMP.
Surprising results were obtained with pCPT-cAMP (Fig. 27A/B, right): VASP 
phosphorylation decreased in the presence of pCPT-cAMP suggesting that this analogue 
in fact acts as a kinase inhibitor instead of an activator. Kinetic analyses revealed that 
one minute of incubation with 1 mM pCPT-cAMP was already sufficient to significantly 
decrease VASP phosphorylation that then remained decreased for at least 30 minutes 
(Fig. 28). 
3.3.5. cAMP inhibits PKA in vitro
The observed inhibitory effect of pCPT-cAMP on VASP phosphorylation (that most 
likely reflects activity of the PKA-like kinases) was unexpected. Two mechanisms could 
account for this inhibition. Firstly, cAMP could interfere with proteins from other signaling 
pathways and thus indirectly cause inhibition via a cross talk mechanism. Cross talk 
between cAMP and cGMP signaling has been proposed to exist in higher eukaryotes 
(reviewed by Abdel-Latif, 2001). Alternatively, cAMP could bind to the cNMP binding sites 
of PKAR but then fail to provoke the structural changes that are necessary for kinase 
activation. cAMP would therefore compete with the physiological activator.
Since cross talk between different signaling pathways is highly complex and for this reason 
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Fig. 27: VASP phosphorylation in the presence of the cyclic nucleotide derivatives pCPT-cGMP
and pCPT-cAMP
VASP expressing cells were harvested (10', 1400g, 4�C) and resuspended in HMI9 at 2.5*107 cells/ml. 20
�l of these cells (corresponding to 5*105 cells) were incubated in the presence of 0, 1, 2, or 5 mM pCPT-
cGMP or pCPT-cAMP (from a 10 mM stock desolved in PBS) for 5 minutes at 37�C on a shaker. The
reactions were stopped with 4 �l 6x Laemmli buffer (5', 99�C). Samples were applied to SDS gels and
VASP was detected with anti-VASP on the resulting Western blots.
A) Western blots of three independent experiments (I, II, III).
B) VASP phosphorylation (VASP-phos. / (VASP-phos + VASP-unphos.)) from A) was quantified using the
Odyssey Software (Licor). Mean values from the three experiments are shown and the standard deviations
are indicated by error bars.
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Fig. 28: VASP phosphorylation remains decreased in the presence of 1 mM pCPT-cAMP for at least
30 minutes
A) VASP expressing cells at 5*105 cells/ml were incubated in the presence of 1 mM pCPT-cAMP
(desolved in PBS as 10 mM stock) or equal volumes of PBS (control) for 0, 1, 5, 10 or 30 minutes at 37�C
on a shaker. Cells were harvested (30", 10000g, 4�C), incubated in Laemmli buffer (5', 99�C) and applied
to SDS PAGE. VASP was detected on a Western blot probed with anti-VASP. Western blots of four
independent experiments (I, II, III, IV) are shown.
B) VASP phopshorylation (VASP-phos. / (VASP-phos + VASP-unphos.)) from the Western blots I, II, III,
and IV from (A) was quantified using the Odyssey Software (Licor). Mean values are shown together with
the standard deviations indicated by error bars.
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difficult to investigate, analyses were in this work restricted to the second hypothesis that 
can easily be tested with an in vitro kinase assay. For this, immunopurified holoenzyme of 
PKA-like kinase (precipitated via Ty1-PKAR) was incubated with different concentrations 
of cAMP, ranging from 0-10 mM, in addition to 1 mM cGMP. Kinase activities (measured 
as the amount of phosphorylated PKA peptide substrate as described in chapter 3.3.2.) 
in the presence of cGMP and cAMP are shown in figure 29A. As previously observed, 
kinase activity increased five fold in the presence of 1 mM cGMP, while cAMP alone 
had no effect. However, in the presence of both cyclic nucleotides kinase activity was 
significantly reduced. With equimolar concentrations of cAMP kinase activity was 
decreased by one third and with a ten fold excess of cAMP, kinase activity was found 
to be near basal activity. Similar (slightly weaker) inhibitory effects of cAMP on PKA 
activity were observed when the holoenzyme was precipitated via the Ty1-epitope tagged 
PKAC1 (Fig. 29B).
Conclusively, cAMP inhibits PKA activity directly, probably by competing with cGMP. 
In order to control the specificity of cAMP as a PKA inhibitor, other cyclic nucleotides were 
tested on their ability to also decrease PKA activity. However, none of the tested cyclic 
nucleotides (cUMP, cCMP, cIMP) had an inhibitory effect on PKA activity, suggesting that 
cAMP does inhibit PKA specifically (data not shown).
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Fig. 29: cAMP inhibits PKA-like
kinase in vitro
The holoenzyme of T. brucei PKA-
like kinase was immunoprecipitated
via Ty1-PKAR (A) or Ty1-PKAC1 (B).
Equal amounts of the
immunoprecipitates were tested on
their abilities to phosphorylate the
PKA specific substrate RRRRSIIFI
(Songyang et al., 1994) with �32P-
ATP in the absence (control) and
presence of different concentrations
of cAMP and/or cGMP.
Each reaction was done in triplicates.
Mean values are shown (white bars)
together with the standard deviations
(error bars). In addition, each
reaction was performed once in the
presence of PKI [5 �M] (grey bars).
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3.4. Role of T. brucei PKA-like kinase in vivo
Two completely different approaches have been used to obtain information about the 
function of the kinase in question.  The phenotypic consequences of altered expression 
of the PKA-like kinase were examined using several reverse genetic approaches. The 
second approach concentrated on the identification of extracellular signals that may 
affect the VASP phosphorylating activity. Although it seems likely that this activity is 
identical with the PKA-like kinases, this is not considered an established fact for the 
following section. 
3.4.1. Changes in VASP phosphorylation due to different extracellular 
stresses
During their complex life cycle trypanosomes are confronted with dramatic changes in their 
environment, especially when they shuttle between their different hosts. Trypanosomes 
must be able to sense theses changes that might on the one hand provide differentiation 
signals and on the other hand require quick adaptations in order to ensure survival. The 
underlying signaling pathways for environmental sensing are still unknown (reviewed in 
Parsons and Ruben, 2000).
3.4.1.1. Effects of increased cell density on VASP phosphorylation
Some of the subsequent experiments addressing the activity of the VASP phosphorylating 
kinase(s) in response to different stresses needed to be performed with cells at increased 
cell densities. In this way, reactions could be stopped directly by the addition of Laemmli 
buffer without the need of a potentially interfering harvesting procedure. 
Thus, the first test was to see whether an increase in cell density had any effect on 
VASP-phosphorylation. For this, cells were concentrated at a cell density of 5*107 cells/ml 
and diluted in fresh medium to obtain cell densities of 5*105, 1*106, 2*106, 5*106, 1*107 
or 5*107 cells/ml. The cells were then incubated on a shaker at 37 °C for 2, 10 or 30 
minutes, harvested and VASP phosphorylation was quantified via a Western blot (Fig. 
30). We did not observe significant differences in VASP phosphorylation between the 
samples of different cell densities for any of the incubation times.
Conclusively, VASP phosphorylation is not affected by an increase in cell density, at least 
not within the first 30 minutes. The VASP-based in vivo kinase assay can therefore be 
used with samples.
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3.4.1.2. VASP phosphorylation increases at low temperatures
The influence of different temperatures on VASP phosphorylation was examined. VASP 
expressing cells (at cell densities of 5*107 cells/ml) were incubated at 0 °C (ice), 4°C, 
12°C, 20°C, 30°C or 37°C for two minutes. The reaction was stopped by the addition of 
6x Laemmli buffer (5ʼ, 99 °C) and VASP phosphorylation was determined by a Western 
blot (Fig. 31). A decrease in temperature resulted in an increase in VASP phosphorylation. 
A significant increase in VASP phosphorylation was already observed at 30°C. VASP 
phosphorylation further increased at 20°C and reached its maximum at 12°C. No further 
increase was observed at 4°C or 0°C. The observed increase in VASP phosphorylation 
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Fig. 30: Effects of cell densities on VASP phosphorylation
VASP expressing cells were harvested (10', 1400g, 37�C) and resuspended in HMI9 at 5*107 cells/ml. 10
�l of these cells were added to 990, 490, 240, 90, 40, 15 and 0 �l HMI9 (pipetting time maximal 1'), to
obtain cell densities of 5*105, 1*106, 2*106, 5*106, 1*107, 2*107 and 5*107 cells/ml, respectively. Cells were
incubated at 37�C on a shaker for 2 minutes (A), 10 minutes (B) or 30 minutes (C). Afterwards cells were
harvested (30", 10000g, 37�C), incubated with 5 �l 6x Laemmli buffer (5', 99�C) and applied to SDS
PAGE. VASP phosphorylation (VASP-phos. / (VASP-phos + VASP-unphos.) was quantified from a
Western blot probed with anti-VASP using the Odyssey Software (Licor).
Each experiment was done three times (I, II, III). The Western blots of the three experiments are shown on
the left site and the corresponding diagrams reflecting VASP phosphorylation are shown on the right site.
Standard deviations are indicated by error bars.
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was reversable: When cells were transferred back to 37°C VASP phosphorlyation 
decreased back to normal. 
0
0.2
0.4
0.6
0.8
1
0
0.2
0.4
0.6
0.8
1
A
B
T [�C]: 0 4 12 20 30 37
Fig. 31: VASP phosphorylation increases at low temperatures
VASP expressing cells were harvested (10', 1400g, 37�C) and resuspended in HMI9 at 5*107 cells/ml. 10
�l of these cells were incubated at 37�C for one minute and subsequently at 0, 4, 12, 20, 30 or 37�C for
two minutes (without shaking). The reaction was stopped by directly adding 2 �l 6x Laemmli buffer to the
cells without removing them from their particular temperatures and subsequently heating them to 99�C for
5 minutes. Samples were subsequently applied to SDS PAGE and VASP was detected with anti-VASP on
a Western blot. The experiment was done three times.
A) I-III) Western blots of three independent experiments. IV) To control for the reversibility of temperature
dependent changes in VASP phosphorylation, cells were treated as described above but incubated for an
additional two minutes at 37�C.
B) VASP phosphorylation (VASP-phos. / (VASP-phos + VASP-unphos.) was quantified using the Odyssey
software (Licor). Data from the three experiments (I, II, III) are summarized and the standard deviations
are shown as error bars (left, grey bars). The data from experiments IV are shown on the right site (white
bars).
transferred back to 37�C from temperature:
0 4 12 20 30 37 �C
Fr
ac
tio
n
of
ph
os
ph
or
yl
at
ed
VA
S
P
T [�C]: 0 4 12 20 30 37
0 4 12 20 30 37 �C
transferred back to 37�C from temperature
I
II
III
IV
In theory the observed changes in VASP phosphorylation could also be due to a reaction 
of the responsible kinase on cell lysis, rather than to a direct influence of the temperature 
change on kinase activity. At different temperatures the reaction of kinase on cell 
lysis could vary, leading to the observed temperature dependent differences in VASP 
phosphorylation. Therefore, a control experiment was performed in order to examine 
whether cell lysis itself had any effect on VASP phosphorylation. 
Cells were incubated for 5 minutes at 37 °C, for one minute at either –196 °C (shock 
frozen in liquid N2), 0 °C (ice) or 37 °C, then for one minute in 6x Laemmli buffer at 
the same temperatures and finally for 5 minutes at 99 °C. VASP phosphorylation was 
quantified via a Western blot (Fig. 32). No difference in VASP phosphorylation was 
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observed between cells that were lysed at 37 °C or –196 °C, while kinase activity was 
increased when cells were incubated on ice. This proves that cell lysis does not affect the 
extent of VASP phosphorylation and that the increase in VASP phosphorylation is in fact 
due to the temperature drop.
Fig.32: Cell lysis has no effect on VASP phosphorlyation
VASP expressing cells were harvested (10', 1400g, 37�C) and resuspended in HMI9 at 5*107 cells/ml. 10
�l of these cells (5*105 cells) were incubated at 37�C for 5 minutes on a shaker. Subsequently, cells were
incubated for one minute either at 37 �C (two samples), or on ice (two samples) or in liquid nitrogen (two
samples). Afterwards, 2 �l 6x Laemmli buffer was added and the cells were incubated first for one
additional minute at their particular temperatures and then at 99�C for 5 minutes. Samples were applied to
SDS PAGE and VASP was detected with anti-VASP on a Western blot.
A) Western blots of two independent experiments (I, II).
B) VASP phosphorylation (VASP-phos. / (VASP-phos + VASP-unphos.) was quantified using the Odyssey
software (Licor). Data from experiment I and II are summarized (thus each bar represents data from
altogether 4 samples) and mean values are shown. Standard deviations are indicated by error bars.
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3.4.1.3. VASP phosphorylation depends on osmolarity
In order to examine whether the VASP phosphorylating kinase activity depends on 
osmolarity, cells were incubated in TDB (5 mM KCl, 1 mM MgSO4, 20 mM Na2HPO4, 
2 mM NaH2PO4, 20 mM glucose, pH 7.7) complemented with different concentrations 
of NaCl. Hypotonic conditions were achieved with NaCl concentrations of 20, 40 and 
60 mM, isotonic conditions with 80 mM NaCl and hypertonic conditions with 100, 120, 
140 and 160 mM NaCl. After 5 minutes incubation, cells were harvested, applied to a 
Western blot and the extent of phosphorylated VASP was determined (Fig. 33, left). 
VASP phosphorylation increased at hypotonic conditions and decreased at hypertonic 
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conditions. 
Two controls were performed to verify that cells were still viable in the different buffers. 
Using phase contrast microscopy we found no changes in morphology or motility after 
10 minutes incubation in each of the buffers (data not shown). Furthermore, the changes 
in VASP phosphorylation were reversible when cells were transferred back into isotonic 
TDB (Fig. 33, right).
0
0.2
0.4
0.6
0.8
1
0
0.2
0.4
0.6
0.8
1
Fr
ac
tio
n
of
ph
os
ph
or
yl
at
ed
VA
S
P
Fr
ac
tio
n
of
ph
os
ph
or
yl
at
ed
VA
S
P
NaCl [mM]: 20 40 60 80 100 120 140 160
NaCl [mM]: 20 40 60 80 100 120 140 160
transferred into isotonic TDB from
A
B
Fig. 33: VASP phosphorylation depends on the osmolarity of the medium
VASP expressing cells were harvested (10', 1400g, 37�C) and resuspended in HMI9 at 5*107 cells/ml. 10
�l of these cells were added to 1 ml TDB buffer containing 20, 40, 60, 80, 100, 120, 140 or 160 mM NaCl.
Cells were incubated at 37�C on a shaker for 5 minutes, harvested (30", 10000g, 37�C), incubated in 6x
Laemmli buffer for 5 minutes at 99�C and applied to SDS Page. VASP phosphorylation was quantified
from a Western blot probed with anti-VASP using the Odyssey Software (Licor).
A) Western blots of three independent experiments (I, II, III). To control for the reversibility of the salt
dependent changes in VASP phosphorylation, cells from experiment II and III were retransferred into
isotonic TDB (80 mM NaCl), incubated for 5 minutes and harvested (IV,V).
B) VASP phosphorylation (VASP-phos. / (VASP-phos + VASP-unphos.) was quantified using the Odyssey
Software (Licor). The data from experiments I to III are summarized and the standard deviations are
indicated by error bars (grey bars, left). The data from the experiments IV and V are also summarized
(white bars, right).
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3.4.1.4. VASP phosphorylation depends on pH
To investigate whether VASP phosphorylation was dependent on the pH value of the 
medium, cells were transferred into HMI9 (pH 7.35) and into HMI9 titrated to different pH 
values (5.5, 6.5, 8.5, 9.5). After 5 minutes incubation, cells were harvested and applied to 
SDS PAGE. VASP phosphorylation was determined from a Western blot (Fig. 34). It can 
be seen that the activity of the VASP phosphorylating kinase(s) is increased at low pH 
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values and decreased at high pH values. VASP phosphorylation was restored to normal 
when cells were transferred back into HMI9 (pH 7.35). 
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Fig. 34: VASP phosphorylation at different pH-values
VASP expressing cells (5*105) were harvested (10', 1400g, 4�C) and resuspended either in neutral HMI9
(pH 7.35) or in HMI9 adapted to different pH values (pH 5.5, 6.5, 8.5 and 9.5). To exclude any influence of
the harvesting procedure on PKA activity, control cells (control) were not transferred to new medium.
Cells in their particular media were then incubated for 5 minutes at 37�C on a shaker, harvested (30'',
10000 g, 4�C), incubated in Laemmli buffer at 99�C for 5 minutes and applied to SDS PAGE. VASP was
detected on a Western blot probed with anti-VASP.
A) Western blots from three independent experiments (I, II, III). An additional control was performed in
parallel to experiment III to control for the reversibility of pH dependent changes in VASP phosphorylation
(IV). For this, cells from the different media were transferred back into neutral HMI9 (pH 7.35), incubated
for 5 minutes (37�C, slightly shaking) and harvested (30'', 10000 g, 4�C).
B) VASP phosphorylation (VASP-phos. / (VASP-phos + VASP-unphos.) was quantified using the Odyssey
software (Licor). The average values from experiment I to III are shown in the left diagram (grey bars) and
the data from experiment IV are shown in the digram on the right site (white bars). Standard deviations for
experiments I to III are shown as error bars.
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The changes in VASP phosphorylation in reaction to the different environmental stimuli 
is summarized in table 3:
Stimuli Change in VASP phosphorylation
Table 3: Overview about the changes in VASP 
phosphorylation upon different stimuli. 
The data from chapter 3.4.1. are summarized.
Cell density increase none
Temperature decrease increase
Osmolarity
hypotonic increase
hypertonic decrease
pH-value
acidic increase
basic decrease
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3.4.2. Revers genetic analyses of T. brucei PKA-like kinase
Several reverse genetic approaches were applied in order to obtain further information 
about the function of T. brucei PKA-like kinase. Thereby each subunit was examined 
individually. To enable an easy comparison between the different subunits, a table was 
inserted at the end of each chapter summarizing all phenotypes described so far. The first 
subunit adressed was the regulatory PKA subunit:
3.4.2.1. Depletion of PKAR with RNA interference
There is evidence that T. brucei PKAR is an important, probably essential protein, 
since overexpression of PKAR caused a growth phenotype (C. Schulte zu Sodingen, 
Ph.D. thesis 2000). For this reason PKAR function was analyzed with inducible RNA 
interference rather than using a gene deletion strategy.
A 500 bp fragment of the PKAR N-terminus was cloned into the p2T7 vector (LaCount 
et al., 2000) and transfected into the tetracycline inducible 13-90 cell line (Wirtz et 
al., 1999). Several independent clonal transfectants were incubated with tetracycline. 
Four clones (#1, #4, #6, #8) showed a strong growth phenotype. From these two were 
chosen for further analyses (#1, #4). Immunoblotting revealed that the amount of PKAR 
was decreased to less than 10% (Fig. 35A). Interestingly, the amounts of the catalytic 
subunits PKAC1 and PKAC2 were equally reduced and the amount of  PKAC3 protein 
was decreased to approximately 50%. The reason for this is probably the loss of stability 
of the uncomplexed C subunits. Similar co-depletions had been previously observed 
by Estévez et al. (2003) when targeting RNAi against components of the proteasome 
complex.
3.4.2.1.1 Repression of PKAR blocks cellular proliferation
After 8 hours of tetracycline incubation, the cell number of both clones did not increase 
further (Fig. 35B). In order to examine whether this growth arrest can be attributed to a 
certain cell cycle phase, tetracycline induced and non-induced cells of both clones were 
stained with the DNA dye DAPI. In trypanosomes, DAPI stains both the nuclear DNA and 
the DNA of the single mitochondrion (kinetoplast), thus, allowing the distinction of three 
cell cycle phases: Cells with one kinetoplast (K) and one nucleus (N) (1K1N), cells with 
two kinetoplasts and one nucleus (2K1N) and cells with two kinetoplasts and two nuclei 
(2K2N). Since the kinetoplast always divides prior to the nucleus, 1K2N cells do not 
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normally occur.  A logarithmically growing trypanosome population contains around 70% 
1K1N cells and around 15% of each 2K1N and 2K2N cells. 
The K/N configurations of tetracycline induced and non-induced PKAR RNAi cells are 
shown in figure 35C. The fraction of 2K2N cells increased from 15% to about 50% within 
10 hours of incubation with tetracycline, while the number of 1K1N cells decreased. 
Additionally, the amount of multinucleated cells (xKyN; x,y>2) rose. There were no 
changes in the number of 2K1N cells. After 8 to 10 hours of tetracycline incubation we 
observed a slight increase in 1K2N cells. Such an increase in 1K2N cells (1 to 4% of 
the total cells) was also observed with other clones (data not shown). Altogether these 
data indicate that the observed growth arrest of the cells is due to a postmitotic cell cycle 
arrest. Cells are able to separate their nuclei and kinetoplasts but are prevented from 
cytokinesis. Instead, they start another round of nuclear and kinetoplast DNA replication 
and become multinucleated. 
3.4.2.1.2. Repression of PKAR still allows the complete partition of the nuclei
BSF cells cannot undergo cytokinesis when mitosis is inhibited (mitotic exit checkpoint) 
(Hammarton et al., 2003a). Therefore, it was at first examined whether an uncompleted 
mitosis was the reason for the cytokinesis block. Although neither nuclear division 
nor separation appeared to be inhibited, the 2K2N cells might still be arrested in the 
very last phase of mitosis, in the partition of the nuclear envelope. During mitosis, the 
nuclear envelope surrounds both nuclei and is only divided upon successful division 
and separation of the nuclei. It can be stained with an antibody against a nuclear pore 
protein (NUP1) anti-Nup (kindly provided by K. Ersfeld; Ogbadoyi et al., 2000). Examples 
of 2K2N cells that have their nuclei completely separated are shown in Fig. 36A and B, 
2K2N cells with their nuclear envelopes still connected are shown in Fig 36C and D. The 
nuclear envelopes of 100 tetracycline induced and 100 non-induced 2K2N cells were 
examined. 81% of the tetracycline induced cells and 74% of the control cells had their 
nuclei completely separated (Fig. 36E). This shows that cells can still separate their nuclei 
upon PKAR depletion and are therefore not arrested at the mitotic exit checkpoint.
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Fig. 35: PKAR depletion by RNA interference:
Cells were incubated in the presence or absence (control) of tetracycline [10�g/ml] for 24 hours. Data from
two independent clonal cell lines (#1 and #4) are shown.
A) Western blots: Protein samples were collected 0,4,8,12 and 24 hours after incubation with and without
tetracycline (control) and applied to SDS PAGE. The resulting Western blots were incubated with anti-
PKAR, anti-PKAC1/2, anti-PKAC3 and anti-Hsp60, the latter serving as a control for equal loading. Since
PKAC3 and PKAC1/2 have equal molecular weights, two Western blots (loaded with the same samples)
were performed for each time course and incubated with either anti-PKAC1/2 or anti-PKAC3, as indicated.
Rabbit Alexa680 (red) and Mouse IRDye800 (green) were used for the detection of anti-PKAR/anti-
PKAC3/anti-PKAC1/2 and anti-Hsp60, respectively, using the Odyssey IR scanner (Licor).
B) Growth curves: Growth curves of induced and uninduced PKAR RNAi cells. Cell densities were kept
below 7*105 cells/ml.
C) K/N configurations: Cells were fixed in methanol after 0, 2, 4, 6, 8, 10 and 12 hours of incubation with
or without tetracycline and subsequently stained with DAPI. K/N configurations of 400 cells were
determined for each time point.
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Fig. 36: PKAR RNAi: 2K2N cells can separate their nuclear
envelopes
PKAR RNAi cells were incubated with or without (control)
tetracycline for 8 hours, fixed with paraformaldehyde, stained
with anti-NUP and detected with Alexa 488 goat anti-mouse
(green). In addition, cells were counterstained with DAPI (blue).
A-B) Examples of 2K2N cells with separated nuclear
enveloppes.
C-D) Examples of 2K2N cells with connected nuclear
enveloppes
E) The nuclear enveloppes of 100 randomly chosen 2K2N cells
of uninduced (control) and tetracycline induced cells were
classified as either connected or separated.
3.4.2.1.3 Cells can initiate cytokinesis but are unable to complete it
The stage of the division furrow of 2K2N cells was determined in tetracycline induced 
and non-induced cells (Fig. 37). Without tetracycline, most cells (55-70%) had no division 
furrow, between 10 to 20% had a division furrow and around 25% of the cells had nearly 
finished cytokinesis and were only attached at their most posterior cell ends. 
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Fig. 37: Division furrow stage of 2K2N cells upon PKAR RNAi:
2K2N cells and 1K2N cells of tetracycline induced and uninduced cultures were classified according to the
stage of their division furrow. 200 2K2N cells were analysed that were incubated with or without
tetracycline for 8 hours.
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In the tetracycline induced cells the amount of cells with division furrow was significantly 
increased to 35 to 40%, while the fraction of cells without division furrow or cells that 
had nearly finished cytokinesis was found decreased. Interestingly, the division furrow 
appeared to always be at approximately the same position, at half of the cell length. This 
accumulation of cells with division furrow suggests that PKAR RNAi cells are able to 
initiate cytokinesis but are unable to carry it through to completion.  
3.4.2.1.4. 2K2N cells have increased kinetoplast distances
A marked difference between the 2K2N cells of tetracycline induced and non-induced 
cells was the position of their kinetoplasts. 
In BSF trypanosomes, kinetoplasts are always located posterior of the posterior nucleus. 
Upon kinetoplast division, the old (mother) and the new (daughter) kinetoplast segregate. 
The mother kinetoplast (that is attached to the basal body with the old flagellum) moves 
towards the anterior cell end, but does not normally reach the posterior nucleus. The 
daughter kinetoplast (that is attached to the basal body that nucleates the new flagellum) 
moves towards the posterior cell end (M. Engstler, unpublished). 
In many induced PKAR RNAi cells the mother kinetoplast was located very close to the 
posterior nucleus and sometimes even between the nuclei. Thus, the distances between 
the mother and the daughter kinetoplast were increased. These unusual kinetoplast 
positions were found both in 2K2N cells without a division furrow as well as in cells 
that had already started dividing (Fig. 38A). The kinetoplast distances of 400 randomly 
chosen tetracycline induced and non-induced 2K2N cells were measured and are shown 
in figure 38B. The average kinetoplast distance was 2.72±0.61 µm in non-induced cells 
and increased to 3.85±1.92 µm upon PKAR depletion. 35.3% of the induced cells had 
kinetoplast distances higher than 4 µM, compared to only 2.5% of the control cells. The 
difference between the kinetoplast distances of induced and non-induced cells is highly 
significant with a t-test P-value (1 tail, unpaired) of 1.21*10-26.
 
3.4.2.1.5. The increased kinetoplast distances are not a consequence of cytokinesis 
block
Two mechanisms could account for the observed increase in kinetoplast distance in 
response to PKAR RNAi. Either PKAR is directly involved in the regulation of kinetoplast 
movement or the increase in kinetoplast distance is a secondary effect that results from 
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the cytokinesis block. 
In order to distinguish between these two possibilities, kinetoplast positions needed to 
be studied with cytokinesis being blocked using method unrelated to PKA-like kinase. In 
T. cruzi, cytokinesis but not kinetoplast movement was found to be blocked with 100 µM 
of the microtubules inhibitor vincristine (Grelllier et al., 1999). In T. brucei, similar effects 
were obtained with 0.2 µM vincristine. Cells were completely growth arrested within 4 
hours. The number of 2K2N cells was significantly increased after 6 hours and nearly two 
thirds of these 2K2N cells (62±3% compared to only 11% of the control cells) possessed 
a cleavage furrow. 2K2N cells were perfectly able to further divide and segregate their 
kinetoplasts, resulting in 4K2N cells. The data are shown in attachment 2.
However, the kinetoplast positions in the vincristine treated cells appeared to be normal. 
The mother kinetoplast was never found to be near the posterior nucleus. The average 
kinetoplast distance for vincristine treated cells was with 2.26±0.52 µm even smaller 
than the kinetoplast distance of untreated control cells (2.83±0.57 µm) (Fig. 38C). The 
slight reduction in kinetoplast distance in response to vincristine incubation is due to the 
unusually high amount of cells (2/3 of all 2K2N cells) that were blocked in the process of 
cell division. When measuring the direct distance, the kinetoplasts move closer towards 
each other during this stage of cytokinesis. 
To summarize, cytokinesis inhibition with vincristine did not result in increased kinetoplast 
distances. Conclusively, the observed increase in kinetoplast distance upon PKAR RNAi 
is probably not a consequence of the cell cycle arrest in cytokinesis. Instead, evidence is 
that T. brucei PKA-like kinase directly regulates basal body segregation.
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The table summarizes all PKA phenotypes describes so far. 
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Fig. 38: Increase in kinetoplast distances after PKAR depletion
A) Photographs of DAPI stained 2K2N cells of tetracycline induced und uninduced (control) PKAR RNAi
cells.
B) Distances between mother and daughter kinetoplast in induced and uninduced PKAR RNAi cells.
Photographs of 400 2K2N cells were randomly taken and the distance between the two kinetoplasts was
determined using the software IP-lab. When the cell was bended, kinetoplast distances were measured
according to cell shape rather than in direct line. Cells with kinetoplast distances variing within 0.1 �m
were pooled. The histogram plots the kinetoplast distance (with a 0.1 �M resolution) to the number of
cells. In addition, the percentage of cells with kinetoplast distances below 2 �M, between 2 and 4 �M and
above 4 �M is indicated for both uninduced and incuded cells. A photograph of a typical 2K2N cell of
tetracycline induced and uninduced PKAR RNAi cells is shown together with each histogram
C) Distances between kinetoplasts in the presence of vincristine:
Cytokinesis was inhibited with 0.2 �M vinristine to examine whether the observed increase in kinetoplast
distance upon PKAR RNAi is due to cytokinesis inhibition. The quantification of the kinetoplast distances
was performed as described in B).
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3.4.2.2. Reverse genetic interference with PKAC1/2
It was shown that the PKA regulatory subunit is involved in the regulation of cytokinesis 
and kinetoplast movement. However, the data described above did not reveal whether 
this phenotype is due to the loss or gain of kinase activity and if there are functional 
differences between the three catalytic subunits of PKA-like kinase. Therefore, in a second 
approach, the functions of the two very homologous subunits, PKAC1 and PKAC2, were 
investigated reverse genetically by gene deletion (knock-out and hemizygous knock-out) 
and inducible RNA interference. 
3.4.2.2.1. Deletion of PKAC2 led to reduced growth and block in cytokinesis
Given that PKAC2 is hardly present in LS cells (compare chapter 3.1.2.) and therefore 
possibly not essential, it was aimed to generate PKAC2 null mutants for the reverse 
genetic investigation of PKAC2 function. The strategy for the deletion of PKAC2 is shown 
in figure 39. At first, one PKAC2 allele of the monomorphic trypanosoma strain MITat1.2 
was replaced by a hygromycin resistance gene upon transfection with the PKAC2 
targeting construct p∆PKAC2HYG (provided by P. Hassan). Several hygromycin resistant 
clones were obtained that had no obvious phenotypes. For the deletion of the second 
PKAC2 allele one of these clones (clone 2) was further transfected with p∆PKAC2NEO 
(provided by P. Hassan), aiming to replace the remaining PKAC2 allele with a neomycin 
resistance gene. 
MCP
MCP PKAC2
PKAC2 PKAC2 genomic locus
PKAC2 genomic locus
NEO
HYGRO
A
B
Fig. 39: Deletion of PKAC2
PKAC2 is shown in a scaled drawing on its genomic locus together with its upstream gene MCP (putative
mitochondrial carrier protein, Tb09.211.2370).
A) Deletion of the first PKAC2 allele: WT PKAC2 was replaced by a hygromycin resistence gene (green)
together with the 5'UTR and 3'UTR of ACTIN (green, unfilled).
B) Deletion of the second PKAC2 allele: WT PKAC2 was replaced by a neomycin resistance gene
(green) together with the 5'UTR and 3'UTR of ACTIN (green, unfilled).
The genomic locus of PKAC1/2 is shown in more detail in attachment 1.
p�PKAC2NEO
p�PKAC2HYG
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After the second transfection only one double resistant clone (clone 2-1) was obtained. 
Southern analyses confirmed that it had both PKAC2 alleles correctly replaced by the 
targeting constructs (Fig. 40A) and did not possess any further WT PKAC2 genes (Fig. 
40B). The PKAC2 knock-out cells did grow unusually slowly. During the first week after 
transfection the population doubling time was about 8.5 hours. It increased slightly during 
the time cells were kept in culture. The very low clone recovery efficiency together with 
the decreased growth rate indicated that PKAC2 is important for normal growth in BSF 
cells, despite of its low abundance in these cell forms. 
The PKAC2 knock-out cells were examined in more detail together with hemizygous 
PKAC2 knock-out cells and WT cells. The later two served as controls. At the time of the 
analysis the population doubling times were 6.8 hours for the knock-out and 6.3 and 5.6 
hours for the hemizygous knock-out and WT, respectively (Fig. 41A). An analysis of the 
K/N configurations revealed that the percentage of 2K2N cells and multinucleated cells 
(xKyN; x,y>2) was slightly increased in the hemizygous PKAC2 knock-out (22±3% 2K2N) 
and significantly higher in the knock-out (31±4% 2K2N) (Fig. 41B). A more detailed 
investigation of the 2K2N cells further showed that an unusually high amount of these 
cells had a division furrow reaching to approximately half of the cell body (Fig. 41C).
To summarize, PKAC2 depletion resulted in block in cytokinesis, similar to what was 
observed after PKAR depletion. In contrast to the PKAR RNAi phenotype we did not find 
changes in kinetoplast positions in the PKAC2 knock-out cells. Surprisingly, the deletion 
of only one PKAC2 allele was already sufficient to achieve the observed phenotype, 
despite of the low PKAC2 expression in blood stream forms.
WT
PKAR PKAC2
RNAi k.o.
Growth PDT:5.5-6 h
growth 
arrest
 [8 h]
PDT: 
6.82 h
[2K2N] 10-15% 40-48% [8 h] 31%
[1K2N] 0% 1.7 -3.9% [8 h] not sign.
[2K2N cells 
with division 
furrow]
8-12% 35-40% [8 h] 25%
increase in 
kinetoplast 
distance
NO YES NO
The table summarizes all PKA phenotypes describes so far.
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A
Fig. 40: Southern analyses of PKAC2 knock-out and PKAC2 hemizygous knock-out cells
A) Both PKAC2 knock-out constructs are integrated at the correct positions
Genomic DNA of WT cells and PKAC2 knock-out cells (k.o.) was digested with the indicated enzymes,
separated on an agarose gel and blotted to a nylon membrane. The blot was probed with digoxigenine
labeled MCP. MCP (Tb09.211.2370) is the gene upstream of PKAC2. It was used instead of a PKAC1/2
probe to enable the detection of the PKAC2 knock-out fragments. Restriction maps are shown for the WT,
�PKAC2HYG and �PKAC2NEO locus. Sizes of the expected DNA fragments are indicated.
B) No PKAC2WT alleles are present
Genomic DNA of WT cells, hemizygous PKAC2 knock-out (h.-k.o.) and PKAC2 knock-out (k.o.) cells was
digested with the indicated enzymes, separated on an agarose gel and blotted to a nylon membrane. The
blot was probed with digoxigenine labeled PKAC1/2 probe. A restriction map of the WT locus is shown on
the right site. Note that the PKAC1/2 probe detects both PKAC1 and PKAC2 but not the deleted PKAC2
allele. The correct integration of the PKAC2 knock-out construct is thus proven by the absence of PKAC2
detection in the PKAC2 knock-out cell line.
The PKAC1/2 genomic locus, including the postions of the PKAC1/2 and MCP probe, is shown in
attachment 1.
10
8
6
[kb]
5
4
3.5
3
2.5
EcoRV PvuII
BamHI NdeI NaeI
WT k.o. WT k.o. WT k.o.
MCP-probe
PKAC1/2-probe
BamHI
SmaI NdeI
WT h-k.o. ko. WT h-k.o. k.o.
10
6
4
3
2
1.5
1
0.5
[kb]
ORF2 MCP PKAC2 RAB7
EcoRV / BamHI (7.7 kb)
PvuII / NdeI (8.9 kb)
NaeI (7.9 kb)
NdeI NaeI
EcoRV
PvuII
NaeI
PvuII
BamHI
RAB7ORF2 MCP HYG
EcoRV / BamHI (8.3 kb)
PvuII / NdeI (4.4 kb)
NaeI (8.6 kb)
NdeI NaeI
EcoRV
NdeI
PvuII
NaeI
PvuII
BamHI
ORF2 MCP NEO RAB7
EcoRV / BamHI (8.2 kb)
PvuII / NdeI (4.3 kb)
NaeI (3.6 kb)
NdeI NaeI
EcoRV
PvuII
NaeI
PvuII NaeI
PvuII
BamHI
B
WT
�PKAC2HYG
PRP8 ORF1 ORF2PKAC1 PKAC2MCP RAB7
NdeI SmaI
BamHI
SmaI NdeI BamHI
3347 bp >16913 bp
3180 bp 9150 bp
SmaI
BamHI / NdeI
�PKAC2NEO
Results
95
3.4.2.2.2. PKAC2 is not essential for differentiation into procyclic cells
PKAC2 expression depends on the life cycle stage showing low expression levels in LS 
cells. These levels increase in SS cells and are at their highest in procyclic cells (compare 
chapter 3.1.2.). Thus, although PKAC2 knock-out cells had only a slight growth phenotype 
in the long slender stage, they might have a stronger phenotype in later developmental 
stages. Therefore, PKAC2 null mutant cells were tested for their ability to transform 
into procyclic cells. An in vitro transformation was performed with PKAC2 knock-out 
cells, PKAC2 hemizygous knock-out cells and WT cells. Growth and morphology was 
monitored simultaneously.
All cells were able to successfully transform into procyclic cells, judged by morphology. 
During the transformation, no significant differences in growth were observed between 
knock-out, hemizygous knock-out and WT cell (Fig. 42). Thus, PKAC2 is not essential for 
the differentiation into procyclic cells. 
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Fig. 41: Phenotypic analyses of PKAC2 knock-
out (k.o.) and PKAC2 hemizygous knock-out
(WT/k.o.) cells
WT cells were used as control.
A) Growth curves: Cell densities were regularely
determined and kept below 7*105 cell/ml.
B) K/N configurations: Three times 400 cells (from
different slides) were analyzed for each cell line. The
standard deviations are shown by error bars.
C) For each cell line three times 200 2K2N cells
(from different slides) were classified according to
the stage of their division furrow. The standard
deviations are indicated by error bars.
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Fig. 42: Growth during transformation of PKAC2
knock-out cells into PCFs
PKAC2 knock-out cells, PKAC2 hemizygous knock-
out cells and WT cells, the latter serving as control,
were in vitro transformed into procyclic cells. The
cell density was measured every 24 hours. The
success of the transformation was additionally
controlled morphologically.
PKAC2 hemizygous knock-out
3.4.2.2.3. Deletion or mutation of one PKAC1 allele results in reduced growth and 
block in cytokinesis
Two different strategies were chosen for the functional analysis of PKAC1, the 
predominant PKAC1/2 isoform in BSF cells. 
At first, one PKAC1 allele was replaced by a blasticidin resistance gene (BSD) with the aim 
to reduce the PKAC1 expression level. Therefore, the targeting construct p∆PKAC1BSD 
(P. Hassan) was transfected into the monomorphic cell line MITat1.2. Several blasticidin 
resistant clonal populations were obtained and one clone (clone 5) was chosen for further 
analysis (PKAC1 hemizygous knock-out). 
Alternatively, PKAC1 was not deleted but replaced by a mutated PKAC1 gene (N165-
>A) resulting in the expression of catalytically inactive PKAC1 (dead mutant). In order to 
enable immunoprecipitations, this dead mutant PKAC1 was further equipped with an N-
terminal Ty1-tag. Several independent Ty1-PKAC1-dead clones were obtained and clone 
11,12 and 14 were chosen for further analysis of PKAC1 function. Immunoprecipitated 
Ty1-PKAC1-dead was catalytically inactive (see Fig. 20, chapter 3.2.3.). 
A summary of the cell lines that were used for the functional PKAC1 analysis is shown 
in figure 43. In addition to the cell lines mentioned above, WT cells and two different 
clones of Ty1-PKAC1 cells (without the dead mutation) were used as controls. Southern 
analyses confirmed that all cell lines had the expected genotype (Fig. 44A). Furthermore, 
all clones (except of course the PKAC1 hemizygous knock-out) expressed Ty1 epitope 
tagged PKAC1 (Fig. 44B). 
Results
97
PRP8 BSD
PRP8 PKAC1
PRP8 PKAC1
PRP8 PKAC1
PRP8 BLE Ty1 PKAC1
PRP8 PKAC1
PRP8 BLE Ty1 PKAC1
PRP8 PKAC1
N->A
WT
PKAC1 hemizygous
knock-out
Ty1-PKAC1
Ty1-PKAC1-dead
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Fig. 43: Overview about the cell lines used to examine PKAC1 function
Schematic non-to-scale drawing of the cell lines that were used for the functional analysis of PKAC1. Both
alleles of the PKAC1 genomic locus (together with the 3' part of its upstream gene PRP8) are shown. The
positions of the blasticidin resistence genes (BSD, blue), the phleomycin resistence genes (BLE, blue), the
Ty1-epitope tags (red) and the dead mutation (N->A, yellow) are indicated. Further information about the
PKAC1/2 genomic locus is available in attachment 1.
A) One WT PKAC1 allele was exchanged by a blasticidin resistance gene using the construct
p�PKAC1BSD (P.Hassan). Clone 5 was used for subsequent phenotypic analysis.
B)One WT PKAC1 allele was replaced by a Ty1-epitope tagged PKAC1 dead mutant using the construct
pTy1-PKAC1-dead. Three clonal transfectants were used for subsequent phenotypic analyses (clones
11,12,14). Ty1-PKAC1-dead is catalytically inactive (Fig. 20, chapter 3.2.3.).
C) One WT PKAC1 allele was replaced by a Ty1-epitope tagged PKAC1. Two clonal transfectants (clone 1
and 2) were used for phenotypic analyses. This cell line served as a control.
D) WT cells (MITat1.2) were used as further control.
dead mutation
A
B
C
D
control
control
All cell lines were now applied to phenotypic characterization. Both Ty1-PKAC1-dead and 
PKAC1 hemizygous knock-out cells had a reduced growth rate (Fig. 45A). Population 
doubling times were 7.9 for Ty1-PKAC1-dead (average value of #11,12,14) and 6.5 
hours for PKAC1 hemizygous knock-out cells, compared to 5.5 hours in WT cells. K/N 
configuration analyses revealed that the amount of 2K2N cells was doubled in both 
the Ty1-PKAC1-dead and PKAC1 hemizygous knock-out cells (Fig. 45B). Additionally, 
one quarter of the cells was multinucleated. A more detailed analysis of the 2K2N 
cells showed that 50% of these cells had a division furrow and were halfway through 
cytokinesis, compared to only 12% of the 2K2N cells from the control cell lines (Fig. 45C). 
Photographs of typical 2K2N and multinucleated cells are shown in figure 45D. Usually, 
the multinucleated cells consisted of several cell bodies attached to each other instead 
of having a single cell body.
The observed phenotype was thus very similar to the phenotype that had been observed 
in the PKAC2 null mutant cell lines and with PKAR RNAi. Cells were unable to successfully 
progress through cytokinesis resulting in an increase in 2K2N cells with a division furrow 
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Fig. 44: Verification of the cell lines Ty1-PKAC1, Ty1-PKAC1-dead and PKAC1 hemizygous knock-
out (WT/k.o.) with Southern and Western blot analyses
A) Southern blot: All cell lines have the expected genotype.
Genomic DNA of the cell lines WT (MITat1.2), Ty1-PKAC1 (# 1, #2), PKAC1 hemizygous knock-out (# 5)
and Ty1-PKAC1-dead (#11, #12, #14) was digested with SmaI, separated on an agarose gel, transferred
to a nylonmembrane and probed with a digoxigenine labeled probe against the C-terminus of PRP8, the
gene upstream of PKAC1 (PRP8 probe). The expected DNA fragment sizes are: 3347 bp (WT), 1850 bp
(Ty1-PKAC1 and Ty1-PKAC1-dead), 3766 bp (�PKAC1BSD). Restriction maps of the genomic loci are
shown for each cell line. More detailed information about the PKAC1/2 genomic locus (including the
position of the PRP8 probe) is given in attachment 1.
B) Western blot: Ty1 epitope tagged PKAC1 is expressed.
Protein extract from 5*106 cells of the cell lines Ty1-PKAC1 (#1, #2), PKAC1 hemizygous knock-out (#5)
and Ty1-PKAC1-dead (#11, #12, #14) was applied to SDS PAGE. The resulting Western blot was probed
with anti-PKAC1/2 (secondary antibody: rabbit Alexa680, red) and anti-Ty1 (secondary antibody:
MouseIRDye800, green). The same blot is shown three times: on top with anti-PKAC1/2 only, in the
middle with both anti-Ty1 and anti-PKAC1/2 (Ty1-PKAC1 appears yellow) and on bottom with anti-Ty1
only. It can be seen that all cell lines express Ty1-epitope tagged PKAC1, with the exception of the
PKAC1 hemizygous knock-out clone that serves as negative control. For a better understanding it is
indicated for each band which PKAC1/2 forms it contains. The Thr324 phosphorylation of PKAC1
(compare chapter 3.1.1.1.) is thereby labeled with "phos". Note that the Ty1-epitope tag and the PKAC1
phosphorylation result in a similar band-shift on SDS page.
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Fig. 45: Deletion or inactivation of one PKAC1 allele prevents cells from cytokinesis progression
The subsequently described analyses were performed with the cell lines introduced in figure 43.
A) Growth curves: Cell densities were measured regularely and kept below 7*105 cells/ml.
B) K/N configuration: Cells were methanol fixed on a slide and K/N configurations of 400 DAPI stained
cells were determined. Three different slides were analyzed from each cell line. Average values from
these three slides are shown in the diagram and standard deviations are indicated as error bars.
C) Stage of the division furrow: 2K2N cells of the slides from (B) were grouped according to the stage
of their division furrows. 200 cells were analyzed from each slide, thus 600 for each cell line. Standard
deviations are indicated by error bars.
D) Photographs of typical multinucleated and 2K2N cells of the PKA dead mutant cell line (#12) are
shown. Cells of the other clones as well as of the PKAC1 hemizygous knock-out cell line look similar.
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reaching to approximately half of the cell body. 
The PKAC1 dead mutant cells showed a stronger growth phenotype compared to the 
hemizygous PKAC1 knock-out cells. While both cell lines lack one functional PKAC1 
allele (gene doses effect), in the PKAC1 dead mutants an additional dominant negative 
effect might occur due to the binding of inactive PKAC1 to the regulatory subunit. 
WT
PKAR PKAC2 PKAC1
RNAi k.o. hemizyg.
k.o.
dead 
mutant
Growth PDT:5.5-6 h
growth 
arrest
 [8 h]
PDT: 
6.82 h
PDT: 
6.5 h
PDT: 
7.9 h
[2K2N] 10-15% 40-48% [8 h] 31% 29% 28%
[1K2N] 0% 1.7 -3.9% [8 h] not sign. not sign.
not 
sign.
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furrow]
8-12% 35-40% [8 h] 25% 43-52% 43%
increase in 
kinetoplast 
distance
NO YES NO NO NO
The table summarizes all PKA phenotypes describes so far.
3.4.2.2.4. Gene conversion of the WT PKAC1 allele in hemizygous PKAC1 dead 
mutants
Further evidence for the essentiality of PKAC1 in BSF trypanosomes was found during the 
generation of the PKAC1 dead mutant cell lines described above. Phleomycin resistant 
clonal transfectants that contained active Ty1-PKAC1 instead of the dead mutant Ty1-
PKAC1 were frequently obtained (data not shown). This interesting phenomenon 
was further examined by a systematic screening of the genomic DNA of 30 clonal 
transfectants for the presence or absence of the dead mutation in Ty1-PKAC1 (done by 
Anne Marinière). It turned out that 18 of these transfectants had WT Ty1-PKAC1 instead 
of the dead mutant Ty1-PKAC1. One example of such a screen is shown in figure 46. 
Thus, it seems that the replacement of one PKAC1 allele by a gene coding for inactive 
PKAC1 favours the selection of cells that repair this gene. This probably occurs by a gene 
conversion event with the aid of the intact WT PKAC1 allele.
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Fig. 46: Screen for gene conversion in hemizygote PKAC1-dead mutants
MITat1.2 WT cells were transfected with the construct pTy1-PKAC1-dead. Genomic DNA was prepared
from 12 clonal transfectants after approximately 25 cell divisions (thus as soon as 50 ml cells were
available). Ty1-PKAC1 was amplified from the genomic DNA (using the oligos 19.11.01 ty1/upper and
PKAC1.seq.l.19/7/01) and screened for the dead mutation (N165->A). This was possible with a HinfI
restriction digest because WT PKAC1 contained one HinfI site more than dead-mutant PKAC1.
The agarose gel with the HinfI digests is shown. The expected fragment sizes for the HinfI digestion of
dead mutant PKAC1 and WT PKAC1 are indicated on the right site. Out of the 12 clones that were
examined in this experiment, 10 had lost their dead mutant PKAC1, these clones are marked with an x.
The experiment was done by Anne Marinière (lab student).
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3.4.2.2.5. Depletion of PKAC1/2 with RNAi results in cytokinesis block and cell 
death
The gene deletion experiments described above for PKAC1 and PKAC2 were exclusively 
performed using stable transfected cell lines. Thus, it may be that these cell lines had 
adapted to compensate for the loss of one PKAC allele before we were able to analyze 
them. For this, an additional experiment based on PKAC1 and PKAC2 reduction by 
inducible RNA interference was performed. 
However, these RNAi experiments proved to be particularly difficult. Although several 
different parts of the PKAC1/2 sequence were used as a template for RNAi (including 
the 5ʼUTRs of PKAC1 and PKAC2) all transfectants did either show no reaction to 
tetracycline or had already a phenotype without tetracycline (data not shown). The most 
likely reason for this is the relatively low concentration of tet repressor in the 13-90 cell 
line. It allows a weak transcription of the target sequence in the p2T7 vector even in the 
absence of tetracycline (leakiness). In the 13-90 cell line the tet repressor is cotranscribed 
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with a hygromycin resistance gene (hygromycin phosphotransferase). Hygromycin is 
inactivated by phosphorylation (thus, a catalytic process), enabling  relatively few proteins 
of hygromycin phosphotransferase to sufficiently inactivate many hygromycin molecules. 
Therefore there is low selective pressure on expression level of the tet repressor. To 
overcome this problem, a different tetracycline inducible cell line was used. In this cell 
line (1313-514, C. Clayton, unpublished) the tet repressor is transcribed together with a 
phleomycin resistance gene (BLE). The BLE protein inactivates phleomycin by binding 
to it. It is therefore needed in at least equimolar concentrations to phleomycin, resulting 
in a selection pressure towards cells with a high transcription rate of the BLE gene and 
therefore also the tet repressor. Additionally, it was necessary to use a different RNAi 
vector (p2T7TAblue, Alibu et al., in press) carrying hygromycin resistance instead of 
phleomycin resistance. 
The PKAC1 N-terminal fragment (corresponding to the amino acids 10 to 216) was 
cloned into the p2T7TAblue vector and transfected into 1313-514 BSF cells (cell line and 
vector kindly provided by C. Clayton, Heidelberg). 
Out of 12 hygromycin resistant clonal populations two were selected showing no or little 
phenotype in the absence of tetracycline but a strong growth phenotype after overnight 
induction (clone 2 and 3). Further analyses revealed that cells stopped growing within 
four hours after tetracycline was added and died within two days (Fig. 47A). Cells looked 
abnormal (fat, shapeless, multiple cell bodies) after 4 to 6 hours. A decrease of PKAC1/2 
protein was observed after 4 to 8 hours (80-90%) accompanied by a slight decrease in 
PKAR protein (20-35%) (Fig. 47B). Considering the high homologies between PKAC1 
and PKAC2 it is probable that both isoforms are affected by RNA interference, although 
they cannot be distinguished on a Western blot. The RNAi phenotype was investigated 
in more detail by a K/N configuration analysis with DAPI stained cells (Fig 47C). A 
significant increase in 2K2N cells and multinucleated cells was already found four hours 
after induction with  tetracycline. Within 8 hours nearly 100% of the population consisted 
of 2K2N and multinucleated cells. After 10 hours more than two thirds of the cells were 
multinucleated. Note that an unsually high fraction of multinucleated cells was also found 
in the non-induced control cells, suggesting that there is still a certain degree of T7 
polymerase dependent transription in the absence of tetracycline even with the 1313-514 
cell line. A very slight increase in 1K2N cells was found after 10 hours (1.2 to 3-5%).
A more detailed examination of the 2K2N cells revealed that an unusually high number 
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of these cells had a division furrow reaching to approximately half of the cell body (Fig. 
47D). Multinucleated cells usually consisted of multiple cell bodies. Typical 2K2N and 
multinucleated cells are shown in figure 47E.
To summarize, the PKAC1/2 RNAi phenotype is qualitatively identical to the phenotypes 
observed after reducing the levels or PKAC1 or PKAC2 by gene deletion. Cells are 
unable to complete cytokinesis and instead proceed to the next M phase. However, the 
RNAi phenotype is stronger than the gene deletion phenotypes.
WT
PKAR PKAC2 PKAC1 PKAC1/2
RNAi k.o. hemizyg.
k.o.
dead 
mutant
RNAi
Growth PDT:5.5-6 h
growth 
arrest
 [8 h]
PDT: 
6.82 h
PDT: 
6.5 h
PDT: 
7.9 h
growth arrest 
[4 h] dead 
[2 d]
[2K2N] 10-15% 40-48% [8 h] 31% 29% 28% 58% [6 h]
[1K2N] 0% 1.7 -3.9% [8 h] not sign. not sign.
not 
sign.
1.2-3.5% 
[10 h]
[2K2N cells 
with division 
furrow]
8-12% 35-40% [8 h] 25% 43-52% 43% 32-40% [6 h]
increase in 
kinetoplast 
distance
NO YES NO NO NO NO
The table summarizes all PKA phenotypes describes so far. 
3.4.2.2.6. The PKAC1/2 specific inhibitor KT5720 led to block in cytokinesis and 
accumulation of 1K2N cells
KT5720 is a specific inhibitor for PKAC1/2 with much less inhibition of PKAC3 (see 
Fig. 26C in chapter 3.3.4.3.). For this reason it was used to further examine  PKAC1/2 
function. 
Cells (MITat1.2) were incubated in the presence of KT5720 dissolved in DMSO. The 
optimal inhibitor concentration for the experiments was found to be 4 µM. Higher 
concentrations killed the cells within 3 hours and lower concentrations showed no effect. 
Growth and K/N configurations of cells treated either with KT5720 or with DMSO (control) 
were analyzed after 3 and 6 hours. 
Within the first 3 hours, KT5720 treated cells grew very slowly and after 6 hours the 
number of cells decreased (Fig. 48A). After 3 hours of incubation with KT5720 the 
number of 2K2N cells was significantly increased to more than 40%, while the number 
of multinucleated cells and 1K2N cells only increased slightly (Fig. 48B). The number 
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Fig. 47: Depletion of PKAC1/2 using inducible RNA interference
PKAC1/2 RNAi cells were incubated in the presence or absence (control) of tetracycline for 52 hours.
Data from two independent clonal cell lines (#2 and #3) are shown.
A) Growth curves of induced and uninduced PKAC1/2 RNAi cells. Cell densities were kept below 7*105
cells/ml.
B) Western blots. Protein samples of uninduced and induced cells were collected at the times indicated
and applied to SDS PAGE. The resulting Western blots were incubated with anti-PKAR, anti-PKAC1/2 and
anti-Hsp60, the latter serving as control for equal loading. Rabbit Alexa680 (red) and Mouse IRDye800
(green) were used for the detection of anti-PKAR/anti-PKAC3/anti-PKAC1/2 and anti-Hsp60, respectively,
using the Odyssey IR scanner (Licor).
C) K/N configurations: Cells were fixed in methanol after 0, 2, 4, 6, 8 and 10 hours of incubation with or
without tetracycline and subsequently stained with DAPI. K/N configurations of 400 cells were determined
for each time point.
D) 2K2N cells and 1K2N cells were classified according to the stage of their division furrows. 200 cells
were analyzed for each clone. Cells had been incubated with or without tetracycline for 6 hours.
E) Photographs of typical multinucleated cells observed after RNAi depletion of PKAC1/2 (6 hours
induction). Nuclei and kinetoplasts are stained with DAPI.
%
2K
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2N
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of 2K2N cells with a division furrow slightly increased in the presence of KT5720 (Fig. 
48C). 
After 6 hours of incubation with KT5720 one forth of the cells had the unusual 1K2N K/N 
configuration (Fig. 48D), many of these cells had a division furrow.
WT
PKAR PKAC2 PKAC1 PKAC1/2
RNAi k.o. hemizyg.
k.o.
dead 
mutant
RNAi KT5720
Growth PDT:5.5-6 h
growth 
arrest
 [8 h]
PDT: 
6.82 h
PDT: 
6.5 h
PDT: 
7.9 h
growth arrest 
[4 h] dead 
[2 d]
growth 
arrest 
[3 h]
[2K2N] 10-15% 40-48% [8 h] 31% 29% 28% 58% [6 h] 41% [3 h]
[1K2N] 0% 1.7 -3.9% [8 h] not sign. not sign.
not 
sign.
1.2-3.5% 
[10 h]
1.7% [3 h]
26.3% [6 h]
[2K2N cells 
with division 
furrow]
8-12% 35-40% [8 h] 25% 43-52% 43% 32-40% [6 h] 16% [3h]
increase in 
kinetoplast 
distance
NO YES NO NO NO NO NO
The table summarizes all PKA phenotypes describes so far. 
3.4.2.3. Depletion of PKAC3 results in cytokinesis block and accumulation of 1K2N 
cells, but not in decreased kinetoplast distances
An increase in 1K2N cells, such as was found upon inhibition of PKAC1/2 with KT5720, 
has already been described for the third catalytic PKA subunit (PKAC3) by Thorsten 
Riek (Diploma thesis 2001). The function of PKAC3 was investigated using inducible 
RNA interference, since it was not possible to obtain BSF knock-out cells. Upon PKAC3 
depletion cells were cell cycle arrested in cytokinesis and around 10% of the cells had the 
unusual 1K2N K/N configuration with a single large kinetoplast.
Together with the observed increase in kinetoplast distance during PKAR knock-down, 
these results led to the hypothesis that T. brucei PKA-like kinase might play a role in 
kinetoplast segregation during cytokinesis. Depletion of PKAC3 by RNAi should then 
result in the opposite phenotype, thus in decreased kinetoplast distances in 2K2N cells. 
The observed 1K2N cells would be the extreme example for no kinetoplast movement. 
In order to test this hypothesis, the RNAi experiment of Thorsten Riek was repeated with 
the aim to quantify kinetoplast distances in 2K2N cells. This time the p2T7TAblue vector 
and the 1313-514 cell line (cell line and vector kindly provided by C. Clayton, Heidelberg) 
were used to obtain higher levels of tet repressor (see above chapter 3.4.2.2.5.). As RNAi 
target served the N-terminal PKAC3 fragment (467 bp). 
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Fig. 48: Effects of the PKAC1/2 specific PKA inhibitor KT5720 on WT cells
WT cells (MITat1.2) were incubated with 4 �M KT5720 (stock: 2 mM desolved in DMSO) or with an equal
volume of DMSO (control). Cell densities were determined regularely and cells were fixed in methanol and
stained with DAPI to enable K/N analyses. Average data from three independent experiments are shown.
Standard deviations are indicated by error bars.
A) Growth curves: Cell densities (cells/ml) were measured 0, 3 and 6 hours after addition of KT5720 or
DMSO.
B) K/N configurations: 400 DAPI stained cells were analyzed for each experiment. Cells had been
incubated with KT5720 for either 3 or 6 hours.
C) Division furrow stage: 2K2N cells and 1K2N cells were classified according to the stage of their
division furrow. 200 cells were analyzed for each experiment. Cells had been incubated with KT5720 or
DMSO for 3 hours.
D) Photographs of typcial 1K2N and 2K2N cells after 6 hours of incubation with KT5720. The cells were
stained with DAPI.
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Out of 11 hygromycin resistant clones four clearly reacted to tetracycline (growth 
decrease, abnormal morphology) after incubation overnight. The others either showed 
no reaction or already had phenotypes in the absence of tetracycline. Two out of 
these four clones were further analyzed (clone 1 and clone 4). After incubation with 
tetracycline, cells reduced their growth rate (Fig. 49A). The population doubling times 
increased from 6 hours (non-induced) to 16.2 /18.6 hours (clone 1/ clone 4). An 80 to 
90% reduction in PKAC3 protein was detectable on a Western blot 36 to 50 hours after 
tetracycline induction for clone 1 and after 12 to 24 hours for clone 4 (Fig. 49B). None 
of the other PKA-like subunits were affected. The number of 2K2N cells and the number 
of multinucleated cells increased with time. The number of 1K2N cells slightly increased 
up to 9% after 10 to 12 hours incubation with tetracycline, but no 1K2N cells were found 
at earlier time points (Fig. 49C). The amount of 2K2N cells with a division furrow slightly 
increased (Fig. 49D) suggesting that the cell cycle arrest was caused by a problem in 
progression through cytokinesis, as observed for the other subunits. This hypothesis 
was further confirmed by the appearance of the multinucleated cells mostly consisting of 
several cell bodies (Fig. 49E).
However, when 2K2N cells were examined in more detail, we could not detect any 
decrease in kinetoplast distances. This already became clear from qualitative microscopy. 
Conclusively, we could not confirm the hypothesis stated above that PKAC3 depletion 
inhibts kinetoplast segregation. The reason for the occurence of 1K2N cells at late time 
points remains unclear.
WT
PKAR PKAC2 PKAC1 PKAC1/2 PKAC3
RNAi k.o. hemizyg.
k.o.
dead 
mutant
RNAi KT5720 RNAi
Growth PDT:5.5-6 h
growth 
arrest
 [8 h]
PDT: 
6.82 h
PDT: 
6.5 h
PDT: 
7.9 h
growth arrest 
[4 h] dead 
[2 d]
growth 
arrest 
[3 h]
reduced growth 
PDT: 
16.2-18.6 h
[2K2N] 10-15% 40-48% [8 h] 31% 29% 28% 58% [6 h] 41% [3 h] 36-45% [10 h]
[1K2N] 0% 1.7 -3.9% [8 h] not sign. not sign.
not 
sign.
1.2-3.5% 
[10 h]
1.7% [3 h]
26.3% [6 h]
7.1 to 9.5% 
[12 h]
[2K2N cells 
with division 
furrow]
8-12% 35-40% [8 h] 25% 43-52% 43% 32-40% [6 h] 16% [3h] 22-24% [10 h]
increase in 
kinetoplast 
distance
NO YES NO NO NO NO NO NO
The table summarizes all PKA phenotypes describes so far. 
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Fig. 49: Depletion of PKAC3 using inducible RNA interference
PKAC3 RNAi cells were incubated in the presence or absence (control) of tetracycline for 76 hours. Data
from two independent clonal cell lines (#1 and #4) are shown.
A) Growth curves of induced and uninduced PKAC3 RNAi cells. Cell densities were kept below 7*105.
B) Western blots. Protein samples of uninduced and induced cells were collected at the times indicated
and applied to SDS PAGE. The resulting Western blots were incubated with anti-PKAC3, anti-PKAR, anti-
PKAC1/2 and anti-Hsp60, the latter serving as control for equal loading. Since PKAC3 and PKAC1/2
have equal molecular weights, two Western blots (containing the same samples) were performed for each
time course, one was incubated with anti-PKAR and anti-PKAC3, the other with anti-PKAC1/2. Rabbit
Alexa680 (red) and Mouse IRDye800 (green) were used for the detection of anti-PKAR/anti-PKAC3/anti-
PKAC1/2 and anti-Hsp60, respectively, using the Odyssey IR scanner (Licor).
C) K/N configurations: Cells were fixed in methanol after 0, 2, 4, 6, 8, 10 and 12 hours of incubation with
or without tetracycline and subsequently stained with DAPI. K/N configurations of 400 cells were
determined for each time point.
D) 2K2N cells and 1K2N cells were classified according to the stage of their division furrows. 200 cells
were analyzed for each clone. Cells had been incubated with or without tetracycline for 10 hours.
E) Photographs of typical multinucleated cells observed after RNAi depletion of PKAC3 (10 hours
induction). Nuclei and kinetoplasts are stained with DAPI.
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3.5. In silico search for further putative subunits of PKA-like 
kinases
Experiments of this Ph.D. project were so far focussed on the isoforms/subunits PKAC1, 
PKAC2, PKAC3 and PKAR. The T. brucei genome sequencing project has only recently 
been finished and might now contain sequences not available at the beginning of this 
work. If the PKA-like kinase characterized in this work doesnʼt transmit the cAMP signal 
thought to stimulate differentiation processes, is there another regulatory PKA subunit 
that actually becomes activated by cAMP?
3.5.1. Hidden regulatory subunits?
Regulatory PKA subunits of most organisms have two conserved sequence motifs. The 
most prominent features are the two cNMP binding sites that are arranged in tandem, 
usually at the C-terminus of the protein. In addition, type II PKARs have an RIIa domain 
at their N-termini mediating the dimerization between the two regulatory subunits and the 
binding to A-kinase anchoring proteins (AKAPs). 
The T. brucei genome database was screened for proteins with these characteristic 
PKAR motifs with the aid of a computational algorithm based on the hidden Markov 
model (HMM) (reviewed by Eddy  2004). In contrast to BLAST searches, HMM based 
searches offer the ability to perform model-based searches against a multiple sequence 
alignment rather than against one single target sequence. This enables a broader 
“space” to be searched.
3.5.1.1. Search for cNMP binding proteins in the T. brucei genome database
The multiple sequence alignments of cNMP binding domains as provided by Pfam (http:
//www.sanger.ac.uk/cgi-bin/Pfam/; version 10.0; Bateman et al., 2004) and by SMART 
(http://smart.embl-heidelberg.de/; version 4.0 , Schultz et al., 1998; Letunic et al., 2004) 
were used as templates for HMM based searches (HMMER version 2.3.2. downloaded 
from http://hmmer.wustl.edu/; default parameters with an e-value threshold of 10) against 
the local copy of the T. brucei genome database (http://www.genedb.org/genedb/tryp/
index.jsp, release 3, the HMM search was performed by M. Kador (this lab)). 14 T. brucei 
proteins were identified with the SMART alignment, 18 with the Pfam alignment and 
11 proteins were found with both alignments. These proteins are shown in the table in 
figure 50A (left columns) together with the e-values of the HMMER searches. They were 
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subsequently examined for cNMP binding domains with the web services of Pfam and 
SMART using default parameters as set by the servers. 14 proteins had predicted Pfam 
cNMP domains out of which 10 had also predicted SMART cNMP domains (Fig. 50A, 
right columns). 
The results from the HMMER search were controlled with a BLAST search using cNMP 
binding domains of PKARs from five different organisms as targets (attachment 3). With 
this alternative approach, we did identify all proteins that had high HMMER e-values 
(marked with an “x” in figure 50A), but none in addition. 
It is therefore likely that all T. brucei proteins with cNMP domains were identified.  
3.5.1.1.1. Three T. brucei proteins have two cNMP binding domains in tandem 
Most of the putative cNMP binding proteins identified above have only one predicted 
cNMP binding site, often with low significance (compare e-values). However, three T. 
brucei proteins (Tb10.70.1860, Tb03.48K5.800, Tb11.01.7890) were found that had two 
predicted cNMP domains with sufficiently high significance (Pfam e-value below 7.2E-3). 
They are therefore possible candidates for new regulatory PKA subunits. The domain 
structures of these three proteins are shown in figure 50B, in comparison with the domain 
structures of the known T. brucei PKAR and bovine PKAR. The cNMP domains of all 
three proteins are arranged in tandem as is the case in regulatory PKAR subunits.
Interestingly, all three PKAR candidates have unusually long C-termini absent from both 
the known T. brucei PKAR and bovine PKAR. In addition, they possess an N-terminal 
extension. Such an N-terminal elongation is also present in the known T. brucei PKAR, 
but we could not identify any homology between the PKAR N-terminus and the N-termini 
of the identified cNMP binding proteins. With the exception of a C2 domain (a Ca2+-
dependent membrane-targeting module) in Tb10.70.1860 no further domains were found 
in any of the PKAR candidates, not even an RIIa domain.  
3.5.1.1.2. Two of the T. brucei PKAR candidates have highest homologies to 
PKARs
The most related proteins were identified for each of the three putative T. brucei PKAR 
proteins using a BLAST search in EMBL nr. For this, the protein database nr at NCBI 
(GenBank (http://www.ncbi.nlm.nih.gov/BLAST/),blastp, default parameters as set by 
the NCBI server; Altschul et al., 1997) was searched with the sequences of the T. brucei 
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PKAR candidates. The results are listed in table 4.
putative T. 
brucei PKAR
highest homology to
protein organism e-value % identity
sequence 
overlap
Tb10.70.1860 Regulatory subunit of the cyclic AMP-dependent protein kinase
Saccharomyces 
cerevisiae
5.0E-10 21 192
cAMP-dependent protein kinase regulatory 
subunit Yarrowia lipolytica 1.0E-7 25 188
KAPR_EMENI CAMP-DEPENDENT 
PROTEIN KINASE REGULATORY CHAIN
Aspergillus 
nidulans FGSC A4
8.0E-6 22 301
Tb11.01.7890 cyclic nucleotide-gated K+ Bdellovibrio 
bacteriovirus
6.0E-7 32 123
cyclic GMP-dependent protein kinase Hydra oligactis 2.0E-5 23 269
cGMP-dependent protein kinase foraging Apis mellifera 2.0E-5 24 169
Tb03.48K5.800
PREDICTED: similar to cAMP-dependent 
protein kinase type I-beta
            regulatory chain
Homo sapiens 4.0E-3 33 62
protein kinase (EC 2.7.1.37), cAMP-
dependent, type I-beta
            regulatory chain - human
Homo sapiens 6.0E-3 22 167
cAMP-dependent protein kinase type I-beta 
regulatory chain Mus musculus 3.2E-2 22 167
Table 4: Blast searches with the three T. brucei PKAR candidates
The protein database nr at NCBI (GenBank (http://www.ncbi.nlm.nih.gov/BLAST/),blastp, default parameters as set by 
the NCBI server; Altschul et al., 1997) was searched with each of the three T. brucei PKAR candidates (Tb10.70.1860,. 
Tb11.01.7890, Tb03.48K5.800). The three proteins with the highest homologies (others than putative proteins) as judged 
by the e-value are indicated for each T. brucei PKAR candidate together with the e-value and the identity and sequence 
overlap to the target sequence. 
Tb10.70.1860 and Tb03.48K5.800 had highest homologies to PKARs from various 
organisms (21-33% ID), while Tb11.01.7890 had highest homology to a cyclic nucleotide 
gated ion channel and to PKGs (23-32% ID). 
3.5.1.1.3. Substrate or pseudosubstrate sequences in the new T. brucei PKAR 
candidates
The substrate or pseudosubstrate sequence RRX [A,T,S]y (y=hydrophobic) is a further 
characteristic feature of regulatory PKA subunits. It is located N-terminal of the cNMP 
binding domain and mediates the binding to the catalytic subunit. 
The N-termini of the three PKAR candidates, corresponding to the region upstream 
of the first cNMP binding site, were searched for such a substrate or pseudosubstrate 
sequence. In Table 5 the substrate or pseudosubstrate sequence is shown for each of 
the putative PKARs together with its position in relation to the first cNMP binding site. For 
comparison, the substrate or pseudosubstrate sequences of bovine PKAR and of the 
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known T. brucei PKAR are also shown. 
 
 
Substrate or Pseudosubstrate Sequence
Sequence Position Distance to 1st cNMP binding site
bovine PKAR RRASV 112-116 38
Tb PKAR RRTTV 206-210 33
Tb10.70.1860 LRMTV 250-254 20 
Tb11.01.7890 RRLAV 200-204 30
Tb03.48K5.800       none 
Table 5: The N-terminal sequences of the PKAR candidate proteins were searched for a substrate or pseudosubstrate 
sequence RRX [A,T,S]y (y=hydrophobic). The position and the distance to the first cNMP binding site (as predicted 
by SMART) is shown. Variations to the classical substrate or pseudosubstrate sequence are shown in italic/bold 
Tb10.70.1860).  For comparison, the substrate/pseudosubstrate sequences are also shown for bovine PKAR (type II, β, 
Acc No.: NP_777074) and the known Tb PKAR.
Only one of the three new PKAR candidates (Tb11.01.7890) has a classical 
pseudosubstrate sequence (RRLAV). It is located 30 amino acids upstream of the first 
cNMP binding site, thus in a similar relative position as in bovine or the known T. brucei 
PKAR. Tb10.70.1860 has a substrate sequence that varies in the first amino acid (L / 
Y instead of R) from the classical substrate sequence and is located 20 amino acids 
upstream of the first cNMP binding site. Variations in that position were already described 
for Paramecium tetraurelia (Carlson and Nelson, 1996). Tb03.48K5.800 has no substrate 
or pseudosubstrate sequence.
3.5.1.1.4. All new PKAR candidates have significant homology to a PKA specific 
conserved 14 amino acid stretch in the cNMP binding sites
cNMP binding domains are also present in several other proteins such as the catabolite 
activator protein (CAP) (Eron et al., 1971; Weber and Steitz 1987), cyclic nucleotide-gated 
ion channels (Nakamura and Gold 1987; Ludwig et al., 1990) and guanine nucleotide 
exchange factors (Kawasaki et al., 1998). 
A method for the univocal identification of regulatory PKA subunits was developed by 
Canavas et al. (2002). They identified a degenerative 14 amino acid stretch in the cNMP 
binding domain of regulatory PKA subunits that is highly conserved between PKARs from 
various species, but absent from cNMP binding domains of other proteins: F-G-E-[LIF]-A-
L-[LIMV]-X(3)-[PV]-R-[ANVQ]-A. 
The sequences of the three putative PKAR subunits of T. brucei were aligned to this PKAR 
specific 14 amino acid stretch (Fig. 51). Bovine PKAR and the known T. brucei PKAR 
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served as positive controls. Two of the T. brucei proteins with only one predicted cNMP 
binding domain (Tb08.26N11.680, Tb07.26A24.610) were used as negative controls.
The known T. brucei PKAR has already several amino acid substitutions to the consensus 
sequence, three in domain A and four in domain B. Four of these substitutions are 
non-conservative. Similar or only slightly higher numbers of amino acid substitutions 
were found for all three T. brucei PKAR candidates (Tb10.70.1860, Tb11.01.7890 
and Tb03.48K5.800). In contrast, T. brucei proteins with only one cNMP domain, 
that are unlikely to be regulatory PKAR subunits, have 11 (Tb08.26N11.680) or 9 
(Tb07.26A24.610) amino acid substitutions to the consensus sequence. 
Fig. 51: The conserved PKA specific sequence in the T. brucei PKAR candidates
The homologous sequence to the conserved sequence stretch in the cNMP binding sites of PKAs as
defined by Canaves et al. (2002) is shown for each of the three putative T. brucei PKARs (Tb10.70.1860,
Tb11.01.7890, Tb03.48K5.800) (*). As positive controls, both bovine PKAR (type II �, Acc No.:NP_777074) and the known T. brucei PKAR are shown (+). As negative controls we used two T. brucei
proteins with only one predicted cNMP domain (Tb08.26N11.680, Tb07.26A24.610) (-) that are unlikely to
be regulatroy PKA subunits. All amino acids that are identical to the consensus sequence are uncolored,
conservative amino acid substitutions to the consensus sequence are shadowed light yellow and non-
conservative amino acid substitutions yellow.
consensus F G E [LIF] A L [LIMV] X X X [PV] R [ANVQ] A F G E [LIF] A L [LIMV] X X X [PV] R [ANVQ] A
bovine PKAR F G E L A L M Y N T P R A A F G E L A L V T N K P R A A
T. brucei PKAR V G E L E L M Y Q T P T V A V G E L E F L N N H A N V A
Tb10.70.1860 F G E V S V I F D E P R C C V G E L F L H P H L W P T D
Tb11.01.7890 V G E F A L V C K E P R S A V G I F E C A C S V N E R K
Tb03.48K5.800 F G E L S V L F G E P R Q F I G E P T I I L H R W P L G
Tb07.26A24.610 F T P T E L A S S L Q E K H
Tb08.26N11.680 A V D V W T R L R T C C C S
1st cNMP binding domain 2nd cNMP binding domain
*
*
*
+
+
-
-
3.5.1.2. Search for T. brucei proteins with RIIa domains
In a second approach, the RIIa domain, present in all type II PKARs, was used as a 
template to identify further related proteins in T. brucei. The multiple sequence alignment 
of RIIa domains provided by Pfam (http://www.sanger.ac.uk/cgi-bin/Pfam/; version 10.0; 
Bateman et al., 2004) was used for an HMM based search (HMMER version 2.3.2. 
downloaded from http://hmmer.wustl.edu/; Durbin et al., 1998; default parameters) 
against the T. brucei genome database (http://www.genedb.org/genedb/tryp/index.jsp, 
release 3). Nine T. brucei proteins were identified that had HMMER e-values below 
1.0. They are listed in the left column of figure 52A. These proteins were subsequently 
screened for RIIa domains and cNMP binding domains with the web services of SMART 
and Pfam. The positions of the RIIa domains together with the e-value as provided by 
SMART or Pfam are indicated (Fig. 52A, right columns). Surprisingly, none of the proteins 
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with predicted RIIa domains had a cNMP domain. In fact, the two proteins with the highest 
probability to have a RIIa domain (Tb09.211.2250 and Tb11.01.5260) are very small and 
did not possess additional known domains (Fig. 52B). It is therefore unlikely that any of 
the identified proteins are regulatory PKAR subunits. 
from to e-value from to e-value
Tb09.211.2250 268 6.6E-10 21 58 1.7E-08 21 58 3.7E-10
Tb11.01.5260 196 3.2E-03 41 78 3.3E-01 41 78 1.6E-03
Tb09.160.1660 81 3.8E-02 18 56 2.7E+00 18 56 1.9E-02
Tb10.70.7640 324 6.0E-02 31 130 3.9E+00 31 130 2.9E-02
Tb11.02.0990 1017 1.4E-01 _ _ _ 975 1009 6.8E-02
Tb10.70.3330 155 1.8E-01 83 119 9.9E+00 83 119 8.7E-02
Tb09.160.1690 76 2.2E-01 23 60 1.2E+01 23 60 1.1E-01
Tb927.1.1530 1742 3.4E-01 _ _ _ 23 56 1.6E-01
Tb05.6E7.1020 260 7.4E-01 17 51 3.3E+01 17 51 3.4E-01
[e-value]
HMMER searchlength[amino
acids]
T. brucei proteins
with predicted
RIIa domains
SMART Pfam
RIIa domain identified by
A
B
Tb09.211.2250
Tb11.01.5260
0 100 200 300
1.2250
amino acid position
Fig. 52: T. brucei proteins with predicted RIIa domains
A) HMMER search for T. brucei proteins with RIIa domains
The multiple sequence alignment of RIIa domains as provided by Pfam (http://www.sanger.ac.uk/cgi-
bin/Pfam/; version 10.0; Bateman et al., 2004) was used as template for a HMM based search (HMMER
version 2.3.2. downloaded from http://hmmer.wustl.edu/; Durbin et al., 1998; default parameters) against
the T. brucei genome database (http://www.genedb.org/genedb/tryp/index.jsp, release 3). All T. brucei
proteins with an e-value lower than 1.0 are indicated (column 1) together with their size (number of amino
acids, column 2) and the e-value of the HMMER search (column 3). Subsequently, the web services of
SMART (http://smart.embl-heidelberg.de/; version 4.0 , Schultz et al., 1998; Letunic et al., 2004) and
Pfam (http://www.sanger.ac.uk/cgi-bin/Pfam/; version 10.0; Bateman et al., 2004) were used to screen the
resulting T. brucei proteins for RIIa domains. The position (from, to) and the coresponding e-value as
provided by SMART and Pfam are indicated for each predicted RIIa domain.
B) Domain structure of T. brucei proteins with predicted RII domains
The domain structure of the two T. brucei proteins with highest probability to contain a RIIa domain
(Tb09.211.2250, Tb11.01.5260) is shown in the graphics. Both proteins are small and do not possess
additional known domains.
RIIa
RIIa
3.5.1.3. T. brucei might contain up to three further PKAR subunits
Altogether, three further proteins with homologies to regulatory PKA subunits were 
identified in T. brucei in addition to the known T. brucei PKAR. They have several PKA 
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specific characteristics that are summarized in table 6. For comparison, the respective 
features are also indicated for the bovine PKAR and the known T. brucei PKAR (first two 
rows). 
cNMP binding 
site
(e-value)
Conserved Amino acids in 
the PKA specific amino acid 
sequence (F-G-E-[LIF]-A-L-
[LIMV]-X(3)-[PV]-R-[ANVQ]-
A) in the cNMP binding sites
substrate / pseudosubstrate
sequence
highest 
homology 
to
domain 
A
domain 
B domain A domain B classical
one 
mismatch
no 
match
bovine PKAR 3.1E-26 9.8E-30 11 11 x PKAR
Tb PKAR 5.6E-10 4.0E-23 8 6 x PKAR
Tb10.70.1860 3.0E-19 4.8E-4 6 4 x PKAR
Tb03.48K5.800 8,3E-11 4.2E-4 8 3 x PKAR
Tb11.01.7890 6.2E-13 7.2E-3 9 2 x
K+ ion 
channel, 
PKG
Table 6: PKAR-characteristic features of the three T. brucei PKAR homologous proteins 
The characteristics of the three T. brucei PKAR homologous proteins (Tb10.70.1860, Tb11.01.7890, Tb03.48K5.800) 
identified in the chapter above are summarized. The first column shows the e-values of the predicted cNMP binding 
sites as calculated by Pfam (http://www.sanger.ac.uk/Software/Pfam/) (see also Fig. 51). The second column shows the 
number of conserved amino acid residues to the 14 amino acid PKAR specific sequence stretch. Since three of the 14 
amino acids are flexible, 100% homology is achieved with 11 conserved amino acids (see chapter 3.5.1.1.4.). The third 
column indicates whether the PKAR has a classical substrate/pseudosubstrate sequence, a non-classical (one mismatch) 
or no match (chapter 3.5.1.1.3.). The forth column shows the protein with the highest homology to the T. brucei PKAR 
homologous proteins as determined by searching GeneDB EMBL nr (see table 4 for more details). For comparison, the 
respective features of bovine PKAR (type II, β, Acc No.: NP_777074) and the known TbPKAR are also indicated (first two 
rows).
All three PKAR candidates have two cNMP binding domains in tandem (with Pfam e-
values between 7.1E-3 and 3E-19) and sufficient homology to the PKA specific 14 amino 
acid stretch (F-G-E-[LIF]-A-L-[LIMV]-X(3)-[PV]-R-[ANVQ]-A). At least two of the PKAR 
candidates have highest homology to a PKAR. Tb11.01.7890 possess a classical PKA 
pseudosubstrate sequence at the correct position and Tb10.70.1860 has a putative 
substrate sequence that differs in one amino acid.
These candidates should be tested for cNMP binding and association with catalytic 
subunits.
3.5.2. T. brucei has no further proteins with homologies to catalytic PKA 
subunits
Due to the lack of a PKAC specific domain, the in silico search for additional catalytic 
PKA subunits proved to be more difficult than the search for PKAR homologous proteins. 
Catalytic PKA subunits mainly consist of a kinase domain, and kinase domains are highly 
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conserved among all existing kinases. Only small segments of PKA sequences, 6-8 
amino acids in length, differ significantly from other kinases  (Hanks and Quinn, 1991). 
They are too small to be used as templates for a HMMER motif search. 
We therefore used a BLAST approach to screen the T. brucei genome database 
(http://www.genedb.org/genedb/tryp/blast.jsp) for PKAC homologous proteins. PKAC 
sequences of T. brucei (PKAC3), H. sapiens (PKAß), C. elegans, D. melanogaster 
and S. cerivisiae were used as targets (blastp, matrix blossum 62). From the resulting 
proteins only T. brucei proteins with at least 270 amino acids sequence overlap to the 
target PKA were considered as potential PKAC candidates. The number of 270 was 
arbitrary chosen. It is slightly higher than the length of a kinase domain (256-258) and 
should therefore reduce the amount of false positive results due to other protein kinases. 
Also, it is smaller than the conserved sequence stretch of PKAs (308-312 amino acids) 
and should still allow the identification of unconventional PKAs. (For an overview about 
conserved regions of PKAs compare PKAC alignment in attachment 4) This way, 35 
T. brucei proteins with homologies to PKAs were identified, including the three known 
PKAC subunits, serving as positive controls (Table 7, left column). 
In the next step, GenBank (http://www.ncbi.nlm.nih.gov/BLAST/, blastp) was searched 
with each of these 35 T. brucei proteins and the protein with the highest homology 
(according to the e-value as defined by Karlin and Altschul, 1990) was determined (Table 
7, right columns). 
It can be seen that all new hits have highest homologies to a kinase other than PKA, while 
the three known T. brucei PKACs (positive controls) have highest homologies to PKAs. 
To summarize, there is no evidence for additional PKA-related kinase catalytic subunits 
in the T. brucei genome. 
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Table 7: T. brucei PKAC homologues
The T. brucei genome data base (http://www.genedb.org/genedb/tryp/blast.jsp, T. brucei predicted proteins, 
default parameters as set by the genedb server) was searched against PKA protein sequences from T. 
brucei (PKAC3), H.sapiens (PKAß, Acc No.:P22694), C.elegans (Acc No.: P21137), D.melanogaster (Acc 
No.: P12370) and S.cerivisiae (PKA1, Acc No.:P06244 ) (blastp, matrix blossum62). All T. brucei proteins with 
at least 270 amino acids sequence overlap to any of these PKAs are indicated (left column) together with the 
percentage of identical amino acids (% ID) and the number of overlapping amino acids (overlap) (left part of 
the table). In adddition each of these T. brucei proteins was used to search the protein database nr at NCBI 
(GenBank (http://www.ncbi.nlm.nih.gov/BLAST/), blastp) with default parameters as set by the NCBI server 
(right part of the table).
The protein with the highest homology according to the stochastic model of Karlin and Altschul (1990) (e-
value) is shown together with its organism and the number of identical residues and sequence overlap to the 
T. brucei homologue PKAC proteins. If possible, characterized proteins were choosen, rather then putative 
ones, thus in some cases the protein with the second or third highest e-value is shown rather than a putative 
protein with the highest e-value. 
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4. Discussion
The aim of ths project has been the characterization of a family of  T. brucei PKA-like 
kinases, that were originally cloned in search for components of the cAMP signaling 
pathway associated with LS to SS differentiation (Vassella et al., 1997). We found, 
however, that these kinases significantly differs from classical PKAs and are in fact not 
activated, but rather inhibited by cyclic AMP. T. brucei PKA-like kinases play an important 
role for progress through cytokinesis. Their activity seems regulated by external stress 
conditions as evidenced by an in vivo kinase assay developed in this work. 
4.1. The catalytic subunits of T. brucei PKA-like kinase
Three different isoforms of catalytic PKA-like subunits have been previously cloned from 
T. brucei (T. Klöckner, Ph.D. thesis 1996). We did not find other closely related kinases 
in the now nearly complete T. brucei genome database. This suggests that these three 
isoforms are the full complement of PKAC subunits in T. brucei. 
Biochemical characteristics of the T. brucei PKAC-like subunits have been studied 
in this and previous work either using immunopurified epitope tagged versions of the 
kinases or a recombinant GST-fusionprotein expressed in the baculovirus system. (N. 
Wild, unpublished results; C. Schulte zu Sodingen, Ph.D. thesis 2000; T. Klöckner, 
Ph.D. thesis 1996; this work). Thereby it was found that all three subunits phosphorylate 
the classical PKA substrate kemptide and are inhibitable with 5 µM of the PKA specific 
peptide inhibitor PKI 5-24. Ki values for inhibition of recombinant PKAC3 with either PKI 
5-24 or full length PKI were one order of magnitude higher than for mammalian PKAs, 
but still in the nanomolar range (N. Wild, unpublished). Here we also tested the effects 
of the PKA specific inhibitor KT5720 on the different immunopurified T. brucei PKAC-like 
subunits. We found an inhibition of PKAC1 and PKAC2 with an IC50 value between 1 
and 5 µM (compare Figure 28 in chapter 3.3.4.3.). This is 20 to 100 times higher than 
the IC50 values of KT5720 for mammalian PKAs (56 nM, Kase et al., 1987). PKAC3 
activity, however, was not affected even with 100 µM KT5720. The different sensitivities 
of PKAC1/2 and PKAC3 towards KT5720 provide a useful tool for the discrimination 
between the isoforms.
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Activity of recombinant PKAC3 was inhibited by purified bovine regulatory PKA subunit 
(N. Wild, unpublished). This inhibition was readily reversed with cAMP in nanomolar 
concentrations. 
We conclude that the three catalytic PKA-like subunits from T. brucei possess all essential 
features in terms of sequence, substrate and inhibitor specificities and interaction with a 
heterologous R subunit that characterize a classical PKA. In comparison to mammalian 
PKAs, binding affinities of inhibitors are lowered for the T. brucei kinases. This is not 
surprising, given the evolutionary distance between T. brucei PKA-like kinase and 
mammalian PKA for which these inhibitors were optimized. 
4.2. The regulatory subunit of T. brucei PKA-like kinase
In addition to the three catalytic PKA-like subunits, one protein with homologies to 
regulatory PKA subunits has been previously identified in T. brucei (C. Schulte zu 
Sodingen, Ph.D. thesis 2000). TbPKAR has two predicted cNMP binding domains and 
possess 38% identity to mammalian PKAR subunits. Unlike the catalytic T. brucei PKA-
like subunits, T. brucei PKAR has several features that clearly distinguish it from PKARs 
of most other organisms.
4.2.1. Holoenzyme formation
An important feature of regulatory PKA subunits is their ability to bind to catalytic PKA 
subunits. This binding is mainly mediated by a conserved inhibitory sequence R R X 
[A/S/T] Ψ (Ψ=hydrophobic amino acid), located N-terminal of the cNMP binding sites. T. 
brucei PKAR, that possess such a classical inhibitor sequence (RRTTV), is in fact able to 
bind each of the three catalytic T. brucei PKA-like subunits PKAC1, PKAC2 and PKAC3. 
This was shown with different coimmunoprecipitation studies in this and previous work 
and provided the first proof for the role of TbPKAR as regulatory subunit of the PKA-like 
kinase. 
In addition to their binding to catalytic subunits, most regulatory PKA subunits studied 
so far dimerize to enable the formation of a tetrameric PKA holoenzyme (R2C2). 
Responsible for dimerization is an N-terminal dimerization/docking domain. T. brucei 
PKAR lacks such a dimerization/docking domain in its N-terminus that is unusually 
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long. Coimmunoprecipitation studies revealed that TbPKAR isunable to form R dimers, 
resulting in a dimeric (RC) rather than tetrameric PKA holoenzyme (compare chapter 3.2.). 
Dimeric PKAs were also found in several other lower eukaryotes, such as Dictyostelium 
discoideum (Mutzel et al.,1987), Paramecium tetraurelia (Hochstrasser and Nelson, 
1989) or the dinoflagellate Amphidinium operculatum (Leighfield et al., 2002). This 
suggests that the development of the tetrameric PKA structure has occurred rather late in 
evolution. PKARs from Paramecium (Carlson and Nelson et al., 1996) and Dictyostelium 
have unusually short N-termini that lack the dimerization domain (Fig. 53). 
050100150200250
B. taurus
T. brucei
D. discoideum
P. tetraurelia
number of amino acids
N-Termini
Substrate / Pseudosubstrate sequence
Fig. 53: Lenght differences in the N-termini of regulatory PKA subunits
The N-termini (here defined as the region N-terminal of the Substrate/Pseudosubstrate sequence) of PKAR
subunits of B. taurus (PKARI�, Acc No. P00514), T. brucei, D. discoideum (Acc No. P05987) and P.
tetraurelia (Acc No. AAC47268) are shown. PKARs from D. discoideum and P. tetraurelia have shorter N-
termini than B. taurus PKAR and lack dimerization domains. In contrast, T. brucei PKAR has an unusually
long N-terminus that is nevertheless devoid of a dimerization domain.
If the N-terminus of T. brucei PKAR does not mediate the binding to another regulatory 
subunit, what is its possible function? Interestingly, similar long N-termini are also present 
in the PKARs of the related organisms Leishmania and T. cruzi and are even highly 
conserved among these trypanosomatidae (Fig. 54). This high degree in conservation 
suggests that they fulfill an important function different from dimerization. Furthermore, 
the PKAR N-termini of kinetoplastida show no significant homologies to proteins from 
any other organisms (http://www.ncbi.nlm.nih.gov/BLAST/, default parameters as set by 
the ncbi server), suggesting that their function might be unique to trypanosomatidae. 
The most obvious function of these unusual N-termini would be the binding to a (yet 
undefined) A kinase anchoring protein (AKAP) to mediate subcellular PKA localization.
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TbPKAR MSEKGTSLNLFLAACQKEGVKQPNTFLVEFFTKKPELSEVEEIDLSKNYIGNRGILALLD 60
TcPKAR MAEEENTLSLFLEACRKEGVKQPNTILMDFFRSNPSPSQIEEIDLSHNYVGNRGILAVLD 60
LmPKAR MSAGDTPVSLFLQACNQEGVKTPNPKLVEFFQSHETFDSILEIDLSNNYIGNRGLLAVLG 60
*: ..:.*** **.:**** **. *::** .: ..: *****:**:****:**:*.
TbPKAR VISELPCFRFLNCSNQKLYNTDLNEDSVRGNATIDRIVDVFKSHPTANALDLSHNPISNY 120
TcPKAR LIEKLPSFRFLNCSNQKLYNTDLSEDSVRGNATVDRIVEVFKVHPTANALDISNNPISNY 120
LmPKAR VIEHLSCFRCLNAMDQKLYNSDFSEEAVKGNAVIDRIVEVFKVHPTANSLNLSNNPISNY 120
:*..*..** **. :*****:*:.*::*:***.:****:*** *****:*::*:******
TbPKAR AGRRLLLLTQNNKRICRVELVDTRIDFELRSRITQQCEKNTIAIWESQAQE-KEEERAFG 179
TcPKAR AGRKLLVLAQVNRRICRVELSETRVDFDLRKRITQQCEKNTIALWEAQASEGADEERGFG 180
LmPKAR AGRKLLSLAQVNRRMCLIEVSDTRIDFDLRNKIAKQCEENTRNMWDAEQDENANSCAVFG 180
***:** *:* *:*:* :*: :**:**:**.:*::***:** :*::: .* :. **
TbPKAR ESVTWVPTQTSADLTAIGGGRKRRTTVRGEGIDPEKAKSYVAPYFEKSEDETALILKLLT 239
TcPKAR EGPVWVPKQAPADLTTIGGGRNRRRTVRSEGIDPEKAKLYQAPYFEKSEDEMNLITKLLT 240
LmPKAR ENLEWVPTQATADLTSLGAGRARRQTVRVEGIDPEAAKNYVPPVHEKSQEDTDMICKLLS 240
*. ***.*:.****::*.** ** *** ****** ** * .* .***::: :* ***:
TbPKAR YNVLFSFLDSRDLMTVAGAMWRVEFKQDDCIMEAGQTTCDKLYIIQDGKADIIKEGQKVY 299
TcPKAR HNVLFSFLNTKDIKVVAGAMQRATFKHDDCIMEAGQTTCNKLYIIQSGHADIIKEGQKVY 300
LmPKAR HNVLFGFLGSKDILTVAGAMYREEFVKDERIIEFGQTHCDKLYVIQSGEADVIKEGQKVF 300
:****.**.::*: .***** * * :*: *:* *** *:***:**.*.**:*******:
TbPKAR LKVEGTAVGELELMYQTPTVATVKVCTPELIAWALDRDTYRHLVMGSAIRRRETYIQFLT 359
TcPKAR LKTEGTAVGELELMYDTPVVATVKVCTDELIAWVLDRDTYRNLVMGTAIRRRETYIQFLA 360
LmPKAR VKTEGTAVGELELLYDTPAVATVKVSTEVLVAWVLDRETYRNLVMGSCIRRRETYMSMLA 360
:*.**********:*:**.******.* *:**.***:***:****:.*******:.:*:
TbPKAR NIPFLSGLDNYEKLQLADALSSDEFEPGDYIIRYGEEGEWLYIILEGSVDVVGRDDDGNE 419
TcPKAR NVPFLGGLDSYEKLQLADALSSEEFSPGEYIIHYGEEGEWLYIIMEGTVEVIGRDADGEP 420
LmPKAR KVPFLQSLDAYERMQIADALTSDEFAAGDYIIHYDEEGEWLYIIIEGTVEVIGRDAAGNK 420
::*** .** **::*:****:*:** .*:***:*.*********:**:*:*:*** *:
TbPKAR KHVWEFGKGDHVGELEFLNNHANVADVVAKTHVVTAKLNRRHFEMCLGPVIDVLKRTSQQ 479
TcPKAR TKVCEFTQGDHIGELEFLNNHRTVADVVATTHVITAKLNRRHFEMCLGPVIDVLKRCADD 480
LmPKAR TKVCEFHSGDHIGELEFLNKHRTVADIVAVTGVTTAKLNRRHFEMCMGPVMDVLKRNSTS 480
.:* ** .***:*******:* .***:** * * ************:***:***** : .
TbPKAR PNYEYYQSKLKTTLRAEGRK--- 499
TcPKAR PKYEYYQNVLKTGAAQPSYVDDV 503
LmPKAR AKYDYYQQVLQQQQQGAPAAVQ- 502
.:*:***. *:
Fig. 54: Alignement of the regulatory PKA-like subunits of T. brucei, T. cruzi and L. major
The T. cruzi PKAR sequence has been published with the accession number AAO33766.1 (Huang et al.,
2003, unpublished). The L. major PKAR sequence was taken from Leishmania major Friedlin chromosome
13 cosmid L2802, accesssion number AL359774 (automatically predicted protein). The alignment was
done with the WEB based services of ClustalW (http://www.ebi.ac.uk/clustalw/) using the default
parameters as set by the EBI server. The cNMP binding pockets are colored red. The substrate sequence
that binds to the catalytic subunit is colored blue. The complete N-termini that show no homology to other
PKAs and lack a dimerization domain are colored in green.
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4.2.2. Activation of the T. brucei PKA-like kinase
Upon cAMP binding, structural changes of the regulatory PKA subunit lead to the release 
of the catalytic subunit from the holoenzyme complex and thus to PKA activation. This, 
however, turned out not to be true for T. brucei PKA-like kinase:
4.2.2.1. T. brucei PKA-like kinase is activated with cGMP in unphysiologically high 
concentrations only
Several different cyclic nucleotides were tested for their abilities to activate T. brucei 
PKA-like kinase in vitro. We could not detect any increase in kinase activity neither with 
the classical PKA activator cAMP nor with cIMP, cUMP, cXMP or cCMP, not even in mM 
concentrations. The only cyclic nucleotide that activated T. brucei PKA-like kinase was 
cGMP. Although this observation was also reported by a different laboratory (Shalaby et 
al., 2001), the role of cGMP as the physiological activator of T. brucei PKA-like kinase 
remains highly doubtable for two main reasons:
Firstly, the cGMP concentrations needed for activation of the PKA-like kinase were 
unusually high. In fact, the concentration necessary for half maximal kinase activation 
(Ka(cGMP)) was higher than 100 µM (compare Fig. 22 in chapter 3.3.2.), which lies at least 
two orders of magnitudes above the Ka values of other cGMP dependent protein kinases 
(see table 8). 
Kinase Ka (cGMP) Reference
T. brucei PKA-like kinase >100 µM this work
T. brucei PKA-like kinase < 20 µM Shalaby et al., 2001
Plasmodium PKG 0.17 µM Deng et al., 2003
C. elegans CGK-1C 0.190 µM Stansberry et al., 2001
E. tenella PKG 2.3 µM Gurnett et al., 2002
D. melanogaster PKG 0.19 µM Foster et al., 1996
T. gondii PKG 1.7 µM Donald et al., 2002
PKG from bovine aorta, type alpha 0.29 µM Wolfe et al., 1989
Human PKG1beta 0.691 µM Richie-Jannetta et al. 2003
Mouse brain CGKII 0.3 µM Uhler, 1993
Dictyostelium PKG 0.001 µM Wanner and Wurster, 1990
Table 8: cGMP concentrations needed for half maximal activation of cGMP dependent kinases from 
different organisms in comparison to T. brucei PKA-like kinase. 
The cGMP dependent kinases were chosen arbitrarily. In the first two rows (bold) the corresponding values 
are shown for T. brucei PKA-like kinase as determined in this work and by Shalaby et al., respectively. 
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Shalaby et al. claimed maximal activation of T. brucei PKA-like with only 20 µM cGMP, 
but even this concentration is unusually high and the authors did not actually show these 
data. 
The second argument against cGMP as the physiological activator of T. brucei PKA-like 
kinase is the absence of any components of cGMP signaling in T. brucei. Neither cGMP, 
nor guanylyl cyclases have yet been found in T. brucei and all T. brucei PDEs that have 
been cloned and characterized so far, were found to be highly specific for cAMP (Zoraghi 
et al., 2001; Zoraghi et al., 2002; Gong et al., 2001; Kunz et al., 2004; Rascon et al., 
2002). 
Whether the observed activation of T. brucei PKA-like kinase with cGMP is accompanied 
by a dissociation of the holoenzyme complex, remains unclear. In fact, we did observe 
a partial dissociation of the T. brucei PKA-like holoenzyme when incubated with 1 mM 
cGMP for 30 min (Fig. 21 in 3.3.1.), but only in the presence of the PKA specific inhibitor 
PKI 5-24. This peptide inhibitor binds to the catalytic center of PKA and this way probably 
inhibits the reassociation of the holoenzyme. Without PKI, the holoenzmye remains 
associated, even when cGMP is added. It therefore remains unlikely that the observed 
holoenzyme dissociation reflects the physiological mechanism of kinase activation. 
Alternatively, the binding of cGMP could cause a structural change in the holoenzyme 
complex which only decreases rather than abolishes the binding affinity between 
regulatory and catalytic subunit. In the presence of PKI, the dissociated subunits would 
accumulate, since the reassociation of the holoenzmye is prevented. 
A dimeric PKA that does not dissociate in the presence of cyclic nucleotides has been 
purified from mouse liver cytosol (Nikolokaki et al., 1999). The authors obtained half 
maximal activity of the kinase with either 0.1 µM cAMP, 0.8 µM cGMP or 2 µM of either 
cCMP or cUMP but could not dissociate the holoenzyme with even 1 µM cAMP, although 
they could show that regulatory and catalytic units of the kinase were on different 
polypeptide chains. 
4.2.2.2. T. brucei PKA-like kinase is inhibited by cAMP
cAMP was not only unable to activate T. brucei PKA-like kinase, it even inhibited cGMP 
stimulated kinase activity. A similar effect has also been observed by Shalaby et al. 
(2001) in some, but not all of their kinase assays. These results were unexpected. There 
are some reports about kinases that are activated with both cAMP and cGMP (Vardanis 
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et al., 1980; Lin and Volcani et al., 1989), but to our knowledge no kinase has yet been 
shown to be actually inhibited by a cyclic nucleotide. 
The most likely mechanism for the inhibition of T. brucei PKA-like kinase by cAMP 
is a competition of cAMP with cGMP (or another yet unknown PKA activating cyclic 
nucleotide) for the cNMP binding pockets of PKAR. Cyclic AMP would bind to the cNMP 
binding sites but fail to cause the structural changes necessary for kinase activation.  
At first sight such a competition between cAMP and cGMP for the cNMP binding sites 
appears contradictory to results from Shalaby et al. (2001). The authors examined the 
binding capabilities of recombinantly expressed cNMP binding domains of T. brucei 
PKAR towards cGMP in the presence of cAMP. According to their data, a 100-fold excess 
of cAMP does not interfere with the cGMP binding to either of the two cGMP domains. 
However, Shalaby and coauthors only worked with single cNMP binding domains, 
instead of the entire protein. Their data might therefore not reflect the physiological 
binding parameters of the cNMP binding sites in their “native environment”. At least for 
mammalian PKAs it has been shown that the binding of cyclic nucleotides to one cNMP 
binding site allosterically influences structure and binding abilities of the second cNMP 
binding site (Ogreid and Doskeland 1981a; Ogreid and Doskeland, 1981b). 
Therefore, competitive binding assays with cAMP and cGMP should be repeated using 
the complete PKAR subunit. 
4.2.2.3. Establishment of an in vivo kinase assay for T. brucei PKA-like kinase
In order to exclude that the failure to activate T. brucei PKA-like kinase with cyclic 
nucleotides was not simply due to an in vitro artefact, an in vivo PKA kinase assay was 
established in this work. It is based on the immunological detection of phosphorylated 
VASP protein, a reporter substrate for PKA activity (Smolenski et al., 1998; compare 
3.3.4.). For this, VASP was transgenically expressed in trypanosomes. From a decrease 
in VASP phosphorylation with the PKA inhibitor KT5720 and from the consistence of the 
results from all in vitro and in vivo kinase assays we conclude that VASP phosphorylation 
does most likely reflect the activity of T. brucei PKA-like kinase. However, KT5720, a 
specific inhibitor of mammalian PKAs that has lower affinities towards T. brucei PKAs 
(compare 4.1) might also inhibit other T. brucei kinases. Therefore, we cannot fully 
exclude that VASP is phosphorylated by another T. brucei kinase.
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With the aid of this in vivo kinase assay we observed an increase in kinase activity with 
the membrane permeable cGMP derivative pCPT-cGMP in high concentrations and a 
decrease with the cAMP derivative pCPT-cAMP. Thus, the in vitro data were confirmed.
4.2.2.4. The cNMP binding sites of T. brucei PKAR 
The reason for the observed unusual reactions of T. brucei PKAR towards cyclic 
nucleotides must lie in its cNMP binding sites. In fact, three amino acids are absent in T. 
brucei PKAR that are highly conserved between PKARs of most species and have been 
shown to contribute synergistically to the binding of cAMP and presumably also cGMP 
(Su et al., 1995). 
First of all, a conserved arginine (218 and 347 in the 1st respectively 2nd cNMP binding 
sites of human PKAR type II alpha) is not present in T. brucei PKAR. This arginine 
normally interacts with the equatorial exocyclic oxygen of the cAMP or cGMP phosphate 
and therefore plays a major role in cNMP binding. A replacement of that arginine with 
the very similar lysine in mammalian PKA already significantly decreases PKA affinity 
towards cAMP (Herberg et al., 1996). 
The second sequence difference affects a conserved alanine (211 and 340 in the 1st 
respectively 2nd cNMP binding sites of human PKAR type II alpha) that is replaced by 
glutamate in both cNMP binding domains of TbPKAR. The alpha amino group of that 
alanine normally forms hydrogen bonds to the equatorial oxygen of the cAMP phosphate. 
The negative charged glutamate of T. brucei PKAR might be unable to fulfill a similar 
function next to the (negatively charged) phosphate group. 
The third difference between T. brucei PKAR and other cyclic nucleotide dependent 
kinases was found at a position that is responsible for the selectivity of the domain 
towards either cGMP or cAMP (219 and 348 in the 1st respectively 2nd cNMP binding 
sites of human PKAR type II alpha). Usually, an alanine is found in PKAs and a serine 
or threonine in PKGs. The hydroxyl group of the serine or threonine forms a hydrogen 
bond with the C2 amino group of the guanine as shown in figure 55. It was shown with 
site directed mutagenesis that this serine or threonine residue is essential for high affinity 
binding of cGMP but does not affect cAMP binding (Shabb et al., 1991; Kaupp et al., 
1992; Reed et al., 1996; Reed et al., 1997). Surprisingly, T. brucei PKAR has neither 
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alanine nor serine/threonine, but valine at this position that cannot form any hydrogen 
bond. The significance for this remains unclear.
 
cAMP binding site
(PKA)
cGMP binding site
(PKG)
Fig. 55: cAMP and cGMP
binding to the binding
pockets of cA and cG kinases:
Specifity towards cAMP or
cGMP of cNMP binding sites is
mediated by a very conserved
amino acid (219 and 348 in
human PKAR type II alpha) that
is alanine in PKAs and serine or
threonine in PKGs. In PKGs
forms the hydroxyl group of the
serine or threonine a hydrogen
bond with the C2 amino group of
the guanine. No such hydrogen
bond is present in PKAs. The
picture is taken from Francis et
al., 1999.
Similar amino acid substitutions are also found in the cNMP binding sites of PKAR 
orthologous proteins from the related kinetoplastida T. cruzi and L. major. In fact, two 
of the three substituted amino acids have been replaced by identical amino acids in T. 
brucei, L. major and T. cruzi (E and V) and are thus conserved between kinetoplastida 
(Table 9). 
Unusual amino acids in the cNMP binding domains of 
kinetoplastida PKAR orthologues
Table 9: Unusual amino acids in 
the cNMP binding domains of 
kinetoplastida PKAR orthologues
Three very conserved amino acids 
present in the cAMP binding pockets 
of most PKARs are absent in all 
kinetoplastida PKAR orthologues. 
The amino acids at the homologous 
positions in kinetoplastida PKAR 
orthologues (A and B) are shown. 
Tb=T. brucei; Tc=T. cruzi; Lm=L. 
major
position relative to 
human PKAR type 
II alpha (domain A/ 
domain B)
human PKAR
(both domains)
Kinetoplastida PKAR orthologues
domain A domain B
Tb Tc Lm Tb Tc Lm
218 / 347 R T V A N T T
211 / 340 A E E E E E E
219 / 348 A V V V V V V
This suggests that PKAR orthologous proteins from other kinetoplastida have similar 
binding properties to cyclic nucleotides compared to T. brucei PKAR. In fact, a kinase 
activity has been purified from L. donovani that has several characteristics of a classical 
PKA, but shows no reaction on either 0.05 mM cAMP or cGMP (Banerjee et al., 1992). It 
might become activated with cGMP in higher concentrations, similar to T. brucei PKAR. 
In contrast, a kinase activity has been purified from T. cruzi that is activated with only 
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nanomolar concentrations of cAMP (Ulloa et al., 1988). There are, however, doubts on 
the reproducibility of these data.
The observed amino acid substitutions appear to be unique to PKAR orthologues from 
Trypanosomatidae. An alignment of the cNMP binding domains from kinetoplastida 
PKAR orthologues with the corresponding domains of PKAs and PKGs from various 
other organisms is shown in figure 56. Of the examined organisms, only Plasmodium 
PKGs have different amino acids at the position of the conserved arginine 218/347. A 
negatively charged amino acid at the position of the highly conserved alanine 211/340 
was not found in any of the examined organisms, only Plasmodium and some fungi have 
a serine or tyrosine at the homologous positions. Alanine 219/348 was only absent in 
domain A of Plasmodium PKGs (F) and in domain B of some fungi/yeasts (N,V,Q). 
Altogether, the observed differences in primary sequence in kinetoplastida PKAR 
orthologues are likely to influence the affinities of the cNMP binding sites towards cyclic 
nucleotides and thus affect the kinase activation mechanism. 
4.2.3. Are there further PKAR homologous proteins in T. brucei?
With HMMER based searches against the nearly completed T. brucei genome database 
three further PKAR related proteins were identified (compare chapter 3.5.1.). All of them 
have two predicted cNMP binding domains in tandem, one has a classical inhibitor 
sequence that might mediate the binding to a catalytic PKA subunit. The new T. brucei 
PKAR homologous proteins are unusually large.
Whether any of these proteins is in fact able to bind to catalytic PKA subunits is currently 
investigated. When the PKA-like holoenzyme is immunoprecipitated via Ty1-PKAC1, the 
only coprecipitated protein that is detectable on a Coomassie stained gel is the TbPKAR 
protein investigated in this work (compare figure 19 in chapter 3.2.2.). Thus, potential 
PKAR subunits should be present in lower amounts than TbPKAR or exclusively bind to 
either PKAC2 or PKAC3; otherwise they would have been detected most likely. 
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PKA T. brucei EGTAVGEL LMYQTPTVATVKVCTP
PKA T. cruzi EGTAVGELELMYDTPVVATVKVCTD
PKA L. major EGTAVGELELLYDTPAVATVKVSTE
PKA A. fumigatus PGGSFGELALMYNAPRAATIVSADP
PKA A. niger PGGSFGELALMYNAPRAATVVSVDP
PKA E. nidulans PGGSFGELALMYNAPRAATIVSTEP
PKA N. crassa EGGSFGELALMYNAPRAATVVSAEP
PKA M. grisea AGGSFGELALMYNAPRAATVMSAEP
PKA T. atroviride AGGSFGELALMYNAPRAATIISAEG
PKA C. lagenarium AGGSFGELALMYNAPRAATVISAEP
PKA C. trifolii AGGSFGELALMYNAPRAATVISAEP
PKA B. emersonii AGGSFGELALMYNAPRAATVVATAE
PKA M. racemosus AGGSFGELALMYNAPRAATIITTSD
PKA C. neoformans EGSSFGELALMHNAPRAASIISLTP
PKA S. pombe PGEYFGELALMYNAPRAASVVSKTP
PKA C. albicans EGSSFGELALMYNSPRAATAVAATD
PKA bovine (RIIbeta) NRGSFGELALMYNTPRAATITATSP
PKA rat (RIIbeta) NRGSFGELALMYNTPRAATITATSP
PKA mouse (RIIalpha) NRGSFGELALMYNTPRAATIIATSE
PKA rat (RIIalpha) NRGSFGELALMYNTPRAATIVATSD
PKA human (RIIalpha) NRGSFGELALMYNTPRAATIVATSE
PKA D. melanogaster (RII) HTGLFGELALLYNMPRAATVQAETS
PKA O. volvulus EGGSFGELALIYGTPRAATVVAKSD
PKA C. elegans EGGSFGELALIYGTPRAATVIAKID
PKA California sea hare EGGSFGELALIYGTPRAATVKAKTD
PKA A. Californica EGGSFGELALIYGTPRAATVKAKTD
PKA bovine (RIalpha) EGGSFGELALIYGTPRAATVKAKTN
PKA rat (RIalpha) EGGSFGELALIYGTPRAATVKAKTN
PKA human (RIalpha) EGGSFGELALIYGTPRAATVKAKTN
PKA mouse (RIbeta) EGGSFGELALIYGTPRAATVKAKTD
PKA D. melanogaster (RI) EGGSFGELALIYGTPRAATVRAKTD
PKA D. discoideium EGGSFGELALIYGSPRAATVIARTD
PKA P. falciparum SKDVFGELALLYNSKRAATATALTK
PKA P. yoelii yoelii SKDVFGELALLYNSKRAATAKALTK
PKA T. gondii PGDAFGELALMYNAPRAATVIAADD
PKA E. octocarinatus PGDAFGELALLYNAPRAATIKAKTE
PKA P. tetraurelia PGESFGELALLYNVPRAATIKAKTD
PKG E. tenella TGQAFGEISLIHNSARTATIKTLSE
PKG E. maxima QGQAFGEISLIHNSARTATIKTLSD
PKG T. gondii KGKAFGEIALIHNTERSATVVASST
PKG P. falciparum KGSSFGEAALIHNTQRSATIIAET-
PKG C. parvum EGTAFGELALIHNTPRSATILVIE-
PKG A. meliffera PGKVLGELAILYNCKRTATITAATD
PKG B. mori (typeII) PGKVFGELAILYNCKRTATIKAATD
PKG bovine (I alpha) PGKVFGELAILYNCTRTATVKTLVN
PKG human (type I) PGKVFGELAILYNCTRTATVKTLVN
PKG rabbit (typeI alpha) PGKVFGELAILYNCTRTATVKTLVN
PKG rat MWTTFGELAILYNCTRTASVKAITN
PKG human (type II) MWTTFGELAILYNCTRTASVKAITN
PKG mouse (type II) MWTTFGELAILYNCTRTASVKAITN
PKG H. oligactis PGELFGELAILYNCTRTASVKAIDD
PKG P. yoelii yoelii RGKSFGDQYVLNQKQKFKHTLKSLE
PKG P. falciparum RGMSFGDQYVLNQKQPFKHTIKSLE
.*: ::
KGDHVGELEFLNNHANVADVVAKT-
QGDHIGELEFLNNHRTVADVVATT-
SGDHIGELEFLNKHRTVADIVAVT-
RGDFFGELALLDDKPRAASVVAKT-
RGDYFGELALLDDKPRAASIVAKT-
RGDYFGELALLDDKPRAASVRAKT-
KGDFFGELALLNDAPRAASVISQT-
KGDFFGELALLNDAPRAASVVSKT-
KGDFFGELALLNDAPRAASVIATS-
KGDFFGELALLNDAPRAASIVATT-
KGDFFGELALLNDAPRAASIVATT-
KGNYFGELALLSDKPRVATIRAKG-
RGSYFGELALLNDAPRAATVVAHG-
QGEYFGELALLNRRTRAATIRAEGP
KGDYFGELALIHETVRNATVQAKT-
KGDYFGELALIKDLPRQATVEALD-
RGQYFGELALVTNKPRAASAHAIG-
RGQYFGELALVTNKPRAASAHAIG-
KGQYFGELALVTNKPRAASAYGVG-
KGQYFGELALVTNKPRAASAYAVG-
KGQYFGELALVTNKPRAASAYAVG-
KGQYFGELALVTHRPRAASVYATGG
SSDYFGEIALLLDRPRAATVIAKT-
MSDYFGEIALLLDRPRAATVVAKT-
PSDYFGEIALLLDRPRAATVVARG-
PSDYFGEIALLLDRPRAATVVARG-
PSDYFGEIALLMNRPRAATVVARG-
PSDYFGEIALLMNRPRAATVVARG-
PSDYFGEIALLMNRPRAATVVARG-
PSDYFGEIALLLNRPRAATVVARG-
SSDYFGEIALLLDRPRAATVVARG-
PSDYFGEIALLTDRPRAATVTSIG-
KGDYFGELALLKNKPRAATIKAQN-
KGDYFGELALLRNQPRAATVKAES-
KGGFFGELALLKDQPRAATVVAKS-
YGDYFGEIALLKNEPRAASVVAKT-
VGDYFGELALIKHEPRAANIVAKS-
RGEYFGERALLYDEPRSATITAEEP
KGDYFGERALLYDEPRSATITAEEE
KGDYFGERALLYKEPRSATITAEEF
KGSYFGERALLYDEPRSATIIAKEP
EGDAFGERSLMFDEPRSATVIANAT
KGDFFGEKALQGDDLRTANIIADDP
KGDFFGEKALQGDDLRTANIVCDSP
KGDWFGEKALQGEDVRTANVIA--A
KGDWFGEKALQGEDVRTANVIA--A
KGDWFGEKALQGEDVRTANVIA--A
KGEYFGEKALISDDVRSANIIAE-E
KGEYFGEKALISDDVRSANIIAE-E
KGEYFGEKALISDDVRSANIIAE-E
QGEYFGEKALLGEDVRTASVVAS-I
KNDYFGERALIYDEPRTASVISTVN
KNDYFGERALLYDEPRTASVISKVN
.** : *
domain A domain B
Figure 56: Conserved sequences in PKA and PKG cNMP binding pockets
The cNMP binding domains of PKAs and PKGs of the indicated organisms were aligned with
the WEB based services of ClustalW (http://www.ebi.ac.uk/clustalw/) using default parameters
as provided by the EBI server. Only a 25 amino acid sequence of each domain (domain A and
domain B) is shown (amino acids 202-227 and 332-357 refering to human PKA type II alpha).
The unusual amino acids of kinetoplastida PKA-like kinases are colored red/bold. Any unusual
amino acids at this position in other organisms are colored blue/bold.
Discussion
133
4.3. Functions of T. brucei PKA-like kinase
Results from several reverse genetic experiments suggest that T. brucei PKA-like 
kinase regulates cell cycle progression and basal body segregation. In addition, we 
provide evidence for a role of the kinase in the regulation of differention processes. 
This is suggested from an increase in (in vivo) kinase activity caused by several 
environmental stresses that have been shown to participate in either LS to SS or SS to 
PCF differentiation.
4.3.1. T. brucei PKA-like kinase: a transmitter of environmental stress? 
4.3.1.1. Kinase activity in the presence of the PDE inhibitors dipyridamole and 
etazolate
The PDE inhibitor etazolate induces differentiation from LS to SS cells (Vassella et 
al., 1997). Dipyridamole, another potent PDE inhibitor, inhibits major T. brucei PDEs 
with higher affinity than etazolate (table 10) but has never been tested on its ability to 
stimulate differentiation. 
IC50 [µM]
Table 10: Inhibition of the known T. brucei PDEs by 
the PDE inhibitors dipyridamole and etazolate. IC50 
values are indicated for TbPDE1, TbPDE2A, TbPDE2B, 
TbPDE2C as determined by Kunz et al., 2004; Zoraghi 
et al., 2000; Rascón et al., 2002 and Zoraghi et al., 2002, 
respectively.
dipyridamole etazolate
TbPDE1 13.0 25.0
TbPDE2A 5.9 30.3
TbPDE2B 27.0 127.0
TbPDE2C 14.6 30.6
We measured in vivo kinase activity in the presence of etazolate or dipyridamole. With 
both PDE inhibitors we observed an increase in kinase activity. With dipyridamole the 
increase in kinase activity was higher than with (equimolar concentrations) of etazolate. 
This might be explained by the different  affinities of the two inhibitors towards T. brucei 
PDEs, but could also be due to several other factors, such as differences in membrane 
passing abilities.
The reason for the observed activation of T. brucei PKA-like kinase in the presence of 
PDE inhibitors remains unclear. In fact, assuming that the kinase activity derived from 
cloned kinases is cNMP stiumulated at all, one would expect an inhibition of kinase 
activity rather than an activation, since all T. brucei PDEs studied so far are highly specific 
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for cAMP (Kunz et al., 2004; Zoraghi et al., 2000; Rascón et al., 2002 and Zoraghi et 
al., 2002). PDE inhibition should therefore result in an increase in cAMP, which has 
in fact been shown for dipyridamole (Zoraghi et al., 2001) and cAMP inhibits PKA-like 
kinase. We cannot, however, exclude that the PDE inhibitors also activate a yet unknown 
T. brucei PDE. This PDE might even be specific for another cyclic nucleotide, given 
that in mammals dipyridamole does not only inhibit cAMP specific PDEs but also the 
cGMP specific PDEs, PDE5 and PDE6, with IC50 values of 0.9 and 0.4 µM respectively 
(reviewed in Essayan et al., 2001). Two further PDEs have already been identified in T. 
brucei but not yet characterized (PDE2D, PDE2E, Seebeck et al., 2001). 
To identify the mechanism of kinase activation by PDE inhibitors it is essential to measure 
both cAMP and cGMP levels in parallel to in vivo kinase activity. 
4.3.1.2. Temperature
A drop in temperature has long been known to play a role in differentiation from short 
stumpy to procyclic cells. For this reason it is frequently used to induce differentiation 
in vitro, together with citrate / cis-aconitate (Ziegelbauer et al., 1990; Rolin et al., 1993; 
Matthews and Gull, 1994; Vassella and Boshart, 1996). The mechanism of cold shock 
sensing in trypanosomes was established by recent studies from this lab. Engstler 
and Boshart (2004) could show that cold shock (37°C->20°C) induces the expression 
of the insect stage specific procyclin in BSF cells by a postranscriptional mechanism. 
Furthermore, although cold shock alone is not sufficient to induce differentiation, it 
dramatically increases the sensitivity of the cells towards the differentiation stimuli cis-
aconitate / citrate. Thus, there is strong evidence for the participation of cold shock in the 
differentiation from short stumpy to procyclic cells.
We measured in vivo activity of T. brucei PKA-like kinase at different temperatures with 
the aid of the VASP reporter substrate and found a significant increase in activity at all 
temperatures below 37°C. Thereby the increase in kinase activity was nearly proportional 
to the decrease in temperature. Kinase activity reached its maximum at 12°C and then 
remained equally high at lower temperatures. Conclusively, the activity of T. brucei PKA 
like kinase is temperature dependent.
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To our knowledge, T. brucei PKA-like kinase is the first PKA homologue that has been 
shown to be activated by changes in temperature. Although temperature sensing has 
been described for many organisms and a large body of information is available on cold 
shock induced (mainly prokaryotic) genes (reviewed in Yamanaka et al., 1999; Los et al., 
1999), surprisingly little is known about the upstream factors of a temperature sensing 
signaling pathway.
In bacteria it was shown that membranes can sense temperature changes (reviewed 
in Rock and Cronan, 1996) and transmit signals as a consequence of changes in their 
membrane phase state and microdomain organization (Vigh et al., 1998; Hoppe et al., 
2000; Suzuki et al., 2000). A two component-signal transduction pathway, consisting 
of a sensor kinase and a response regulator, has been shown to transmit cold shock 
signals across the bacterial plasma membrane (Aguilar et al., 2001). For plants, a similar 
cold shock sensing mechanism has been proposed. There is evidence that membrane 
structures of plants change after cold shock and that these membrane changes cause 
an influx in Ca2+ and subsequent activation of cold shock dependent MAP kinases 
(Sangwan et al., 2002a; Gimalov et al., 2003; Jonak et al., 1996). Using cell free extracts 
it was shown that a heat shock activated MAP kinase is even able to sense temperature 
shifts directly (Sangwan et al., 2002b). The involvement of MAP kinases in cold and 
heat shock response is not restricted to plants but has also been shown in yeast (Soto 
et al., 2002). Most interestingly, heat shock response in Leishmania was found to be 
accompanied by an Ca2+ influx, both from internal pools and from the outside milieu 
(Sarkar et al., 1995). 
It is tempting to speculate that T. brucei PKA-like kinase participates in the upstream 
signaling events in response to cold shock. It has already been shown that a temperature 
drop below 26°C results in major changes in the T. brucei plasma membrane (Ter Kuile 
et al., 1992). 
4.3.1.3. pH value
Similar to cold shock, mild acid stress also induces differentiation. This was not only 
shown for T. brucei (Rolin et al., 1998) but also for the related kinetoplastida T. cruzi 
(Kanbara et al., 1990; Tomlinson et al., 1995) and Leishmania (Zilberstein et al., 1991; 
Bates et al., 1992; Zilberstein et al., 1994). In T. brucei, mild acid stress can induce the 
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transformation of short stumpy cells into the insect stage form even in the absence of 
citrate/cis-aconitate, although very inefficiently (Rolin et al., 1998). It still remains unclear 
whether mild acid stress has any relevance for in vivo differentiation, since the pH value 
in the alimentary tracts of the tsetse fly is alkaline rather than acid (J.Van Den Abbeele, 
unpublished). However, mild acid stress might occur at some stage on the way from the 
mammalian blood to the intestine of the insect vector and there act as differentiation 
stimulus.
We measured in vivo activity of T. brucei PKA-like kinase of cells in both acid and alkaline 
medium and found a linear dependency between kinase activity and the extracellular 
pH values. Low pH values resulted in kinase activation and high pH values in kinase 
inhibition. The tested pH values ranged from 5.5 to 9.5 and had no effect on the viability 
and motility of the cells during the time of observation, as judged by phase microscopy. 
Furthermore, changes in kinase activity were reversible. Conclusively, the activity of T. 
brucei PKA-like kinase is depending on the pH value of the environment. 
The signaling events that underlie mild acid stress response in T. brucei were studied by 
Rolin et al. (1996). The authors found an increase in adenylate cyclase activity at pH 5.5. 
With an artificial acidification of the cytosol by a protonophore they observed the same 
effect even at neutral extracellular pH. This suggests that adenylate cyclase is activated 
due to a slight acidification of the cytosol. Interestingly, the activation of adenylate cyclase 
after mild acid stress was restricted to LS trypanosomes, but absent from the insect stage 
(Rolin et al., 1996) and the cell cycle arrested fly-preadapted short stumpy stage (Nolan 
et al., 2000). 
Whether the observed activation of PKA-like kinase at mild acid stress is dependent on 
the activation of adenylate cyclases remains to be shown. Like the observed activation of 
PKA-like kinase with PDE inhibitors, this would be contradictory to the fact that T. brucei 
PKA-like kinase is inhibited by cAMP.
4.3.1.4. Life cycle stage dependent differences in expression and posttranslational 
modification of PKAC1 and PKAC2
In search of a putative function for T. brucei PKA-like kinase in differentiation, two of the 
catalytic PKA-like subunits were studied in more detail. These isoforms, that have nearly 
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identical sequences, are of particular interest in this context, since both their expression 
and posttranslational modification had been shown to be developmentally regulated. 
We found that PKAC1 and PKAC2 protein levels are inversely regulated, with PKAC1 
being mainly expressed in blood stream form cells and PKAC2 in the insect stage form. 
Thereby the overall protein level of PKAC1/2 remained constant.  mRNA levels (E. 
Vassella, unpublished) roughly corresponded to protein levels, suggesting that expression 
of PKAC1 and PKAC2 is mainly regulated by mRNA abundance. T. brucei PKAC1 and 
PKAC2 thus belong to the 2% of all T. brucei genes that are currently thought to be 
regulated in a life cycle stage dependent manner (number estimated from transcriptome 
analysis, Diehl et al., 2002). 
The second difference between the two PKAC isoforms was a life cycle stage dependent 
phosphorylation found in PKAC1 of SS cells, but not in PKAC2 (T. Klöckner, Ph.D. thesis 
1996; S. Schimpf, Diploma thesis 2000, this work). In this work the phosphorylation site 
was mapped to the C-terminal Thr324 of PKAC1 using mass spectrometry. We could 
not, however, identify any function of this phosphorylation with reverse genetics. Thus, 
PKAC1 might simply be “accidentally” phosphorylated by a kinase that is expressed or 
active in the short stumpy stage only. NetPhosK, a neural network based phosphorylation 
prediction software (Blom et al., 1999; Sicheritz-Ponten et al., in preparation; 
NetPhosK, http://www.cbs.dtu.dk/services/NetPhosK/) predicts Thr324 of PKAC1 to be 
phosphorylated by a cyclin dependent kinase  (Cdk5, probability 0.7). In fact, several 
cyclin dependent kinases of kinetoplastida have been shown to be activated in a life cycle 
stage dependent way (Mottram et al., 1993; Grant et al., 1998; Wang et al., 1998). An 
experimental confirmation of these in silico predictions was, however, out of the focus of 
this work, given the negative functional data.
The stumpy specific PKAC1 phosphorylation nevertheless constitutes a new marker for 
the still insufficiently characterized short stumpy stage of T. brucei. Most known stumpy 
markers are rather unspecific, such as morphological changes (Vickerman, 1965) or cell 
cycle arrest in G1 (Shapiro et al., 1984) . They do not allow the unequivocal classification 
of a certain cell population. Specific stumpy markers are confined to the detection of 
metabolic changes (e.g. NADH diaphorase activity and dihydrolipoamide dehydrogenase 
(Tyler et al., 1997)), changes in biosynthesis (e.g. ribonucleotide reductase (Breidbach 
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et al., 2000)) and changes in protein trafficking and processing (Kelley et al., 1995). The 
PKAC1 phosphorylation, easily detectable as band shift on a Western blot, constitutes 
the first stumpy marker that is based on stumpy specific changes in signaling pathways. 
We were unable to identify any functional differences between PKAC1 and PKAC2 that 
could explain the observed life cycle stage specific differences between the isoforms. Any 
reverse genetic interference with either PKAC1 or PKAC2 always resulted in the same 
cytokinesis block phenotypes. In fact, it seems that the two isoforms can even complement 
each other. PKAC2 null mutants were perfectly able to transform into procyclic cells, that 
normally exclusively express PKAC2. Thus, the reason for the differential expression and 
modification of PKAC1 and PKAC2 remains unknown.
4.3.2. Role for T. brucei PKA-like kinase in cell cycle regulation
4.3.2.1. T. brucei PKA-like kinase is essential for cytokinesis progression
Evidence for a function of T. brucei PKA-like kinase during cytokinesis progression 
is provided by results from several reverse genetic experiments targeted against the 
different PKA-like subunits. Every interference with the abundance of either subunit 
prevented cells from completing cell division, while S-phase, mitosis and cytokinesis 
entry were not affected. It thereby appears that cytokinesis is blocked at a distinct point, 
since division furrows of cytokinesis blocked cells were of approximately equal sizes.
Two observations might help to evaluate the role of T. brucei PKA-like kinase in cell 
cycle regulation. The first was that minor changes in kinase protein level were already 
sufficient to severely interfere with cell cycle progression. The best example for this was 
the deletion of one PKAC2 allele that led to significantly reduced growth. This was a 
surprising result, given that PKAC2 is hardly expressed in LS trypanosomes. The second 
observation was that RNAi experiments targeted against PKAR not only led to PKAR 
depletion but also to a decrease of all three catalytic subunits. Obviously, cells keep the 
ratio of regulatory and catalytic subunit, and thus, the „net“ kinase activity constant. We 
conclude from this that a constant activity of PKA-like kinase, strictly kept within a very 
narrow range, is essential for accurate cell cycle progression.  
Interestingly, we could not detect any qualitative differences between the phenotypes of 
the different PKA-like subunits, with the exception of the basal body phenotype discussed 
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below. In theory, depletion of the regulatory subunit should result in increased kinase 
activity, while depletion of the catalytic subunit should decrease kinase activity. One would 
therefore expect opposite phenotypes upon RNAi with PKAR and PKAC. However, due to 
the co-depletion of the PKAC-like subunits by RNAi targeted against PKAR, the change 
in net kinase activity for each particular RNAi experiment is unpredictable. Furthermore, 
depletion of catalytic and regulatory PKA-like subunits might at first result in opposite 
(non-visible) phenotypes that then both subsequently lead to the same cytokinesis block 
phenotypes.
4.3.2.2. Role for T. brucei PKA-like kinase in basal body movement
Data from RNA interference experiments targeted against PKAR also suggests the 
involvement of T. brucei PKA-like kinase in another major cell cycle event: the basal body 
segregation. 
Basal bodies are the key regulators of the trypanosomal cell cycle. They are responsible 
for the nucleation of the new flagellum and mediate the segregation of the mitochondrial 
genome (Robinson et al., 1991; Ogbadoyi et al., 2003). At the end of their segregation, 
they adapt particular, highly conserved positions (Woodward and Gull 1990; Robinson 
et al., 1995) that are thought to determine the position of the division furrow later on. 
Nothing is yet known about the underlying signaling pathways that regulate basal body 
movement, but evidence for an involvement of protein kinases in this complex process 
has been provided by Das et al. (1994). The authors treated cells with the phosphatase 
inhibitor ocadaic acid, which probably increases net kinase activity, and found basal body 
segregation inhibited. 
Data from this work provide evidence that one of these basal body regulating kinases 
is identical to PKA-like kinase. When the regulatory PKA subunit was depleted by RNA 
interference we found enhanced basal body movement, thus the opposite phenotype 
described by Das et al. In fact, basal bodies were obviously incapable in recognizing 
their normal stop positions, but instead continued to segregate until they reached most 
unusual, far too anterior positions. 
We at first thought that this observed extension in basal body movement was simply a 
secondary effect of the cytokinesis inhibition that occurred in parallel (see above). In 
theory, the process of cytokinesis itself could cease basal body segregation. Thus, in 
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the absence of cytokinesis basal bodies would continue to move. However, we could not 
confirm this hypothesis, since basal body movement was not affected when cytokinesis 
(but not basal body movement) was inhibited with the microtubules inhibitor vincristine. 
We therefore suggest that the T. brucei PKA-like kinase is directly involved in the control 
of basal body segregation. 
So far, the only study that approaches the regulation of basal body segregation was 
performed by Kohl et al. (2003) using RNAi targeted against components of intraflagellar 
transport. The authors found decreased basal body distances in the absence of 
intraflagellar transport and conclude that the flagellum plays an essential role in the 
regulation of basal body movement. In addition, they also provide indirect evidence for 
a function of the flagellum in the regulation of cytokinesis, since cells without flagella fail 
to divide.
Given that 1) PKA-like kinase is localized in the trypanosomal flagellum (C. Krumbholz, 
this lab) and 2) both the flagellum and PKA-like kinase have been shown to be important 
for basal body movement and cytokinesis, is there any connection between the flagellar 
localization of the PKA-like kinase and its function as a cell cycle regulator?
4.3.2.3. The trypanosomal flagellum: a signaling compartment for cell cycle 
regulation?
The flagellum of T. brucei consists of the classical axoneme and an additional lattice-like 
structure called the paraflagellar rod (PFR) (reviewed in Gull, 1999). With the exception 
of its distal tip, it is attached along the length of the cell body. This attachment is mediated 
by cytoskeletal structures that lie underneath the plasma membrane and follow the path 
of the flagellum, the flagellum attachment zone (FAZ). 
Increasing evidence suggests that the function of trypanosomal flagella is not restricted 
to motility. They probably also play an important role in cell cycle regulation, control of 
basal body movement, the positioning of the FAZ and the positioning of the division furrow 
(Kohl et al., 1999; Kohl et al., 2003, reviewed in McKean 2003). The outgrowth of the 
daughter flagellum can thus be seen as a pivotal event in trypanosomal morphogenesis. 
These complex processes require strict regulations mediated by signaling pathways. 
It is therefore not surprising that several proteins have been identified in flagella that 
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have (predicted) functions distinct from motility. Examples are adenylate kinase in 
trypanosomal flagella (Pullen et al., 2004; DʼAngelo et al., 2002) and a MAP kinase in the 
flagellum of Leishmania (Wiese et al., 2003). 
With PKA-like kinase we have now identified a further flagellar protein that is involved 
in cell cycle regulation, to be more precise, in cytokinesis progression and basal body 
segregation. In this chapter we will concentrate on the discussion of possible mechanisms 
for the role of the flagellar localized PKA-like kinase in basal body movement. We can 
think of two mechanism that could explain the observed elongated basal body movement 
upon PKAR RNAi: 
The first is that the kinase regulates the outgrowth of the daughter flagellum. The depletion 
of PKAR by RNAi would then result in uncontrolled growth of the daughter flagellum. 
Since the daughter flagellum is essential for basal body segregation (Kohl et al., 2003), 
its uncontrolled growth could result in the observed changes in basal body positions. 
Alternatively, PKA-like kinase could act as a sensor of flagellum length. One could 
speculate that both the mother and the daughter flagellum send signals to the basal body 
at the origin of each  flagellum. As long as the flagella have different lengths, the basal 
bodies obtain signals of different strength and move. If both flagella reach equal lengths, 
both basal bodies obtain equally strong signals and stop moving. This way PKA-like 
kinase would ensure that basal body movement stops as soon as the daughter flagellum 
has reached its full length. It has been shown that both basal body movement and 
flagella growth are correlated in a nearly linear way and that both events are completed 
simultaneously (Robinson et al., 1995; BSF cells: M. Engstler, unpublished). 
4.4. T. brucei PKA-like kinase: current view and outlook 
The aim of this last chapter is to highlight the remaining unsolved questions and possible 
experimental approaches.
The current view is that T. brucei has one regulatory PKA-like subunit and three isoforms 
for catalytic PKA subunits. The catalytic subunits PKAC1, PKAC2 and PKAC3 appear to 
be conventional PKAs as judged from substrate and inhibitor specificities and the fact that 
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PKAC3 forms a heterologous holoenzyme complex with bovine PKARs that dissociates in 
the presence of cAMP (T. Klöckner, Ph.D. thesis 1996; N. Wild unpublished, this work).
The regulatory subunit has several features that distinguish it from a classical regulatory 
PKA subunit, such as its unusually long N-terminus that lacks a dimerization domain 
and several substitutions of conserved amino acids in its cNMP binding pockets. It has, 
however, a classical inhibitor sequence (substrate sequence) and is able to bind each of 
the catalytic subunits to form a dimeric holoenzyme. 
With the exception of PKAC3, all PKA subunits are expressed and, in the case of PKAC1, 
also phosphorylated in a life cycle stage dependent manner (C. Schulte zu Sodingen, 
Ph.D. thesis 2000; T. Klöckner, Ph.D. thesis 1996; this work). The reason for this remains 
unknown. Data from several reverse genetic experiments provide evidence for a function 
of T. brucei PKA-like kinase in cell cycle regulation, especially in basal body segregation 
and cytokinesis progression. T. brucei PKA-like kinase is localized in the flagellum, in a 
subdomain of the paraflagellar rod proximal to the axoneme (C. Krumbholz, this lab). 
So far, T. brucei PKA-like kinase possess all features that characterize a classical PKA. 
Problems start, however, when it comes to the question of kinase activation:
It has been shown, both in vitro and in vivo, that T. brucei PKA-like kinase is activated by 
cGMP, but in unphysiologically high concentrations only. In fact, cGMP concentrations 
needed for activation of T. brucei PKA-like kinase were 2-5 orders of magnitudes higher 
then cGMP concentrations needed for activation of other cGMP dependent kinases. 
The role of cGMP as the physiological activator of PKA-like kinase thus remains 
highly doubtable, even more so, since neither guanylyl cyclases, nor cGMP dependent 
phosphodiesterases or cGMP itself have yet been found in T. brucei. 
Even more surprising with the finding, that cAMP not only failed to activate T. brucei PKA-
like kinase but instead inhibited it. Again, this was shown both in vitro and in vivo. These 
results are in contradiction to other observations: If PKA is inhibited with cAMP, why is 
it activated with several stimuli that have been shown to activate adenylate cyclases or 
increase intracellular cAMP concentrations, such as PDE inhibitors and mild acid stress? 
We were so far unable to solve these contradictions. 
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What are the next important steps on the way to further understanding of the T. brucei 
PKA-like kinase ?
A major aim will be to finally solve the activation mechanism of the kinase. Correlations 
between in vivo activity of the PKA-like kinase and cyclic nucleotides are so far either 
based on indirect observations only or on the use of membrane permeable cNMP 
derivatives. None of these methods allows to directly correlate in vivo activity of PKA-like 
kinase with a certain cyclic nucleotide. It is therefore important to extent the in vivo kinase 
assay and measure not only phosphorylation of the PKA reporter substrate VASP but in 
parallel also changes in intracellular cGMP and cAMP concentrations. Also, instead of 
using membrane permeable cNMP derivatives that might differ in their affinities towards 
PKA compared to cNMPs, cAMP and cGMP should be added directly using living, 
permeabilized cells. In order to understand if and how cAMP acts as a PKA inhibitor, 
biochemical data about the binding affinities of T. brucei PKAR towards different cyclic 
nucleotides would be most useful.
The second major aim will be to use the VASP based in vivo kinase assay established in 
this work to study the role of T. brucei PKA in both LS to SS and SS to PCF differentiation. 
For this, VASP needs to be expressed in pleomorphic T. brucei cell lines, since the 
laboratory adapted monomorphic cell lines are unable to differentiate into SS cells. 
Kinase activity can then be directly monitored during the whole differentiation processes 
and correlated to other events that characterize differentiation.
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AKAP A kinase anchoring protein
APS ammonium persulfate
ATP adenosine 3ʼ phosphate
BCIP 5-Bromo-4-chloro-3-indolyl-phosphate, 4-toluidine salt
BSD blasticidin S deaminase
BLE bleomycin resistance protein
bp base pair
BSA bovine serume albumine
BSF blood stream form
cAMP cyclic adanosine monophosphate
cCMP Cytidine- 3ʼ, 5ʼ- cyclic monophosphate 
cGMP cyclic guanosine monophosphate
cIMP Inosine- 3ʼ, 5ʼ- cyclic monophosphate
CPM counts per minute
cUMP Uridine- 3ʼ, 5ʼ- cyclic monophosphate
cXMP Xanthosine- 3ʼ, 5ʼ- cyclic monophosphate
Da dalton
DAPI 4,6-Diamidino-2-phenylindole
dCTP 2ʼ-deoxycytidine 5ʼ-triphosphate
dNTP 2ʼ-deoxynucleosid 5ʼ-triphosphate
dsRNA double stranded RNA
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
EGTA tetra(acetoxymethyl ester)
ESAG expression site associated gene
FCS fetal calf serume
GAF cGMP-specific and -stimulated phosphodiesterases, 
Anabaena adenylate cyclases and E.coli FhtA
HMM Hidden Markov Model
HYG hygromycin phosphotransferase
IP immunoprecipitate / immunoprecipitation
IPTG isopropyl thio-b-D-galactoside
LAR Leukocyte antigen related
LB Luria Bertani
LS long slender
MCP mitochondrial carrier protein
mRNA messenger RNA
NBT nitro blue tetrazolium chloride
NEO neomycin phosphotransferase
ORF open reading frame
PARP procyclic acidic repetitive protein
PBS phosphate-buffered saline
PCF procyclic form
PDT population doubling time
PFR paraflagellar rod
PKA cAMP dependent protein kinase
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PKI protein kinase inhibitor (PKA specific)
PVDF polyvinylidene fluoride
RNAi RNA interference
RT room temperature
SDM semi defined medium
SDS sodium dodecyl sulfate
SIF stumpy induction factor
SN supernatant
SP stationary phase (monomorphic SS-like cells)
SS short stumpy 
T7POL T7 polymerase
TBS Tris-buffered saline
TDB trypanosome dilution buffer
TEMED N,N,Nʼ,N-Tetramethylethylen-diamin
Tet tetracycline
TETR tetracycline repressor
Tris hydroxymethyl aminomethane
UTR untranslated region
UV ultra violett
VASP vasidolator stimulated phoshpoprotein
VSG variant surface glycoprotein
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pCK34-1pC3-1 pC3-3 pC3-2 pCK34-2
XhoI HindIII HindIII XhoI BamHI
phage clone C3 phage clone CK34
A
PRP8 PKAC1 ORF1 ORF2 PKAC2MCP RAB7
B XhoI BglII XhoI SalI
PRP8 PKAC1 ORF1 ORF2 PKAC2MCP RAB7
Attachment 1: The genomic locus of PKAC1 and PKAC2
The complete sequence of the PKAC1/2 genomic locus had been previsiously cloned in this laboratory
(T.Klöckner, P.Hassan, unpublished). In addition to PKAC1 and PKAC2 it contains a gene for PRP8 (a
splice factor, Lücke et al., 1997), for a putative MCP (mitochondrial carrier protein) and for a putative
RAB7 protein. Two open reading frames (ORF1 and ORF2) show no homologies to any other proteins but
are expressed (data not shown).
A) Names and positions of the phage clones C3 and CK34 that were used for the cloning T.Klöckner. In
addition, the DNA of these phage clones was subcloned into the plasmids pC3-1, pC3-3, pC3-2, pCK34-1
and pCK34-2.
B) The positions of the probes used for hybridisation experiments in this work are shown. They were
prepared from the corresponding plasmids (compare A) with the restriction enzymes as indicated.
C) Genes and putative genes of the PKAC1/2 genomic locus. The systematic name (Acc. No), the size of
the open reading frame and the characteristics of the corresponding proteins (size, molecular weight,
isoelectric point) are indicated.
gene Acc No. ORF [bp]
amino
acids
molecular
mass [kDa]
predicted
isoelctric point
PRP8 Tb09.211.2420 7209 2403 276.9 8.3
PKAC1 Tb09.211.2410 1002 334 38.0 9.1
ORF1 Tb09.211.2400 1983 661 72.2 6.23
ORF2 Tb09.211.2380 1635 545 58.6 9.3
MCP Tb09.211.2370 888 296 52.2 9.2
PKAC2 Tb09.211.2360 1008 336 38.6 9.3
RAB7 Tb09.211.2330 660 220 23.8 5.2
C
MCP PKAC1/2PKAC1/2PRP8
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Attachment 2: Cytokinesis inhibition with vincristine
A) Growth of T.brucei WT cells in the presence of vincristine at different concentrations. The minimal
vincristine concentration that caused a complete growth arrest of the cells was found to be 0.2 �M. It was
used for all further experiments.
B C D) Cell densities were measured 0,2,4,6, and 8 hours after incubation with or without (control) 0.2 �M
vincristine (B) The K/N configurations were analyzed for each time point, using 400 cells (C). Additionaly,
2K2N cells (after 6 hours of vincristine incubation) were classified according to the stage of their division
furrows (D).
Average values from three independent experiments are shown. Standard deviations are indicated by
error bars.
E) Photographs of typical 2K2N cells and 4K2N cells after 6 hours of incubation with 0.2 �M vincristine.
The cells are stained with DAPI. It can be seen that kinetoplast segregation was not inhibited.
E 2K2N 4K2N
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Attachment 4: Conserved regions in catalytic PKA subunits
Catalytic PKA subunits from H. sapiens (Hs, PKA �, Acc No.:P22694), M. musculus (Mm, PKA �, Acc
No.:NP_035230), B. taurus (Bt, PKA �, Acc No.: P24256), D. melanogaster (Dm, Acc No.: P12370), C.
elegans (Ce, Acc No.: P21137), P. falciparum (Pf, Acc No.: NP_704880), E. gracilis (Eg, Acc No.:
BAA76665) and S. cerevisiae (Sc, PKA1, Acc No.:P06244) were aligned with ClustalW
(http://www.ebi.ac.uk/clustalw/, Higgins et al., 1994) using default parameters as set by the EBI server. The
kinase domains are colored red and the additional conserved regions at the C-termini are colored blue.
While the N-termini of the different PKAs have no homology, the kinase domains are highly conserved
(red, 32% identity, 59% homology) and the C-termini have also some homology (blue, 11% identity, 18.5%
homology). Thus, the conserved sequence stretch of PKA is between 308 and 312 amino acids long and
consists of the kinase domain and the C-terminus.
TbC1 -----------------MTTT-----------------------------------------------PTGDGQ--LFTKPDTSGWKLSDFEMGDTLGTGSFGRVRIAKLKSRGEY--YA 52
TbC2 -----------------MPVA-----------------------------------------------TSTEPQTYVFTKPDTSGWKLSDFEMGDTLGTGSFGRVRIAKLKSRGEY--YA 54
TbC3 ------------MTGEVHTNQ-----------------------------------------------DPLDKSDGCLTRKDVSSWKLQDLEIRETIGTGTFGRVRLCRHRASGQY--VV 59
Eg -------------MAQTIPDQ-----------------------------------------------TALP---------DTTNWQLSDLTLKETLGTGTFGRVRLCLHKSSGNY--YA 49
Hs -------------MGNAATAK-------------KGSE---------------------VESVKEFLAKAKEDFLKKWENPTQNNAGLEDFERKKTLGTGSFGRVMLVKHKATEQY--YA 71
Mm -------------MGNTAIAK-------------KGSE---------------------VESVKEFLAKAKEDFLRKWENPPPSNAGLEDFERKKTLGTGSFGRVMLVKHKATEQY--YA 71
Bt -MAAYREVPCNQYTGTTALQKLEGFASRLFHRHSKGTAHDQKTALENDSLHFSEHTALWDRSMKEFLAKAKEDFLKKWENPAPNNAGLEDFERKKTLGTGSFGRVMLVKHKATEQY--YA 117
Dm -------------MGNNATTS------------NKKVD--------------------AAETVKEFLEQAKEEFEDKWRRNPTNTAALDDFERIKTLGTGSFGRVMIVQHKPTKDY--YA 73
Ce ---------MLKFLKPKSSDE----------GSSKDNK--------------------NSASLKEFLDKAREDFKQRWENPAQNTACLDDFDRIKTLGTGSFGRVMLVKHKQSGNY--YA 79
Pf ----------MQFIKNLQLNK------------KKDSD-----------------------SSEQVLTNKK------------NKMKYEDFNFIRTLGTGSFGRVILATYK-NGNYPPVA 62
Sc MSTEEQNGGGQKSLDDRQGEESQKGETSERETTATESGNESKSVEKEG----GETQEKPKQPHVTYYNEEQYKQFIAQARVTSGKYSLQDFQILRTLGTGSFGRVHLIRSRHNGRY--YA 114
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